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Abstract  
 
Misregulation of tau, an intrinsically disordered protein, is implicated in 
Alzheimer’s disease (AD) and more than 15 related tauopathies. These diseases 
are characterized by the accumulation of tau aggregates into insoluble 
neurofibrillary tangles (NFTs), which contribute to neurodegeneration. As 
discussed in Chapter 1, accelerating the clearance of tau is an emerging 
treatment strategy. The molecular chaperone heat shock protein 70 (Hsp70) 
binds tau and facilitates its degradation, making it a particularly attractive target 
for normalizing tau homeostasis. It was recently discovered that the 
rhodacyanine MKT-077 and its analogs bind Hsp70 and accelerate the 
degradation of pathogenic tau in multiple disease models. In Chapter 2, I was 
interested in using MKT-077 analogs as probes to better understand this 
mechanism. We found that MKT-077 analogs bind to an allosteric site on Hsp70, 
stabilizing the ADP-bound conformation and increasing tau binding. These 
molecules also disrupted protein-protein interactions between Hsp70 and its co-
chaperones. These findings suggest that the affinity of Hsp70 for its substrates, 
like tau, is correlated with degradation. While exciting, it still was not clear which 
of the Hsp70 paralogs was most important for this process. There are thirteen 
Hsp70 genes in humans, including those expressed in the mitochondria and 
endoplasmic reticulum (ER). In Chapter 3, I used CRISPR/cas9 technology to 
 xv 
understand the targets of the MKT-077 analogs, showing that some of the 
compounds are selective for mitochondrial Hsp70, while others require the ER 
paralog. This selectivity seemed to emerge from differential subcellular 
partitioning of the analogs, as suggested by fluorescence microscopy. These 
results are important for better understanding the roles of Hsp70 in tau 
homeostasis, because we could then select molecules that were relatively 
paralog-selective and ask how well they reduce tau levels. Using this approach, I 
found that the ER version of Hsp70 seemed to be an excellent target for 
accelerating tau degradation, potentially through regulating stress response. 
Consistent with this finding, I found that over-expression of ER Hsp70 promotes 
tau clearance. As discussed in Chapter 4, these results have important 
implications for therapeutic treatment of tauopathies. In addition, these findings 
provide new insights into mechanisms of Hsp70-mediated tau homeostasis.  
 1 
Chapter 1 
Molecular Chaperones as Therapeutic Targets  
for Restoring Tau Homeostasis 
 
 
1.1 Introduction 
Normal tau homeostasis is achieved when there is balance in its synthesis, 
processing and degradation. Together, the pathways that regulate tau 
homeostasis ensure that the protein is at the proper levels and that its post-
translational modification (PTMs) and subcellular localization are appropriately 
controlled. These pathways include the enzymes responsible for PTMs, those 
systems that regulate mRNA splicing and the molecular chaperones that control 
tau turnover and its binding to microtubules. In tauopathies, this delicate balance 
is disturbed. Tau becomes abnormally modified by PTMs, it loses affinity for 
microtubules and it accumulates in proteotoxic aggregates. How and why does 
this imbalance occur? In this chapter, we discuss how molecular chaperones and 
other components of the protein homeostasis (e.g. proteostasis) network 
normally govern tau quality control. We also discuss how aging might reduce the 
capacity of these systems and how tau mutations might further tip the balance. 
Finally, we discuss how small molecules are being used to probe and perturb the 
tau quality control systems, playing a particularly prominent role in revealing the 
logic of tau homeostasis. As such, there is now interest in developing these 
chemical probes into therapeutics, with the goal of restoring normal tau 
homeostasis to treat disease. 
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1.2 Tau’s role in neurodegenerative diseases 
Tau is a microtubule-associated protein that is normally soluble but has a 
propensity to aggregate into oligomers, paired helical filaments (PHFs) and 
neurofibrillary tangles (NFTs). A group of neurodegenerative diseases that are 
characterized by the appearance of NFTs are classified as tauopathies, including 
some forms of Alzheimer’s disease (AD), frontotemporal dementia with 
parkinsonism linked to chromosome-17 (FTDP-17) and progressive supranuclear 
palsy (PSP). A subset of FTDP-17 cases are caused by mutations in tau, 
providing a direct link between tau dysfunction and disease [1]. Moreover, the 
levels of NFT pathology closely correlate with AD progression [2] indicating that 
normal wild-type tau is readily corrupted by the cellular conditions that promote 
disease. There is also evidence from an AD mouse model indicating that tau is 
required for some aspects of the observed pathologies [3]. Recent reviews 
further detail the links between tau and neurodegeneration [4, 5] and outline the 
features of the animal models [6]. Here, we will focus on how tau protein levels 
are maintained, how disease-associated changes in tau disrupt this balance and 
how this knowledge can be used to design new therapeutic strategies.  
 
1.3 Tau structure and function 
Tau is a member of a family of microtubule-associated proteins (MAPs) that 
directly bind tubulin and are implicated in microtubule dynamics. Tau was 
originally identified as an important factor for microtubule assembly or stability [7] 
however, more recent studies argue that this particular function is not essential or 
is redundant with other MAPs [8, 9]. Tau expression is mainly restricted to the 
nervous system, where it is abundant in neurons and at much lower levels in glial 
cells, such as oligodendrocytes and astrocytes [10-12]. In neurons, tau is 
primarily localized to the axons where it co-localizes with microtubules [13]. The 
tau protein is encoded by the MAPT gene and alternative splicing of exons 2, 3 
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and 10 generates the 6 main isoforms that are expressed in the adult brain [14]. 
NMR studies have shown that tau proteins are disordered in solution, only 
transiently sampling secondary structures [15]. Nevertheless, tau sequence 
characteristics can be used to define major regions within the protein including 
an N-terminal domain, a poly-proline region, a microtubule-binding repeat  
(MTBR) region, and a C-terminal segment (Figure 1.1). The MTBR region is 
comprised of imperfect repeat sequences (31 or 32 residues each) that, along 
  
Figure 1.1 Map of the modifications and interaction sites on the tau sequence. A schematic of the longest 
adult isoform of tau (2N4R) is depicted. Several regions within the tau sequence are highlighted including 
two amino terminal inserts (N1, N2), a poly-proline region and the microtubule-binding repeat region 
composed of 4 imperfect repeat sequences (R1-R4). Alternative splicing of N1, N2, or R2 leads to the 
generation of 6 tau isoforms expressed in adults. The sequences of the two known aggregation motifs are 
shown, located within R2 and R3 of tau. All the known disease-associated missense mutations and the risk 
factor variant, A152T (grey), are mapped. Intronic mutations linked to tauopathies are not shown. Missense 
mutations observed to kinetically favor increased (red) or decreased (green) aggregation in vitro are colored. 
Grey boxes show mutations that alter splicing of the R2 repeat. Dashed underlines show mutations that 
display decreased affinity for microtubules. A selection of post-translational modifications associated with 
disease are mapped and color-coded as indicated in the figure. Below the tau sequence schematic, regions 
of tau that interact with binding-partners are charted. 
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with the polyproline region, mediate interactions with microtubules [16-18]. 
Differential splicing of exon 10 generates either 4 or 3 microtubule-binding 
repeats (termed 4R or 3R) and the 4R forms have tighter affinity for microtubules 
[19] and nucleate microtubule assembly better than 3R isoforms [20].  
 
1.4 Normal protein-protein interactions with tau 
Like many intrinsically disordered proteins (IDPs), tau interacts with multiple 
protein partners (for an overview see [21]) (Figure 1.1). In addition to tubulin, tau 
also binds actin [22], kinesin [23, 24] and dynactin [25, 26]. These interactions 
strongly link tau to trafficking and axonal transport. Indeed, overexpression of tau 
impairs both vesicle and mitochondrial transport [27-29]. Tau also binds to a 
number of kinases, phosphatases, proteases and acetylases that are involved in 
post-translational modifications (PTMs). For example, fyn kinase binds PXXP 
motifs in the polyproline region of tau [30] and phosphorylates its N-terminus at 
Tyr18 [31]. Finally, as discussed in greater detail within this chapter, molecular 
chaperones are also prominent protein partners of tau. For example, heat shock 
protein 70 (Hsp70) and heat shock protein 90 (Hsp90) both bind tau within the 
MTBRs [32, 33] and regulate its turnover [34]. Together, these protein-protein 
interactions (PPIs) between tau and its many protein partners help regulate its 
trafficking, its PTMs and its turnover. Thus, to understand tau homeostasis, one 
must understand its interactions with itself (i.e. aggregation) and its interactions 
with these partners. 
 
1.5 Aberrant interactions of tau  
One of the hallmarks of tauopathies is that tau’s PPIs are altered [21], meaning 
that some of the interactions are favored and others are reduced. The most 
dramatic example of this change is the increase in tau-tau interactions, which 
lead to its aggregation. Two aggregation motifs within the MTBRs are required 
this process and several mutations in this region prevent self-assembly [35, 36]. 
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However, this same region is also required for binding to microtubules. When tau 
is not in contact with microtubules, these regions acquire an abnormal, beta-
sheet-rich structure that favors amyloid formation [17, 35, 37]. Further, cysteines 
within the MTBRs can cross-link tau monomers, which also promotes 
aggregation [38]. The importance of the MTBRs suggests that the loss of tau-
microtubule interactions and the build up of unbound cytosolic tau may be a step 
towards aggregation. However, tau is surprisingly soluble in vitro. Accelerants, 
particularly poly-anionic molecules such as heparin or fatty acid micelles, are 
required to initiate aggregation in vitro [39]. It is thought that a similar aggregation 
trigger, such as RNA or polyglutamates [40, 41], might be similarly required in 
vivo.  
 
Tau aggregation leads to the formation of an ensemble of aggregate structures, 
including oligomers and fibrils, that are found in tissue samples from AD and PSP 
[42, 43]. Although it isn’t yet clear which tau structures are most toxic, it is likely 
that oligomers are especially detrimental to cells as they decrease cell viability 
more potently than tau fibrils [44] and antibodies against oligomers of tau are 
protective when administered to tauopathy animal models [45, 46]. Further, tau 
oligomers seem to spread in the brain and in cell culture, exhibiting prion-like 
characteristics [47-50]. A cell-to-cell transmission of tau aggregates fits with the 
characteristic spreading of pathology from an epicenter to connected brain 
regions observed in disease.  
 
1.6 Tau mutations and disease-associated PTMs 
Thus far, 53 pathogenic mutations within the MAPT gene encoding tau have 
been reported [51] (Figure 1.1). There are also reports of risk factors linked to 
MAPT including the A152T variant within the protein coding region [52] and the 
MAPT variation associated with the H1 haplotype [53]. The pathogenic mutations 
can be broadly characterized as missense/deletion mutations or intronic 
mutations. The vast majority of the mutations cluster to the MTBRs, perhaps 
underscoring the role played by dynamic microtubule binding and self-assembly. 
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The mechanism(s) of toxicity that occur due to MAPT mutations remain poorly 
understood. The intronic mutations and even some coding mutations promote 
inclusion of exon10 and lead to increased expression of 4R tau [54, 55]. In vitro, 
4R tau binds to microtubules with a higher affinity than 3R isoforms [20, 56] but 
4R tau also aggregates with faster kinetics than 3R tau [38] and 3R can inhibit 
4R aggregation [57]. Thus, one could speculate that an imbalance in 3R versus 
4R contributes to disease. Other coding mutations do not seem to alter splicing. 
Rather, they reduce microtubule affinity and/or increase aggregation compared to 
wild-type (Figure 1.1) [58-62]. It is tempting to speculate that these biochemical 
features are the major determinants of tauopathy. However, this possibility is 
unlikely because the age of onset, duration, clinical symptoms, and 
neuropathology differ between individuals harboring related mutants and 
sometimes for patients with the same mutation [63]. This data strongly suggests 
that other factors contribute to tau pathology. One possibility is that 
environmental or other genetic factors tune the response to tau mutations [64-
66]. Another fascinating possibility is that specific mutations alter tau’s PPI 
network (see Figure 1.1), perhaps releasing proteins that protect against disease 
and/or favoring partners that are detrimental.    
 
Although mechanistically informative, the vast majority of tauopathies are not 
associated with tau variants. Rather, abnormal PTMs appear to be closely linked 
to NFTs and disease. Tau is potentially subject to over 100 PTMs, including 
phosphorylation, acetylation, proteolytic cleavage, glycosylation, ubiquitination, 
sumoylation, amination, nitration, oxidation, and methylation [67, 68]. Increases 
in tau phosphorylation have been most extensively linked to tau pathology. Tau 
in normal brain is phosphorylated at an average of 2-3 residues per molecule, 
while tau from AD brain contains 3- to 4-fold more phosphorylated residues [69]. 
Indeed, antibodies recognizing phospho-epitopes, such as AT8, AT180, PHF1, 
are commonly used to mark neuropathology in all tauopathies [70, 71]. However, 
a clear cause-and-effect relationship between hyperphosphorylation and disease 
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initiation remains to be demonstrated and tau hyperphosphorylation is associated 
with normal development [72] and animal hibernation [73]. Despite this, there is 
some evidence that hyperphosphorylated tau has weakened activity in 
microtubule assembly assays and that it assembles into oligomers more readily 
[74]. Multiple kinases have been reported to phosphorylate tau but the kinases 
and sites relevant to disease remain poorly defined [67]. The kinases GSK3β, fyn 
and Cdk5 have all been implicated in abnormal tau phosphorylation and 
inhibitors for these kinases are currently being developed as therapeutics [75-
77]. One phosphatase, PP2A, has also been identified as the major tau 
dephosphatase in vivo and there are small molecules that enhance PP2A’s 
activity and reduce tau phosphorylation [78-80]. Ubiquitination of tau may serve 
to mark abnormal or free cytosolic tau for chaperone-mediated degradation [81, 
82]. Multiple ubiquitination sites have been identified through mass spec analysis 
of PHF-tau preparations [83-85] however, the requirement of these specific sites 
for the degradation of tau has not been confirmed. At least two acetylation sites 
on tau, at residues K280 and K274, correlate with other markers of tau 
neuropathology [86]. In vitro, multiply acetylated tau has a decreased propensity 
to form fibrils [87, 88], perhaps suggesting that acetylation is protective. Cleaved 
fragments of tau are released by proteolysis and these fragments have been 
observed in NFTs isolated from AD patients [89, 90]. The most well characterized 
cleavage site, at D421, is generally attributed to proteolytic activity of caspase 3 
[91] although multiple caspases can cleave the same site in vitro [92]. Cellular 
assays provide evidence that truncation at D421 leads to defects in microtubule 
binding [93], preferential degradation by autophagy [94], mitochondrial 
dysfunction [95], and enhanced secretion from cells [96]. Interestingly, D421 
truncated tau has been detected in the CSF from AD patients and its levels 
inversely correlate with cognitive decline [97]. Methylation is the main 
modification of tau lysines observed in normal brain [98] and its levels are 
decreased in AD tau samples [85]. 
 
Similar to what was discussed for disease-associated mutations, one can 
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imagine how aberrant PTMs might weaken favorable PPIs and/or strengthen 
self-association. These events might even be synergistic, as evident by 
observations that the R406W tau mutation leads to higher rates of tau 
phosphorylation in vitro [99]. The emerging theme is that tau normally engages in 
a dynamic series of PPIs and PTMs. These events are important for tau’s 
function in trafficking and its normal turnover. However, disruption of this delicate 
balance, either triggered by aging, mutations, trauma or other initiating event, 
leads to a re-modeling of the tau-associated PPIs. The net effect of this abnormal 
PPI state is that tau becomes aggregated and loses affinity for microtubules.  
 
1.7 Points of intervention for treating tauopathies 
The path towards the treatment of neurodegenerative tauopathies will likely 
involve the re-balancing of tau interactions (Figure 1.2). Perhaps the simplest 
form of this concept is to directly inhibit its aggregation [100]. Other initiatives 
have focused on small molecules that favor the normal PPIs of tau by stabilizing 
microtubules [101]. The idea behind this approach is that tau cannot aggregate if 
it is bound to microtubules because the MTBRs contain the essential aggregation 
motif. As mentioned above, other approaches have targeted the enzymes 
involved in tau PTMs, such as kinases or phosphatases. The challenges with 
these approaches is that it isn’t clear whether the small molecules can be safely 
deployed in a way that normalizes tau PPIs and PTMs. However, ongoing pre-
clinical programs are likely to answer this critical question. 
 
Another promising way to treat tauopathies is to accelerate its turnover or reduce 
its levels. Tau-/- knockout mice display only subtle phenotypes [3, 102], arguing 
that tau may not be critical in adult animals or that it can be compensated for by 
other MAPs. One means of clearing tau is to target tau at the mRNA level with 
anti-sense oligonucleotides [103]. Another is with therapeutic antibodies [104, 
105] or molecules that block tau translation [106]. As above, these approaches 
are being explored in pre-clinical programs. In the next sections, we focus on 
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another way to normalize tau homeostasis by targeting proteins that maintain its 
quality control.  
 
 
Figure 1.2 Possible mechanisms for restoring tau homeostasis. Tau homeostasis is defined as a product of 
its synthesis, its normal cycling on microtubules, its chaperone-mediated clearance, its aggregation and its 
spreading from cell-to-cell. Each of these stages of tau’s life cycle is a potential site of pharmacological 
intervention. The goal would be to normalize tau homeostasis and re-balancing its levels. 
 
1.8 Molecular chaperones regulate tau homeostasis 
The molecular chaperone network consists of several chaperone systems, which 
intersect and work cooperatively to maintain protein homeostasis. Chaperones 
are particularly vital for maintenance of proper tau structure and function [107-
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109]. For example, Hsp90 and Hsp70 assist in proper tau assembly with the 
microtubule [110]. In addition, Hsp90 and Hsp70 can facilitate the clearance of 
toxic forms of tau by acting as scaffolding proteins for degradation pathways, 
including both the UPS and autophagy-lysosome pathways [111-115].  
 
1.9 The Hsp70 sub-network regulates tau stability  
The 70 kDa molecular chaperone, Hsp70, has two domains: a nucleotide-binding 
domain (NBD) responsible for binding and hydrolyzing ATP and a substrate-
binding domain (SBD) that interacts with clients (Figure 1.3), such as tau. The 
nucleotide-state of the NBD allosterically regulates substrate binding in the SBD 
[116]. Specifically, ATP binding causes the SBD to dock with the NBD, allowing 
clients to bind. Then, hydrolysis of ATP releases the SBD-NBD interaction, which 
causes a “lid” subdomain in the SBD to close on top of its clients [117]. The 
cycling of Hsp70 through these conformations is regulated by co-chaperones 
(Figure 1.3). J-proteins bind between the NBD and SBD to accelerate ATP 
hydrolysis [118], while nucleotide exchange factors (NEFs) bind the NBD and 
help release ADP [119]. Other co-chaperones for Hsp70 include the C-terminus 
of Hsc70 interacting protein (CHIP), which is an E3 ligase that adds ubiquitin 
chains to tau [81]. Overexpression of CHIP decreases tau levels [81, 82, 113], 
showing the dramatic effect of this system on tau homeostasis. Binding of tau to 
the Hsp70-CHIP complex leads to ubiquitin-mediated degradation of tau and 
subsequent prevention of tau aggregation [111, 120, 121]. Other co-chaperone 
interactions also regulate tau levels. For example, Bag-1 is a NEF for Hsp70 that, 
when over-expressed, increases total tau levels [122]. Knockdown of Bag-1 
decreases total tau, but, counter-intuitively, increases the levels of hyper-
phosphorylated tau [122]. Bag-1 also links the Hsp70 chaperone network to the 
UPS [123, 124], and may associate with Hsp70 client proteins to target them for 
degradation. Another Hsp70 NEF, Bag-2, promotes ubiquitin independent 
degradation of phosphorylated tau [125]. Thus, the fate of tau is partly 
determined by which NEF (i.e. Bag-1 vs. Bag-2) is associated with the Hsp70-tau 
complex. The J-proteins are also linked to controlling tau homeostasis. DnaJA1 
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is a co-chaperone that facilitates degradation of tau through the UPS [126]. 
Likewise, overexpression of DnaJB1 and DnaJB2 also reduce tau levels in an 
Hsp70 dependent manner [127]. Finally, Hsp70 isoforms can have distinct effects 
on tau stability [33]. Hsc70 (HSPA8), the cytosolic paralog, partitions tau onto 
microtubules [33, 128]. In contrast, Hsp72 (HSPA1A), the closely related and 
stress inducible paralog, promotes tau dissociation from microtubules and its 
trafficking to the proteasome [33]. This result is highly surprising, as Hsc70 and 
Hsp72 are nearly identical, yet subtle differences in their C-terminal domains 
appears to dictate diametrically opposed activities, as revealed by chimeric 
proteins [33]. 
 
Figure 1.3 Hsp70 ATPase cycle is regulated by co-chaperones. J-proteins and NEFs facilitate ATP 
hydrolysis and ADP release respectively. Co-chaperones like CHIP, when bound to the C-terminus of 
Hsp70, lead to ubiquitination of Hsp70 substrates. 
In many ways Hsp70 acts as a scaffold, which binds tau and uses co-chaperone 
PPIs to shuttle it to either degradation or retention pathways. Accordingly, a key 
interaction for tau homeostasis is its direct binding to Hsp70s. There are multiple 
binding sites for Hsc70 and Hsp72 on tau. Peptide microarray experiments and 
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mutations have shown that Hsp70s bind three sites in or near the MTBRs and an 
additional site in the N-terminus [129, 130]. The N-terminal tau binding site is 
specific for Hsp72 and may contribute to the selective pro-degradation effects of 
this isoform on tau [129]. NMR results confirm that Hsp70 binds two short 
sequences of 4R0N tau in the second and third repeat regions, specifically the 
aggregation motifs 275VQIINK280 and 306VQIVYK311 [33]. Binding of Hsp70s to 
these hydrophobic, repeat domains suggests that they may work to prevent tau 
aggregation by sequestering free tau that has been released from the 
microtubule. In other words, tau aggregation may be suppressed by being bound 
to either microtubules or Hsp70s. Indeed, Hsp70 can block tau aggregation in 
vitro [131].   
 
Figure 1.4 Focus on the molecular chaperones, Hsp70 and Hsp90, that are important for tau homeostasis. 
(A) Hsp70 and (B) Hsp90 are shown, along with a sampling of the co-chaperones and chemical inhibitors 
discussed in the text. Together, these systems coordinate tau quality control. Chemicals that inhibit specific 
aspects of chaperone function have been shown to promote tau turnover. 
1.9.1 Modulators of Hsp70 and their effects on tau stability 
In part, the central role of Hsp70 in tau homeostasis has been clarified and 
revealed through the use of small molecule agonists and antagonists. This 
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“chemical biology” approach is based on the idea that perturbing the function of 
Hsp70 and its PPIs with co-chaperones might be a powerful way to find drug 
targets within the Hsp70 sub-network. This concept is illustrated by recent 
studies using the rhodacyanine MKT-077 and its analogs (Figure 1.4A). These 
compounds bind the NBD of Hsp70 [132] and allosterically decouple NEF 
interactions [133, 134]. Treatment with these molecules reduces the levels of 
phosphorylated tau in multiple cellular models of tauopathy [127, 135]. Treatment 
with one analog, YM-01, also reduces tau levels in brain slices from rTg4510 tau 
transgenic mice and restores normal long-term potentiation (LTP) [127]. The 
same molecule has no effect on wild type tau from normal mice and, in cell 
models, YM-01 has preferential activity against hyper-phosphorylated tau. 
However, if the microtubule network is chemically disrupted, YM-01 is now able 
to effectively reduce even wild type tau. Together, these results suggest that 
Hsp70 only acts on tau that is dissociated from microtubules, consistent with the 
known binding site of the chaperone. This is an important distinction because 
eventual clinical use of an Hsp70 agonist might depend on the safe and selective 
activity on only abnormal, and not functional, tau. In Chapter 2, I describe my 
efforts to describe the molecular mechanisms by which YM-01 and its analogs 
promote clearance of tau through Hsp70 and in Chapter 4, I further explore the 
paralogs of Hsp70 that are responsible for the compound’s activity. 
 
Beyond these compounds, other modulators of the Hsp70 multi-protein system 
have been described [136, 137]. Of note, the flavonoid-based natural product 
myricetin reduces tau levels through inhibition of Hsp70 interactions with J-
proteins [136, 138]. In contrast, the dihydropyrimidines SW-02 and 115-7c 
activated Hsp70 ATPase turnover, which resulted in an increase in total tau 
levels in vivo [136, 137]. Interestingly, additional neurodegenerative markers 
such as alpha-synuclein and TDP-43 were not sensitive to treatment with Hsp70 
modulators, indicating that chemical manipulation of Hsp70 can selectively target 
tau without necessarily interrupting homeostasis of other proteins [136].  
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1.9.2 Hsp90 and its co-chaperones regulate tau stability  
Hsp90 is another molecular chaperone that tightly controls tau fate [139]. Hsp90 
is a homodimer with each protomer consisting of three domains: an N-terminal 
ATP-binding domain (NTD), a middle domain (MD) for binding client proteins and 
a C-terminal domain (CTD), which stabilizes Hsp90 dimer formation (Figure 
1.4.B). Like Hsp70, Hsp90 has an ATPase cycle that is regulated by co-
chaperones, which direct conformational changes between open and closed 
states of Hsp90 [140]. The co-chaperone Aha1 binds the MD of Hsp90 and 
increases ATP hydrolysis through stabilization of the closed ATP-bound state of 
Hsp90 [140, 141]. The NTD binding co-chaperone p23 also stabilizes the closed 
state of Hsp90 and traps substrate clients while accelerating ATP hydrolysis 
[142]. In the closed ATP state, Hsp90 has a high affinity for its substrates. These 
trapped client proteins can then be modified by Hsp90 co-chaperones to initiate 
refolding or degradation, and upon ATP hydrolysis, substrates are released from 
the MD. For example, Hsp90 and CHIP coordinate to ubiquitinate phosphorylated 
tau, like the Hsp70-CHIP complex, leading to its degradation by the UPS [143]. 
Another co-chaperone, Cdc37, inhibits Hsp90 ATPase activity through binding to 
the NTD and MD and delaying the formation of the closed state of Hsp90, a rate-
limiting step of the ATPase cycle [144]. Hsp90 and its co-chaperones have been 
linked to tau proteostasis through promotion of tau degradation as well as tau 
“refolding” (e.g. re-binding to microtubules). Knockdown of Aha1, p23 or Cdc37 
decreases both total and phospho-tau levels [143, 145]. Upregulation of Cdc37 
preserves total tau and phospho-tau but has no effect on alpha-synuclein [146]. 
Cdc37 localizes kinases important for tau phosphorylation to the Hsp90-tau 
complex; therefore, it is not surprising that changes in expression of this co-
chaperone have dramatic effects on tau retention and clearance. Similarly, the 
Hsp90 co-chaperone, FKBP51, stabilizes tau and promotes its aggregation by 
preventing CHIP-mediated ubiquitination [147]. FKBP52 is another Hsp90 co-
chaperone close in structure and function to FKBP51; however, this co-
chaperone preferentially binds phospho-tau and prevents it accumulation in vivo 
[148]. The differential effects of co-chaperones on Hsp90-tau complexes 
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emphasizes that the outcome of client interactions are dependent on which co-
chaperones are bound [149]. This model further supports the idea that targeting 
specific chaperone PPIs may be the most tunable approach to removing distinct, 
abnormal pools of tau.  
 
The Hsp90 network is linked to the Hsp70 network through the shared co-
chaperone, HOP. Hsp90 and Hsp70 form well characterized complexes with 
HOP, which allow for the exchange of substrate clients between these protein 
networks [150, 151]. In the case of tau, it is reported that tau can be transferred 
from Hsp70 to Hsp90 before its degradation [129, 152]. The Hsp90 binding site 
on 4R0N tau consists of the entire MTBR which overlaps with the two Hsp70 
binding sites in the 3R and 4R repeat domains, suggesting that these 
chaperones likely do not bind tau simultaneously [32, 129]. Interestingly, transfer 
of tau between Hsp70 and Hsp90 may also facilitate tau refolding, as 
overexpression of HOP has been shown to increase levels of both total tau and 
phospho-tau [145].  
 
1.9.3 Inhibitors of Hsp90 clear tau 
Inhibitors of Hsp90, such as PU24FCl, bind to the NTD and compete with 
nucleotide. [153]. Treatment with PU24FCl reduces hyper-phosphorylated tau 
and insoluble tau in cellular models [143, 154] while no effect is seen on normal 
tau [154], suggesting that Hsp90 and its co-chaperones preferentially act on 
abnormal tau. Another competitive inhibitor of Hsp90, 17-(allyllamino)-17-
demethoxygeldanamycin (17AAG), also reduces P301L tau levels [154], so this 
effect seems to occur independent of chemotype (Figure 1.4B). Hsp90 inhibitors 
are being explored in numerous clinical trials for cancer [155, 156], so there is 
some possibility that the compounds might be suitable for eventual exploration in 
tauopathies.  However, such an approach would likely require a more chronic 
dosing schedule and the safety of long-term chaperone manipulation is 
uncertain.  
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Another distinct class of Hsp90 inhibitors, including novobiocin, bind to the CTD 
instead of the NTD [157]. Upon binding to Hsp90, novobiocin prevents 
dimerization of the CTDs and stalls the Hsp90 cycle by a unique mechanism 
[158]. Novobiocin analogues and other CTD-binding small molecules have been 
developed [159] and shown to reduce tau levels in cellular models [160, 161]. It 
is worth making the distinction between N- and C-terminal Hsp90 inhibitors 
because the C-terminal inhibitors do not seem to activate a stress response 
[162]. It isn’t yet clear how a stress response might contribute to the activity of 
Hsp90 inhibitors, but the pharmacological tools to ask this question are becoming 
available.  
 
1.10 Other pathways for reducing tau levels 
Although Hsp70 and Hsp90 may be the best-studied tau-binding partners, there 
are many other possible targets in the proteostasis network. The goal in any of 
these approaches is to reduce the accumulation of aberrant tau (e.g. hyper-
phosphorylated, free from microtubules, etc). It isn’t yet clear whether these 
strategies necessarily need to spare normal tau (e.g. microtubule-bound), but this 
remains an important consideration in any drug discovery strategy. In the next 
sections, we introduce some of the most likely, emerging targets, which (in most 
cases) have more speculative links to tau quality control. 
 
1.10.1 Hsp27 
Hsp27 is a small heat shock protein that interacts with client proteins, including 
tau, as part of a multi-protein oligomer [163]. Upon stress-induced 
phosphorylation, Hsp27 disassembles from larger oligomers into smaller 
complexes, which seem to be potent chaperones for IDPs [164]. Indeed, Hsp27 
preferentially binds phosphorylated tau in AD brain homogenates and neuronal 
cell models, and this chaperone is correlated with its dephosphorylation and 
degradation [165]. Overexpression of Hsp27 reduces tau fibril formation and 
restores long-term-potentiation in a transgenic mouse model expressing mutant 
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P301L tau [166, 167]. However, a gap in our understanding of this system is how 
phosphorylation regulates Hsp27 client binding. Moreover, small molecule 
activators of this system have not been described. However, this goal seems 
worthwhile because Hsp27 levels are increased 20% in AD brains [168]. 
 
1.10.2 PPIases 
Peptidyl-prolyl isomerases (PPIases) are another class of co-chaperones known 
to effect tau homeostasis by catalyzing the isomerization of proline residues 
[169]. One major protein in this class, Pin1, is highly expressed in neurons and is 
implicated in amyloid β pathology [170] and tauopathies like FTDP-17 and AD 
[171, 172]. Pin1 binds tau phosphorylated at several major phosphorylation sites 
and localizes with NFTs in AD brains [172, 173]. Upon binding to phospho-tau, 
specifically pT231, Pin1 converts cis-prolines preceding phosphorylated serine 
and threonine residues into trans-prolines [174]. Cis-tau accumulates and 
aggregates in AD brains and is unable to polymerize microtubules [174]. As a 
result, Pin1 conversion of cis-tau to trans-tau restores microtubule assembly 
[173, 175], highlighting the significant role of Pin1 in maintaining cis-trans tau 
homeostasis. Pin1 expression is reduced in AD brains [173]; therefore, 
normalizing expression of Pin1 may be one therapeutic strategy to prevent the 
accumulation of hyperphosphorylated tau.  
 
1.10.3 Clusterin 
Genome wide association studies have implicated the molecular chaperone, 
clusterin, in AD [176, 177]. This chaperone, which is highly expressed in 
neurons, especially in AD and PD patients, is reported to promote amyloid beta 
pathology and is correlated with the deposition of amyloid beta fibrils [178]. 
Clusterin has also been linked to tau pathology due to elevated levels of 
intracellular clusterin in transgenic tau mouse models [179]. While there is clinical 
evidence to suggest that clusterin plays a critical role in AD, the molecular 
biology of this protein and its effects on tau remain unknown. One possible 
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explanation for clusterin’s role in amyloid beta and tau pathology is that, in 
addition to modulating apoptosis and cell signaling pathways, clusterin is also a 
member of the autophagy/beclin-1 interactome [180]. It will be interesting to see 
if chemical probes targeting clusterin can be developed to aid in understanding 
how this protein regulates tau pathology.   
 
1.10.4 HDAC6  
Histone deacetylase 6 (HDAC6) is another key partner for tau that directly 
impacts its homeostasis, especially after inhibition of the proteasome [181]. 
HDAC6 plays an important role in autophagic clearance of tau, and HDAC6 
inhibitors lead to increased tau acetylation and aggregation [182, 183]. However, 
to illustrate the delicate balance required for proper tau homeostasis, inhibition of 
HDAC6 actually reduced phospho-tau in some models [88, 184, 185], likely 
because of competition between acetylation and phosphorylation [88].  
 
1.10.5 Autophagy and UPS targets 
Chaperone-mediated autophagy (CMA) and the ubiquitin-proteasome system 
(UPS) are the major clearance pathways for removing tau [112, 115, 186]. 
Consistent with this idea, activation of autophagy by rapamycin reduces tau 
phosphorylation and tau tangle formation in cellular models of tauopathy as well 
as P301S tau transgenic mice [186, 187]. Rapamycin treatment also reduces 
phosphorylation of tau by the kinase GSK3β (glycogen synthase kinase 3 beta), 
highlighting the possibility that combinations of autophagy activators with kinase 
inhibitors may be effective at reducing the levels of hyperphosphorylated tau 
[187]. To accelerate clearance through the UPS, one enticing idea is to activate 
the proteasome with UPS14 inhibitors [188]. USP14 is a deubiquitinating enzyme 
that dampens turnover of proteasome substrates. Therefore, inhibitors of USP14 
might be expected to re-balance tau homeostasis. In both the autophagy and 
UPS cases, specific targets would be expected to counter-act the age-dependent 
loss of clearance capacity, perhaps normalizing tau levels.  
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1.11 The future of tau reduction therapies 
Tauopathies result from the failure of neurons to maintain proper tau 
homeostasis. Therefore, one approach to therapy may be to modulate targets 
that control the flux of tau (see Figure 1.2). As mentioned above, this goal might 
be achieved by blocking tau transcription or translation, preventing its 
aggregation or by accelerating its clearance using antibodies. An alternative 
approach is to target the host factors that normally regulate tau homeostasis to 
accelerate turnover of abnormal tau. However, the path forward for tau-based 
therapies remains at the pre-clinical stage. In our opinion, antibodies that bind to 
tau, especially phospho-tau and oligomeric tau, seem to offer the most 
immediate paths to clinical testing of the tau reduction hypothesis [189-191]. 
However, to overcome limitations associated with the cost and delivery of 
antibodies to the CNS, second-generation approaches might be focused on small 
molecule tau aggregation inhibitors and activators of chaperone-mediated tau 
turnover [192-194]. The major concern with these approaches will be safety 
because it is unclear whether any of them will be able to selectively reduce 
abnormal tau without causing proteostatic collapse.  
 
One of the best-characterized ways to reduce tau levels with small molecules is 
through analogs of MKT-077, as described above. These molecules are known 
to act through Hsp70 to promote the turnover of tau and tau variants. In addition, 
recent efforts in the Gestwicki laboratory have generated analogs, such as YM-
08, that have good blood-brain barrier permeability. While these results are 
promising, the mechanisms by which MKT-077 analogs activate turnover through 
Hsp70 are not known. In my thesis work, I explored this important question and, 
in Chapter 2, describe how MKT-077 analogs promote the interaction between 
Hsp70 and tau to stimulate turnover. In Chapter 3, I further characterize the 
paralogs of Hsp70 that are required for the activity of MKT-077 and its analogs. 
Together, these studies advance our knowledge of the role of Hsp70 in tau 
turnover and help validate it as a drug target for tauopathies.  
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Finally, a hallmark of tauopathy is the seeding and spreading of tau aggregation 
and pathology through the uptake of extracellular tau fibrils [195]. The 
mechanisms of cell-to-cell transmission remains unclear, but cell and animal 
models are in development [196-199], providing, for the first time, an opportunity 
to target proteins important in this process. Accordingly, a key part of Chapter 4 
is to describe my efforts in building new tauopathy models that are specifically 
geared towards studying these mechanisms. We predict that a better 
understanding of the mechanisms of spreading will reveal unexpected, new drug 
targets. These targets hold the currently unfulfilled promise of better selectivity 
and safety.  
 
Notes 
This chapter is based on a chapter in a book titled “Prion Diseases” which is in 
press at Cold Harbor Spring Laboratory Press. Zapporah Young, Sue Ann Mok 
and Jason Gestwicki contributed intellectually to this work.  
 
 
1.12 References 
 
[1] Ghetti B, Wszolek ZK, Boeve BF, Spina  S, Goedert M. Frontotemporal 
Dementia and Parkinsonism 
Linked to Chromosome 17. In: Dickson DW, Weller RO, ed.^eds., 
Neurodegeneration: The Molecular Pathology of Dementia and Movement 
Disorders, 2011. 
[2] Braak H, Braak E. Neuropathological stageing of Alzheimer-related 
changes. Acta Neuropathol, 1991; 82: 239-59. 
[3] Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, 
Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates 
amyloid beta-induced deficits in an Alzheimer's disease mouse model. 
Science, 2007; 316: 750-4. 
[4] Frost B, Hemberg M, Lewis J, Feany MB. Tau promotes 
neurodegeneration through global chromatin relaxation. Nat Neurosci, 
2014; 17: 357-66. 
[5] Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet 
Neurol, 2013; 12: 609-22. 
 21 
[6] Noble W, Hanger DP, Gallo JM. Transgenic mouse models of tauopathy in 
drug discovery. CNS Neurol Disord Drug Targets, 2010; 9: 403-28. 
[7] Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor 
essential for microtubule assembly. Proc Natl Acad Sci U S A, 1975; 72: 
1858-62. 
[8] Fanara P, Husted KH, Selle K, Wong PY, Banerjee J, Brandt R, 
Hellerstein MK. Changes in microtubule turnover accompany synaptic 
plasticity and memory formation in response to contextual fear 
conditioning in mice. Neuroscience, 2010; 168: 167-78. 
[9] Qiang L, Yu W, Andreadis A, Luo M, Baas PW. Tau protects microtubules 
in the axon from severing by katanin. J Neurosci, 2006; 26: 3120-9. 
[10] LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, Binder LI. 
Functional implications for the microtubule-associated protein tau: 
localization in oligodendrocytes. Proc Natl Acad Sci U S A, 1995; 92: 
10369-73. 
[11] Shin RW, Iwaki T, Kitamoto T, Tateishi J. Hydrated autoclave 
pretreatment enhances tau immunoreactivity in formalin-fixed normal and 
Alzheimer's disease brain tissues. Lab Invest, 1991; 64: 693-702. 
[12] Trojanowski JQ, Schuck T, Schmidt ML, Lee VM. Distribution of tau 
proteins in the normal human central and peripheral nervous system. J 
Histochem Cytochem, 1989; 37: 209-15. 
[13] Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the 
mammalian central nervous system. J Cell Biol, 1985; 101: 1371-8. 
[14] Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple 
isoforms of human microtubule-associated protein tau: sequences and 
localization in neurofibrillary tangles of Alzheimer's disease. Neuron, 1989; 
3: 519-26. 
[15] Mukrasch MD, Bibow S, Korukottu J, Jeganathan S, Biernat J, Griesinger 
C, Mandelkow E, Zweckstetter M. Structural polymorphism of 441-residue 
tau at single residue resolution. PLoS Biol, 2009; 7: e34. 
[16] Fauquant C, Redeker V, Landrieu I, Wieruszeski JM, Verdegem D, 
Laprevote O, Lippens G, Gigant B, Knossow M. Systematic identification 
of tubulin-interacting fragments of the microtubule-associated protein Tau 
leads to a highly efficient promoter of microtubule assembly. J Biol Chem, 
2011; 286: 33358-68. 
[17] Mukrasch MD, Biernat J, von Bergen M, Griesinger C, Mandelkow E, 
Zweckstetter M. Sites of tau important for aggregation populate {beta}-
structure and bind to microtubules and polyanions. J Biol Chem, 2005; 
280: 24978-86. 
[18] Sillen A, Barbier P, Landrieu I, Lefebvre S, Wieruszeski JM, Leroy A, 
Peyrot V, Lippens G. NMR investigation of the interaction between the 
neuronal protein tau and the microtubules. Biochemistry, 2007; 46: 3055-
64. 
[19] Goode BL, Chau M, Denis PE, Feinstein SC. Structural and functional 
differences between 3-repeat and 4-repeat tau isoforms. Implications for 
 22 
normal tau function and the onset of neurodegenetative disease. J Biol 
Chem, 2000; 275: 38182-9. 
[20] Goedert M, Jakes R. Expression of separate isoforms of human tau 
protein: correlation with the tau pattern in brain and effects on tubulin 
polymerization. EMBO J, 1990; 9: 4225-30. 
[21] Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein 
in neurofibrillary degeneration. Cold Spring Harb Perspect Med, 2012; 2: 
a006247. 
[22] Moraga DM, Nunez P, Garrido J, Maccioni RB. A tau fragment containing 
a repetitive sequence induces bundling of actin filaments. J Neurochem, 
1993; 61: 979-86. 
[23] Jancsik V, Filliol D, Rendon A. Tau proteins bind to kinesin and modulate 
its activation by microtubules. Neurobiology (Bp), 1996; 4: 417-29. 
[24] Seitz A, Kojima H, Oiwa K, Mandelkow EM, Song YH, Mandelkow E. 
Single-molecule investigation of the interference between kinesin, tau and 
MAP2c. EMBO J, 2002; 21: 4896-905. 
[25] Patterson KR, Ward SM, Combs B, Voss K, Kanaan NM, Morfini G, Brady 
ST, Gamblin TC, Binder LI. Heat shock protein 70 prevents both tau 
aggregation and the inhibitory effects of preexisting tau aggregates on fast 
axonal transport. Biochemistry, 2011; 50: 10300-10. 
[26] Magnani E, Fan J, Gasparini L, Golding M, Williams M, Schiavo G, 
Goedert M, Amos LA, Spillantini MG. Interaction of tau protein with the 
dynactin complex. EMBO J, 2007; 26: 4546-54. 
[27] Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow 
E. Overexpression of tau protein inhibits kinesin-dependent trafficking of 
vesicles, mitochondria, and endoplasmic reticulum: implications for 
Alzheimer's disease. J Cell Biol, 1998; 143: 777-94. 
[28] Ittner LM, Fath T, Ke YD, Bi M, van Eersel J, Li KM, Gunning P, Gotz J. 
Parkinsonism and impaired axonal transport in a mouse model of 
frontotemporal dementia. Proc Natl Acad Sci U S A, 2008; 105: 15997-
6002. 
[29] Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks 
traffic of organelles, neurofilaments, and APP vesicles in neurons and 
enhances oxidative stress. J Cell Biol, 2002; 156: 1051-63. 
[30] Reynolds CH, Garwood CJ, Wray S, Price C, Kellie S, Perera T, Zvelebil 
M, Yang A, Sheppard PW, Varndell IM, Hanger DP, Anderton BH. 
Phosphorylation regulates tau interactions with Src homology 3 domains 
of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src 
family kinases. J Biol Chem, 2008; 283: 18177-86. 
[31] Sharma VM, Litersky JM, Bhaskar K, Lee G. Tau impacts on growth-
factor-stimulated actin remodeling. J Cell Sci, 2007; 120: 748-57. 
[32] Karagoz GE, Duarte AM, Akoury E, Ippel H, Biernat J, Moran Luengo T, 
Radli M, Didenko T, Nordhues BA, Veprintsev DB, Dickey CA, Mandelkow 
E, Zweckstetter M, Boelens R, Madl T, Rudiger SG. Hsp90-Tau complex 
reveals molecular basis for specificity in chaperone action. Cell, 2014; 
156: 963-74. 
 23 
[33] Jinwal UK, Akoury E, Abisambra JF, O'Leary JC, 3rd, Thompson AD, Blair 
LJ, Jin Y, Bacon J, Nordhues BA, Cockman M, Zhang J, Li P, Zhang B, 
Borysov S, Uversky VN, Biernat J, Mandelkow E, Gestwicki JE, 
Zweckstetter M, Dickey CA. Imbalance of Hsp70 family variants fosters 
tau accumulation. FASEB J, 2013; 27: 1450-9. 
[34] Miyata Y, Koren J, Kiray J, Dickey Ca, Gestwicki JE. Molecular 
chaperones and regulation of tau quality control: strategies for drug 
discovery in tauopathies. Future medicinal chemistry, 2011; 3: 1523-37. 
[35] von Bergen M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM, 
Mandelkow E. Mutations of tau protein in frontotemporal dementia 
promote aggregation of paired helical filaments by enhancing local beta-
structure. J Biol Chem, 2001; 276: 48165-74. 
[36] von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, 
Mandelkow E. Assembly of tau protein into Alzheimer paired helical 
filaments depends on a local sequence motif ((306)VQIVYK(311)) forming 
beta structure. Proc Natl Acad Sci U S A, 2000; 97: 5129-34. 
[37] Goux WJ, Kopplin L, Nguyen AD, Leak K, Rutkofsky M, 
Shanmuganandam VD, Sharma D, Inouye H, Kirschner DA. The formation 
of straight and twisted filaments from short tau peptides. J Biol Chem, 
2004; 279: 26868-75. 
[38] Barghorn S, Mandelkow E. Toward a unified scheme for the aggregation 
of tau into Alzheimer paired helical filaments. Biochemistry, 2002; 41: 
14885-96. 
[39] Chirita CN, Necula M, Kuret J. Anionic micelles and vesicles induce tau 
fibrillization in vitro. J Biol Chem, 2003; 278: 25644-50. 
[40] Friedhoff P, Schneider A, Mandelkow EM, Mandelkow E. Rapid assembly 
of Alzheimer-like paired helical filaments from microtubule-associated 
protein tau monitored by fluorescence in solution. Biochemistry, 1998; 37: 
10223-30. 
[41] Kampers T, Friedhoff P, Biernat J, Mandelkow EM, Mandelkow E. RNA 
stimulates aggregation of microtubule-associated protein tau into 
Alzheimer-like paired helical filaments. FEBS Lett, 1996; 399: 344-9. 
[42] Gerson JE, Sengupta U, Lasagna-Reeves CA, Guerrero-Munoz MJ, 
Troncoso J, Kayed R. Characterization of tau oligomeric seeds in 
progressive supranuclear palsy. Acta Neuropathol Commun, 2014; 2: 73. 
[43] Maeda S, Sahara N, Saito Y, Murayama M, Yoshiike Y, Kim H, Miyasaka 
T, Murayama S, Ikai A, Takashima A. Granular tau oligomers as 
intermediates of tau filaments. Biochemistry, 2007; 46: 3856-61. 
[44] Flach K, Hilbrich I, Schiffmann A, Gartner U, Kruger M, Leonhardt M, 
Waschipky H, Wick L, Arendt T, Holzer M. Tau oligomers impair artificial 
membrane integrity and cellular viability. J Biol Chem, 2012; 287: 43223-
33. 
[45] Castillo-Carranza DL, Guerrero-Munoz MJ, Sengupta U, Hernandez C, 
Barrett AD, Dineley K, Kayed R. Tau immunotherapy modulates both 
pathological tau and upstream amyloid pathology in an Alzheimer's 
disease mouse model. J Neurosci, 2015; 35: 4857-68. 
 24 
[46] Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves 
CA, Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, 
Kayed R. Passive immunization with Tau oligomer monoclonal antibody 
reverses tauopathy phenotypes without affecting hyperphosphorylated 
neurofibrillary tangles. J Neurosci, 2014; 34: 4260-72. 
[47] Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, 
Probst A, Winkler DT, Reichwald J, Staufenbiel M, Ghetti B, Goedert M, 
Tolnay M. Brain homogenates from human tauopathies induce tau 
inclusions in mouse brain. Proc Natl Acad Sci U S A, 2013; 110: 9535-40. 
[48] de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, 
Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones 
TL, Hyman BT. Propagation of tau pathology in a model of early 
Alzheimer's disease. Neuron, 2012; 73: 685-97. 
[49] Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz 
MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R. Alzheimer brain-
derived tau oligomers propagate pathology from endogenous tau. Sci 
Rep, 2012; 2: 700. 
[50] Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-
synaptic spread of tau pathology in vivo. PLoS One, 2012; 7: e31302. 
[51] Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M. 
Invited review: Frontotemporal dementia caused by microtubule-
associated protein tau gene (MAPT) mutations: a chameleon for 
neuropathology and neuroimaging. Neuropathol Appl Neurobiol, 2015; 41: 
24-46. 
[52] Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-
Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R, Lane JR, Karydas AM, 
Kenet RO, Biernat J, Wang LS, Cotman CW, Decarli CS, Levey AI, 
Ringman JM, Mendez MF, Chui HC, Le Ber I, Brice A, Lupton MK, Preza 
E, Lovestone S, Powell J, Graff-Radford N, Petersen RC, Boeve BF, Lippa 
CF, Bigio EH, Mackenzie I, Finger E, Kertesz A, Caselli RJ, Gearing M, 
Juncos JL, Ghetti B, Spina S, Bordelon YM, Tourtellotte WW, Frosch MP, 
Vonsattel JP, Zarow C, Beach TG, Albin RL, Lieberman AP, Lee VM, 
Trojanowski JQ, Van Deerlin VM, Bird TD, Galasko DR, Masliah E, White 
CL, Troncoso JC, Hannequin D, Boxer AL, Geschwind MD, Kumar S, 
Mandelkow EM, Wszolek ZK, Uitti RJ, Dickson DW, Haines JL, Mayeux R, 
Pericak-Vance MA, Farrer LA, Alzheimer's Disease Genetics C, Ross OA, 
Rademakers R, Schellenberg GD, Miller BL, Mandelkow E, Geschwind 
DH. Evidence for a role of the rare p.A152T variant in MAPT in increasing 
the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet, 
2012; 21: 3500-12. 
[53] Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy 
J, Lynch T, Bigio E, Hutton M. Association of an extended haplotype in the 
tau gene with progressive supranuclear palsy. Hum Mol Genet, 1999; 8: 
711-5. 
[54] Niblock M, Gallo JM. Tau alternative splicing in familial and sporadic 
tauopathies. Biochem Soc Trans, 2012; 40: 677-80. 
 25 
[55] Qian W, Liu F. Regulation of alternative splicing of tau exon 10. Neurosci 
Bull, 2014; 30: 367-77. 
[56] Panda D, Samuel JC, Massie M, Feinstein SC, Wilson L. Differential 
regulation of microtubule dynamics by three- and four-repeat tau: 
implications for the onset of neurodegenerative disease. Proc Natl Acad 
Sci U S A, 2003; 100: 9548-53. 
[57] Adams SJ, DeTure MA, McBride M, Dickson DW, Petrucelli L. Three 
repeat isoforms of tau inhibit assembly of four repeat tau filaments. PLoS 
One, 2010; 5: e10810. 
[58] Barghorn S, Zheng-Fischhofer Q, Ackmann M, Biernat J, von Bergen M, 
Mandelkow EM, Mandelkow E. Structure, microtubule interactions, and 
paired helical filament aggregation by tau mutants of frontotemporal 
dementias. Biochemistry, 2000; 39: 11714-21. 
[59] Beharry C, Cohen LS, Di J, Ibrahim K, Briffa-Mirabella S, Alonso Adel C. 
Tau-induced neurodegeneration: mechanisms and targets. Neurosci Bull, 
2014; 30: 346-58. 
[60] Chang E, Kim S, Yin H, Nagaraja HN, Kuret J. Pathogenic missense 
MAPT mutations differentially modulate tau aggregation propensity at 
nucleation and extension steps. J Neurochem, 2008; 107: 1113-23. 
[61] Combs B, Gamblin TC. FTDP-17 tau mutations induce distinct effects on 
aggregation and microtubule interactions. Biochemistry, 2012; 51: 8597-
607. 
[62] Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L, Miller 
BI, Geschwind DH, Bird TD, McKeel D, Goate A, Morris JC, Wilhelmsen 
KC, Schellenberg GD, Trojanowski JQ, Lee VM. Mutation-specific 
functional impairments in distinct tau isoforms of hereditary FTDP-17. 
Science, 1998; 282: 1914-7. 
[63] Ghetti B, Wszolek ZK, Boeve BF, Spina S, Goedert M. Frontotemporal 
Dementia and Parkinsonism Linked to Chromosome 17. In: Dickson DW, 
Weller RO, ed.^eds., Neurodegeneration: The Molecular Pathology of 
Dementia and Movement Disorders, 2011. 
[64] Bugiani O, Murrell JR, Giaccone G, Hasegawa M, Ghigo G, Tabaton M, 
Morbin M, Primavera A, Carella F, Solaro C, Grisoli M, Savoiardo M, 
Spillantini MG, Tagliavini F, Goedert M, Ghetti B. Frontotemporal 
dementia and corticobasal degeneration in a family with a P301S mutation 
in tau. J Neuropathol Exp Neurol, 1999; 58: 667-77. 
[65] Reed LA, Wszolek ZK, Hutton M. Phenotypic correlations in FTDP-17. 
Neurobiol Aging, 2001; 22: 89-107. 
[66] Saito Y, Geyer A, Sasaki R, Kuzuhara S, Nanba E, Miyasaka T, Suzuki K, 
Murayama S. Early-onset, rapidly progressive familial tauopathy with 
R406W mutation. Neurology, 2002; 58: 811-3. 
[67] Martin L, Latypova X, Terro F. Post-translational modifications of tau 
protein: implications for Alzheimer's disease. Neurochem Int, 2011; 58: 
458-71. 
[68] Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A, Burlingame 
AL, Mucke L. Tau post-translational modifications in wild-type and human 
 26 
amyloid precursor protein transgenic mice. Nat Neurosci, 2015; 18: 1183-
9. 
[69] Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I. 
Microtubule-associated protein tau. Abnormal phosphorylation of a non-
paired helical filament pool in Alzheimer disease. J Biol Chem, 1993; 268: 
24374-84. 
[70] Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau 
phosphorylation sites correlate with severity of neuronal cytopathology in 
Alzheimer's disease. Acta Neuropathol, 2002; 103: 26-35. 
[71] Mercken M, Vandermeeren M, Lubke U, Six J, Boons J, Van de Voorde A, 
Martin JJ, Gheuens J. Monoclonal antibodies with selective specificity for 
Alzheimer Tau are directed against phosphatase-sensitive epitopes. Acta 
Neuropathol, 1992; 84: 265-72. 
[72] Kenessey A, Yen SH. The extent of phosphorylation of fetal tau is 
comparable to that of PHF-tau from Alzheimer paired helical filaments. 
Brain Res, 1993; 629: 40-6. 
[73] Arendt T, Stieler J, Strijkstra AM, Hut RA, Rudiger J, Van der Zee EA, 
Harkany T, Holzer M, Hartig W. Reversible paired helical filament-like 
phosphorylation of tau is an adaptive process associated with neuronal 
plasticity in hibernating animals. J Neurosci, 2003; 23: 6972-81. 
[74] Tepper K, Biernat J, Kumar S, Wegmann S, Timm T, Hubschmann S, 
Redecke L, Mandelkow EM, Muller DJ, Mandelkow E. Oligomer formation 
of tau protein hyperphosphorylated in cells. J Biol Chem, 2014; 289: 
34389-407. 
[75] Hoglinger GU, Huppertz HJ, Wagenpfeil S, Andres MV, Belloch V, Leon T, 
Del Ser T, Investigators TM. Tideglusib reduces progression of brain 
atrophy in progressive supranuclear palsy in a randomized trial. Mov 
Disord, 2014; 29: 479-87. 
[76] Kimura T, Ishiguro K, Hisanaga S. Physiological and pathological 
phosphorylation of tau by Cdk5. Front Mol Neurosci, 2014; 7: 65. 
[77] Nygaard HB, van Dyck CH, Strittmatter SM. Fyn kinase inhibition as a 
novel therapy for Alzheimer's disease. Alzheimers Res Ther, 2014; 6: 8. 
[78] Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, 
Williamson R, Fuchs M, Kohler A, Glossmann H, Schneider R, Sutherland 
C, Schweiger S. Biguanide metformin acts on tau phosphorylation via 
mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S 
A, 2010; 107: 21830-5. 
[79] Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein 
phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau 
phosphorylation. Eur J Neurosci, 2005; 22: 1942-50. 
[80] van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Gotz J, Ittner LM. Sodium 
selenate mitigates tau pathology, neurodegeneration, and functional 
deficits in Alzheimer's disease models. Proc Natl Acad Sci U S A, 2010; 
107: 13888-93. 
[81] Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee WC, Zehr C, 
West G, Cao S, Clark AM, Caldwell GA, Caldwell KA, Eckman C, 
 27 
Patterson C, Hutton M, Petrucelli L. Deletion of the ubiquitin ligase CHIP 
leads to the accumulation, but not the aggregation, of both endogenous 
phospho- and caspase-3-cleaved tau species. J Neurosci, 2006; 26: 6985-
96. 
[82] Sahara N, Murayama M, Mizoroki T, Urushitani M, Imai Y, Takahashi R, 
Murata S, Tanaka K, Takashima A. In vivo evidence of CHIP up-regulation 
attenuating tau aggregation. Journal of Neurochemistry, 2005; 94: 1254-
1263. 
[83] Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, Yang AJ. Alzheimer 
disease-specific conformation of hyperphosphorylated paired helical 
filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 
ubiquitin conjugation. J Biol Chem, 2006; 281: 10825-38. 
[84] Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K, 
Ihara Y. Ubiquitin is conjugated with amino-terminally processed tau in 
paired helical filaments. Neuron, 1993; 10: 1151-60. 
[85] Thomas SN, Funk KE, Wan Y, Liao Z, Davies P, Kuret J, Yang AJ. Dual 
modification of Alzheimer's disease PHF-tau protein by lysine methylation 
and ubiquitylation: a mass spectrometry approach. Acta Neuropathol, 
2012; 123: 105-17. 
[86] Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VM, 
Trojanowski JQ. Acetylated tau, a novel pathological signature in 
Alzheimer's disease and other tauopathies. Brain, 2012; 135: 807-18. 
[87] Grinberg LT, Wang X, Wang C, Sohn PD, Theofilas P, Sidhu M, Arevalo 
JB, Heinsen H, Huang EJ, Rosen H, Miller BL, Gan L, Seeley WW. 
Argyrophilic grain disease differs from other tauopathies by lacking tau 
acetylation. Acta Neuropathol, 2013; 125: 581-93. 
[88] Cook C, Carlomagno Y, Gendron TF, Dunmore J, Scheffel K, Stetler C, 
Davis M, Dickson D, Jarpe M, DeTure M, Petrucelli L. Acetylation of the 
KXGS motifs in tau is a critical determinant in modulation of tau 
aggregation and clearance. Human Molecular Genetics, 2014; 23: 104-
116. 
[89] Basurto-Islas G, Luna-Munoz J, Guillozet-Bongaarts AL, Binder LI, Mena 
R, Garcia-Sierra F. Accumulation of aspartic acid421- and glutamic 
acid391-cleaved tau in neurofibrillary tangles correlates with progression 
in Alzheimer disease. J Neuropathol Exp Neurol, 2008; 67: 470-83. 
[90] Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, 
Carroll CA, Weintraub ST, Bennett DA, Cryns VL, Berry RW, Binder LI. 
Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's 
disease. J Neurosci, 2004; 24: 7895-902. 
[91] Fasulo L, Ugolini G, Visintin M, Bradbury A, Brancolini C, Verzillo V, 
Novak M, Cattaneo A. The neuronal microtubule-associated protein tau is 
a substrate for caspase-3 and an effector of apoptosis. J Neurochem, 
2000; 75: 624-33. 
[92] Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, 
Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, 
Cryns VL. Caspase cleavage of tau: linking amyloid and neurofibrillary 
 28 
tangles in Alzheimer's disease. Proc Natl Acad Sci U S A, 2003; 100: 
10032-7. 
[93] Ding H, Matthews TA, Johnson GV. Site-specific phosphorylation and 
caspase cleavage differentially impact tau-microtubule interactions and 
tau aggregation. J Biol Chem, 2006; 281: 19107-14. 
[94] Dolan PJ, Johnson GV. A caspase cleaved form of tau is preferentially 
degraded through the autophagy pathway. J Biol Chem, 2010; 285: 
21978-87. 
[95] Quintanilla RA, Matthews-Roberson TA, Dolan PJ, Johnson GV. Caspase-
cleaved tau expression induces mitochondrial dysfunction in immortalized 
cortical neurons: implications for the pathogenesis of Alzheimer disease. J 
Biol Chem, 2009; 284: 18754-66. 
[96] Plouffe V, Mohamed NV, Rivest-McGraw J, Bertrand J, Lauzon M, Leclerc 
N. Hyperphosphorylation and cleavage at D421 enhance tau secretion. 
PLoS One, 2012; 7: e36873. 
[97] Ramcharitar J, Albrecht S, Afonso VM, Kaushal V, Bennett DA, Leblanc 
AC. Cerebrospinal fluid tau cleaved by caspase-6 reflects brain levels and 
cognition in aging and Alzheimer disease. J Neuropathol Exp Neurol, 
2013; 72: 824-32. 
[98] Funk KE, Thomas SN, Schafer KN, Cooper GL, Liao Z, Clark DJ, Yang 
AJ, Kuret J. Lysine methylation is an endogenous post-translational 
modification of tau protein in human brain and a modulator of aggregation 
propensity. Biochem J, 2014; 462: 77-88. 
[99] Alonso Adel C, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K. 
Promotion of hyperphosphorylation by frontotemporal dementia tau 
mutations. J Biol Chem, 2004; 279: 34873-81. 
[100] Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E. Tau protein and tau 
aggregation inhibitors. Neuropharmacology, 2010; 59: 276-89. 
[101] Brunden KR, Yao Y, Potuzak JS, Ferrer NI, Ballatore C, James MJ, 
Hogan AM, Trojanowski JQ, Smith AB, 3rd, Lee VM. The characterization 
of microtubule-stabilizing drugs as possible therapeutic agents for 
Alzheimer's disease and related tauopathies. Pharmacol Res, 2011; 63: 
341-51. 
[102] Morris M, Hamto P, Adame A, Devidze N, Masliah E, Mucke L. Age-
appropriate cognition and subtle dopamine-independent motor deficits in 
aged tau knockout mice. Neurobiol Aging, 2013; 34: 1523-9. 
[103] DeVos SL, Goncharoff DK, Chen G, Kebodeaux CS, Yamada K, Stewart 
FR, Schuler DR, Maloney SE, Wozniak DF, Rigo F, Bennett CF, Cirrito 
JR, Holtzman DM, Miller TM. Antisense reduction of tau in adult mice 
protects against seizures. J Neurosci, 2013; 33: 12887-97. 
[104] Sigurdsson EM. Immunotherapy targeting pathological tau protein in 
Alzheimer's disease and related tauopathies. Journal of Alzheimer's 
disease : JAD, 2008; 15: 157-68. 
[105] Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, 
Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M. Passive 
immunization with anti-Tau antibodies in two transgenic models: reduction 
 29 
of Tau pathology and delay of disease progression. J Biol Chem, 2011; 
286: 34457-67. 
[106] Lee VMY, Brunden KR, Hutton M, Trojanowski JQ. Developing 
Therapeutic Approaches to Tau, Selected Kinases, and Related Neuronal 
Protein Targets. Cold Spring Harbor Perspectives in Medicine:, 2011; 1: 
a006437. 
[107] Patury S, Miyata Y, Gestwicki JE. Pharmacological Targeting of the Hsp70 
Chaperone. Current topics in medicinal chemistry, 2009; 9: 1337-51. 
[108] Gestwicki JE, Garza D. Protein quality control in neurodegenerative 
disease. Progress in molecular biology and translational science, 2012; 
107: 327-53. 
[109] Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP. Targeting 
Hsp90/Hsp70-Based Protein Quality Control for Treatment of Adult Onset 
Neurodegenerative Diseases. Annual Review of Pharmacology and 
Toxicology, 2015; 55: 353-371. 
[110] Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, 
Greengard P, Xu H. Chaperones increase association of tau protein with 
microtubules. Proc Natl Acad Sci U S A, 2003; 100: 721-6. 
[111] Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia 
M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall 
A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M. CHIP 
and Hsp70 regulate tau ubiquitination, degradation and aggregation. 
Human molecular genetics, 2004; 13: 703-14. 
[112] Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow 
EM, Cuervo AM, Mandelkow E. Tau fragmentation, aggregation and 
clearance: the dual role of lysosomal processing. Hum Mol Genet, 2009; 
18: 4153-70. 
[113] Dickey CA, Koren J, Zhang YJ, Xu YF, Jinwal UK, Birnbaum MJ, Monks 
B, Sun M, Cheng AQ, Pattersonl C, Bailey RM, Dunmore J, Soresh S, 
Leon C, Morgan D, Petrucelli L. Akt and CHIP coregulate tau degradation 
through coordinated interactions. Proceedings of the National Academy of 
Sciences of the United States of America, 2008; 105: 3622-3627. 
[114] Kruger U, Wang Y, Kumar S, Mandelkow EM. Autophagic degradation of 
tau in primary neurons and its enhancement by trehalose. Neurobiol 
Aging, 2012; 33: 2291-305. 
[115] Wong ESP, Tan JMM, Soong W-E, Hussein K, Nukina N, Dawson VL, 
Dawson TM, Cuervo AM, Lim K-L. Autophagy-mediated clearance of 
aggresomes is not a universal phenomenon. Human Molecular Genetics, 
2008; 17: 2570-2582. 
[116] Zhuravleva A, Gierasch LM. Allosteric signal transmission in the 
nucleotide-binding domain of 70-kDa heat shock protein (Hsp70) 
molecular chaperones. Proceedings of the National Academy of Sciences 
of the United States of America, 2011; 108: 6987-92. 
[117] Zhuravleva A, Clerico EM, Gierasch LM. An interdomain energetic tug-of-
war creates the allosterically active state in Hsp70 molecular chaperones. 
Cell, 2012; 151: 1296-307. 
 30 
[118] Ahmad A, Bhattacharya A, McDonald RA, Cordes M, Ellington B, 
Bertelsen EB, Zuiderweg ERP. Heat shock protein 70 kDa 
chaperone/DnaJ cochaperone complex employs an unusual dynamic 
interface. Proceedings of the National Academy of Sciences, 2011; 108: 
18966-18971. 
[119] Brehmer D, Rüdiger S, Gässler CS, Klostermeier D, Packschies L, 
Reinstein J, Mayer MP, Bukau B. Tuning of chaperone activity of Hsp70 
proteins by modulation of nucleotide exchange. Nature structural biology, 
2001; 8: 427-32. 
[120] Shimura H, Schwartz D, Gygi SP, Kosik KS. CHIP-Hsc70 complex 
ubiquitinates phosphorylated tau and enhances cell survival. The Journal 
of biological chemistry, 2004; 279: 4869-76. 
[121] Laiq-Jan Saidia MP, Kevin R. Kaya, Laura Sancheza, Eva-Maria 
Mandelkow,, Spires-Jones BTHaTL. Carboxy Terminus Heat Shock 
Protein 70 Interacting Protein Reduces Tau-Associated Degenerative 
Changes. J Alzheimers Dis, 2015; 44: 937-47. 
[122] Elliott E, Tsvetkov P, Ginzburg I. BAG-1 associates with Hsc70.Tau 
complex and regulates the proteasomal degradation of Tau protein. The 
Journal of biological chemistry, 2007; 282: 37276-84. 
[123] Lüders J, Demand J, Höhfeld J. The ubiquitin-related BAG-1 provides a 
link between the molecular chaperones Hsc70/Hsp70 and the 
proteasome. The Journal of biological chemistry, 2000; 275: 4613-7. 
[124] Demand J, Alberti S, Patterson C, Hohfeld J. Cooperation of a ubiquitin 
domain protein and an E3 ubiquitin ligase during chaperone/proteasome 
coupling. Curr Biol, 2001; 11: 1569-77. 
[125] Carrettiero DC, Hernandez I, Neveu P, Papagiannakopoulos T, Kosik KS. 
The cochaperone BAG2 sweeps paired helical filament- insoluble tau from 
the microtubule. J Neurosci, 2009; 29: 2151-61. 
[126] Abisambra JF, Jinwal UK, Suntharalingam A, Arulselvam K, Brady S, 
Cockman M, Jin Y, Zhang B, Dickey CA. DnaJA1 antagonizes constitutive 
Hsp70-mediated stabilization of tau. Journal of molecular biology, 2012; 
421: 653-61. 
[127] Abisambra J, Jinwal UK, Miyata Y, Rogers J, Blair L, Li X, Seguin SP, 
Wang L, Jin Y, Bacon J, Brady S, Cockman M, Guidi C, Zhang J, Koren J, 
Young ZT, Atkins CA, Zhang B, Lawson LY, Weeber EJ, Brodsky JL, 
Gestwicki JE, Dickey CA. Allosteric Heat Shock Protein 70 Inhibitors 
Rapidly Rescue Synaptic Plasticity Deficits by Reducing Aberrant Tau. 
Biological psychiatry, 2013; 74: 367-374. 
[128] Fontaine SN, Martin MD, Akoury E, Assimon VA, Borysov S, Nordhues 
BA, Sabbagh JJ, Cockman M, Gestwicki JE, Zweckstetter M, Dickey CA. 
The active Hsc70/tau complex can be exploited to enhance tau turnover 
without damaging microtubule dynamics. Hum Mol Genet, 2015; 24: 3971-
81. 
[129] Thompson AD, Scaglione KM, Prensner J, Gillies AT, Chinnaiyan A, 
Paulson HL, Jinwal UK, Dickey CA, Gestwicki JE. Analysis of the tau-
 31 
associated proteome reveals that exchange of Hsp70 for Hsp90 is 
involved in tau degradation. ACS chemical biology, 2012; 7: 1677-86. 
[130] Sarkar M, Kuret J, Lee G. Two motifs within the tau microtubule-binding 
domain mediate its association with the hsc70 molecular chaperone. 
Journal of neuroscience research, 2008; 86: 2763-73. 
[131] Voss K, Combs B, Patterson K, Binder LI, Gamblin TC. Hsp70 alters tau 
function and aggregation in an isoform specific manner. Biochemistry, 
2012; 51: 888-98. 
[132] Rousaki A, Miyata Y, Jinwal UK, Dickey Ca, Gestwicki JE, Zuiderweg 
ERP. Allosteric drugs: the interaction of antitumor compound MKT-077 
with human Hsp70 chaperones. Journal of molecular biology, 2011; 411: 
614-32. 
[133] Li X, Colvin T, Rauch JN, Acosta-Alvear D, Kampmann M, Dunyak B, 
Hann B, Aftab BT, Murnane M, Cho M, Walter P, Weissman JS, Sherman 
MY, Gestwicki JE. Validation of the Hsp70–Bag3 Protein–Protein 
Interaction as a Potential Therapeutic Target in Cancer. Molecular Cancer 
Therapeutics, 2015; 14: 642-648. 
[134] Colvin TA, Gabai VL, Gong J, Calderwood SK, Li H, Gummuluru S, 
Matchuk ON, Smirnova SG, Orlova NV, Zamulaeva IA, Garcia-Marcos M, 
Li X, Young ZT, Rauch JN, Gestwicki JE, Takayama S, Sherman MY. 
Hsp70–Bag3 Interactions Regulate Cancer-Related Signaling Networks. 
Cancer Research, 2014; 74: 4731-4740. 
[135] Miyata Y, Li X, Lee H-F, Jinwal U, Srinivasan SR, Seguin SP, Young ZT, 
Brodsky JL, Dickey CA, Sun D, Gestwicki JE. Synthesis and Initial 
Evaluation of YM-08, a Blood-Brain Barrier Permeable Derivative of the 
Heat Shock Protein 70 (Hsp70) Inhibitor MKT-077, Which Reduces Tau 
Levels. ACS chemical neuroscience, 2013; 4: 930-939. 
[136] Jinwal UK, Miyata Y, Koren J, Jones JR, Trotter JH, Chang L, O'Leary J, 
Morgan D, Lee DC, Shults CL, Rousaki A, Weeber EJ, Zuiderweg ERP, 
Gestwicki JE, Dickey Ca. Chemical manipulation of hsp70 ATPase activity 
regulates tau stability. The Journal of neuroscience : the official journal of 
the Society for Neuroscience, 2009; 29: 12079-88. 
[137] Chang L, Bertelsen EB, Wisén S, Larsen EM, Zuiderweg ERP, Gestwicki 
JE. High-throughput screen for small molecules that modulate the ATPase 
activity of the molecular chaperone DnaK. Analytical biochemistry, 2008; 
372: 167-76. 
[138] Chang L, Miyata Y, Ung PMU, Bertelsen EB, McQuade TJ, Carlson Ha, 
Zuiderweg ERP, Gestwicki JE. Chemical screens against a reconstituted 
multiprotein complex: myricetin blocks DnaJ regulation of DnaK through 
an allosteric mechanism. Chemistry & biology, 2011; 18: 210-21. 
[139] Salminen A, Ojala J, Kaarniranta K, Hiltunen M, Soininen H. Hsp90 
regulates tau pathology through co-chaperone complexes in Alzheimer's 
disease. Prog Neurobiol, 2011; 93: 99-110. 
[140] Hessling M, Richter K, Buchner J. Dissection of the ATP-induced 
conformational cycle of the molecular chaperone Hsp90. Nat Struct Mol 
Biol, 2009; 16: 287-293. 
 32 
[141] Retzlaff M, Hagn F, Mitschke L, Hessling M, Gugel F, Kessler H, Richter 
K, Buchner J. Asymmetric activation of the hsp90 dimer by its 
cochaperone aha1. Mol Cell, 2010; 37: 344-54. 
[142] McLaughlin SH, Sobott F, Yao Z-p, Zhang W, Nielsen PR, Grossmann JG, 
Laue ED, Robinson CV, Jackson SE. The Co-chaperone p23 Arrests the 
Hsp90 ATPase Cycle to Trap Client Proteins. Journal of Molecular 
Biology, 2006; 356: 746-758. 
[143] Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, Ash 
P, Shoraka S, Zlatkovic J, Eckman CB, Patterson C, Dickson DW, Jr NSN, 
Hutton M, Burrows F, Petrucelli L. The high-affinity HSP90-CHIP complex 
recognizes and selectively degrades phosphorylated tau client proteins. 
The Journal of clinical investigation, 2007; 117. 
[144] Eckl JM, Rutz DA, Haslbeck V, Zierer BK, Reinstein J, Richter K. Cdc37 
(cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by 
interaction with N-terminal and middle domain binding sites. J Biol Chem, 
2013; 288: 16032-42. 
[145] Jinwal UK, Koren J, Dickey CA. Reconstructing the Hsp90/Tau Machine. 
Current enzyme inhibition, 2013; 9: 41-45. 
[146] Jinwal UK, Trotter JH, Abisambra JF, Koren J, Lawson LY, Vestal GD, 
O'Leary JC, Johnson AG, Jin Y, Jones JR, Li Q, Weeber EJ, Dickey CA. 
The Hsp90 Kinase Co-chaperone Cdc37 Regulates Tau Stability and 
Phosphorylation Dynamics. Journal of Biological Chemistry, 2011; 286: 
16976-16983. 
[147] Jinwal UK, Koren J, Borysov SI, Schmid AB, Abisambra JF, Blair LJ, 
Johnson AG, Jones JR, Shults CL, O'Leary JC, Jin Y, Buchner J, Cox MB, 
Dickey CA. The Hsp90 Cochaperone, FKBP51, Increases Tau Stability 
and Polymerizes Microtubules. The Journal of Neuroscience, 2010; 30: 
591-599. 
[148] Chambraud B, Sardin E, Giustiniani J, Dounane O, Schumacher M, 
Goedert M, Baulieu E-E. A role for FKBP52 in Tau protein function. 
Proceedings of the National Academy of Sciences, 2010; 107: 2658-2663. 
[149] Rohl A, Rohrberg J, Buchner J. The chaperone Hsp90: changing partners 
for demanding clients. Trends Biochem Sci, 2013; 38: 253-62. 
[150] Alvira S, Cuellar J, Rohl A, Yamamoto S, Itoh H, Alfonso C, Rivas G, 
Buchner J, Valpuesta JM. Structural characterization of the substrate 
transfer mechanism in Hsp70/Hsp90 folding machinery mediated by Hop. 
Nat Commun, 2014; 5: 5484. 
[151] Rohl A, Wengler D, Madl T, Lagleder S, Tippel F, Herrmann M, Hendrix J, 
Richter K, Hack G, Schmid AB, Kessler H, Lamb DC, Buchner J. Hsp90 
regulates the dynamics of its cochaperone Sti1 and the transfer of Hsp70 
between modules. Nat Commun, 2015; 6. 
[152] Fontaine SN, Rauch JN, Nordhues BA, Assimon VA, Stothert AR, Jinwal 
UK, Sabbagh JJ, Chang L, Stevens SM, Jr., Zuiderweg ER, Gestwicki JE, 
Dickey CA. Isoform-selective Genetic Inhibition of Constitutive Cytosolic 
Hsp70 Activity Promotes Client Tau Degradation Using an Altered Co-
chaperone Complement. J Biol Chem, 2015; 290: 13115-27. 
 33 
[153] Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, 
Spampinato C, Modrich P, Chiosis G. Targeting Wide-Range Oncogenic 
Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90. 
Chemistry & Biology, 2004; 11: 787-797. 
[154] Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu 
N, Greengard P, Chiosis G. Roles of heat-shock protein 90 in maintaining 
and facilitating the neurodegenerative phenotype in tauopathies. 
Proceedings of the National Academy of Sciences, 2007; 104: 9511-9516. 
[155] Do K, Speranza G, Chang L-C, Polley E, Bishop R, Zhu W, Trepel J, Lee 
S, Lee M-J, Kinders R, Phillips L, Collins J, Lyons J, Jeong W, Antony R, 
Chen A, Neckers L, Doroshow J, Kummar S. Phase I study of the heat 
shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a 
daily for 2 consecutive days per week dosing schedule in patients with 
advanced solid tumors. Investigational New Drugs, 2015; 33: 921-930. 
[156] Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, 
Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, 
Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone 
G, Doroshow JH, Murgo AJ. Phase I trial of 17-dimethylaminoethylamino-
17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, 
administered twice weekly in patients with advanced malignancies. 
European Journal of Cancer, 2010; 46: 340-347. 
[157] Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins 
and depletion of heat shock protein 90-dependent signaling proteins. J 
Natl Cancer Inst, 2000; 92: 242-8. 
[158] Matts RL, Dixit A, Peterson LB, Sun L, Voruganti S, Kalyanaraman P, 
Hartson SD, Verkhivker GM, Blagg BSJ. Elucidation of the Hsp90 C-
Terminal Inhibitor Binding Site. ACS Chemical Biology, 2011; 6: 800-807. 
[159] Moroni E, Zhao H, Blagg BS, Colombo G. Exploiting conformational 
dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with 
improved activities. J Chem Inf Model, 2014; 54: 195-208. 
[160] Khalid S, Paul S. Identifying a C-terminal ATP binding sites-based novel 
Hsp90-Inhibitor in silico: a plausible therapeutic approach in Alzheimer's 
disease. Med Hypotheses, 2014; 83: 39-46. 
[161] Ansar S, Burlison JA, Hadden MK, Yu XM, Desino KE, Bean J, Neckers L, 
Audus KL, Michaelis ML, Blagg BS. A non-toxic Hsp90 inhibitor protects 
neurons from Abeta-induced toxicity. Bioorg Med Chem Lett, 2007; 17: 
1984-90. 
[162] Wang Y, McAlpine SR. C-terminal heat shock protein 90 modulators 
produce desirable oncogenic properties. 
[163] Jakob U, Gaestel M, Engel K, Buchner J. Small heat shock proteins are 
molecular chaperones. J Biol Chem, 1993; 268: 1517-20. 
[164] Jovcevski B, Kelly Megan A, Rote Anthea P, Berg T, Gastall Heidi Y, 
Benesch Justin LP, Aquilina JA, Ecroyd H. Phosphomimics Destabilize 
Hsp27 Oligomeric Assemblies and Enhance Chaperone Activity. 
Chemistry & Biology, 2015; 22: 186-195. 
 34 
[165] Shimura H, Miura-Shimura Y, Kosik KS. Binding of Tau to Heat Shock 
Protein 27 Leads to Decreased Concentration of Hyperphosphorylated 
Tau and Enhanced Cell Survival. Journal of Biological Chemistry, 2004; 
279: 17957-17962. 
[166] Abisambra JF, Jinwal UK, Jones JR, Blair LJ, Koren J, 3rd, Dickey CA. 
Exploiting the diversity of the heat-shock protein family for primary and 
secondary tauopathy therapeutics. Curr Neuropharmacol, 2011; 9: 623-
31. 
[167] Abisambra JF, Blair LJ, Hill SE, Jones JR, Kraft C, Rogers J, Koren J, 
Jinwal UK, Lawson L, Johnson AG, Wilcock D, O'Leary JC, Jansen-West 
K, Muschol M, Golde TE, Weeber EJ, Banko J, Dickey CA. 
Phosphorylation Dynamics Regulate Hsp27-Mediated Rescue of Neuronal 
Plasticity Deficits in Tau Transgenic Mice. The Journal of Neuroscience, 
2010; 30: 15374-15382. 
[168] Bjorkdahl C, Sjogren MJ, Zhou X, Concha H, Avila J, Winblad B, Pei JJ. 
Small heat shock proteins Hsp27 or alphaB-crystallin and the protein 
components of neurofibrillary tangles: tau and neurofilaments. J Neurosci 
Res, 2008; 86: 1343-52. 
[169] Blair LJ, Baker JD, Sabbagh JJ, Dickey CA. The emerging role of peptidyl-
prolyl isomerase chaperones in tau oligomerization, amyloid processing, 
and Alzheimer's disease. J Neurochem, 2015; 133: 1-13. 
[170] Pastorino L, Sun A, Lu P-J, Zhou XZ, Balastik M, Finn G, Wulf G, Lim J, Li 
S-H, Li X, Xia W, Nicholson LK, Lu KP. The prolyl isomerase Pin1 
regulates amyloid precursor protein processing and amyloid-[beta] 
production. Nature, 2006; 440: 528-534. 
[171] Yotsumoto K, Saito T, Asada A, Oikawa T, Kimura T, Uchida C, Ishiguro 
K, Uchida T, Hasegawa M, Hisanaga S-i. Effect of Pin1 or Microtubule 
Binding on Dephosphorylation of FTDP-17 Mutant Tau. Journal of 
Biological Chemistry, 2009; 284: 16840-16847. 
[172] Kimura T, Tsutsumi K, Taoka M, Saito T, Masuda-Suzukake M, Ishiguro 
K, Plattner F, Uchida T, Isobe T, Hasegawa M, Hisanaga S-i. Isomerase 
Pin1 Stimulates Dephosphorylation of Tau Protein at Cyclin-dependent 
Kinase (Cdk5)-dependent Alzheimer Phosphorylation Sites. Journal of 
Biological Chemistry, 2013; 288: 7968-7977. 
[173] Lu P-J, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 
restores the function of Alzheimer-associated phosphorylated tau protein. 
Nature, 1999; 399: 784-788. 
[174] Nakamura K, Greenwood A, Binder L, Bigio Eileen H, Denial S, Nicholson 
L, Zhou Xiao Z, Lu Kun P. Proline Isomer-Specific Antibodies Reveal the 
Early Pathogenic Tau Conformation in Alzheimer's Disease. Cell, 2012; 
149: 232-244. 
[175] Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, Uchida T, Bronson 
R, Bing G, Li X, Hunter T, Lu KP. Role of the prolyl isomerase Pin1 in 
protecting against age-dependent neurodegeneration. Nature, 2003; 424: 
556-61. 
 35 
[176] Lambert J-C, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, 
Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens 
K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De 
Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de 
Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, 
Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni 
G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, 
Blanche H, Dartigues J-F, Tzourio C, Gut I, Van Broeckhoven C, 
Alperovitch A, Lathrop M, Amouyel P. Genome-wide association study 
identifies variants at CLU and CR1 associated with Alzheimer's disease. 
Nat Genet, 2009; 41: 1094-1099. 
[177] Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, 
Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, 
Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, 
Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown 
KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, 
Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, 
Collinge J, Maier W, Jessen F, Schurmann B, Heun R, van den Bussche 
H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, 
Hull M, Rujescu D, Goate AM, Kauwe JSK, Cruchaga C, Nowotny P, 
Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, 
Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, 
Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, 
Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel K-H, Klopp N, 
Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, 
O'Donovan M, Owen MJ, Williams J. Genome-wide association study 
identifies variants at CLU and PICALM associated with Alzheimer's 
disease. Nat Genet, 2009; 41: 1088-1093. 
[178] Desikan RS, Thompson WK, Holland D, et al. THe role of clusterin in 
amyloid-β–associated neurodegeneration. JAMA Neurology, 2014; 71: 
180-187. 
[179] Zhou Y, Hayashi I, Wong J, Tugusheva K, Renger JJ, Zerbinatti C. 
Intracellular Clusterin Interacts with Brain Isoforms of the Bridging 
Integrator 1 and with the Microtubule-Associated Protein Tau in 
Alzheimer's Disease. PLoS ONE, 2014; 9: e103187. 
[180] Salminen A, Kaarniranta K, Kauppinen A, Ojala J, Haapasalo A, Soininen 
H, Hiltunen M. Impaired autophagy and APP processing in Alzheimer's 
disease: The potential role of Beclin 1 interactome. Progress in 
Neurobiology, 2013; 106–107: 33-54. 
[181] Ding H, Dolan PJ, Johnson GV. Histone deacetylase 6 interacts with the 
microtubule-associated protein tau. J Neurochem, 2008; 106: 2119-30. 
[182] Noack M, Leyk J, Richter-Landsberg C. HDAC6 inhibition results in tau 
acetylation and modulates tau phosphorylation and degradation in 
oligodendrocytes. Glia, 2014; 62: 535-47. 
 36 
[183] Leyk J, Goldbaum O, Noack M, Richter-Landsberg C. Inhibition of HDAC6 
modifies tau inclusion body formation and impairs autophagic clearance. J 
Mol Neurosci, 2015; 55: 1031-46. 
[184] Cook C, Stankowski J, Carlomagno Y, Stetler C, Petrucelli L. Acetylation: 
a new key to unlock tau's role in neurodegeneration. Alzheimer's 
Research & Therapy, 2014; 6: 29. 
[185] Cook C, Gendron TF, Scheffel K, Carlomagno Y, Dunmore J, DeTure M, 
Petrucelli L. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal 
tau accumulation. Hum Mol Genet, 2012; 21: 2936-45. 
[186] Ozcelik S, Fraser G, Castets P, Schaeffer V, Skachokova Z, Breu K, 
Clavaguera F, Sinnreich M, Kappos L, Goedert M, Tolnay M, Winkler DT. 
Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau 
Transgenic Mice. PLoS ONE, 2013; 8: e62459. 
[187] Jiang T, Yu J-T, Zhu X-C, Zhang Q-Q, Cao L, Wang H-F, Tan M-S, Gao 
Q, Qin H, Zhang Y-D, Tan L. Temsirolimus attenuates tauopathy in vitro 
and in vivo by targeting tau hyperphosphorylation and autophagic 
clearance. Neuropharmacology, 2014; 85: 121-130. 
[188] Lee B-H, Lee MJ, Park S, Oh D-C, Elsasser S, Chen P-C, Gartner C, 
Dimova N, Hanna J, Gygi SP, Wilson SM, King RW, Finley D. 
Enhancement of proteasome activity by a small-molecule inhibitor of 
USP14. Nature, 2010; 467: 179-84. 
[189] Ittner A, Bertz J, Suh LS, Stevens CH, Götz J, Ittner LM. Tau-targeting 
passive immunization modulates aspects of pathology in tau transgenic 
mice. Journal of Neurochemistry, 2015; 132: 135-145. 
[190] Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI. Distinct 
Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial 
Clearance Versus Blocking Neuronal Uptake. J Biol Chem, 2015; 290: 
21652-62. 
[191] Selenica ML, Davtyan H, Housley SB, Blair LJ, Gillies A, Nordhues BA, 
Zhang B, Liu J, Gestwicki JE, Lee DC, Gordon MN, Morgan D, Dickey CA. 
Epitope analysis following active immunization with tau proteins reveals 
immunogens implicated in tau pathogenesis. J Neuroinflammation, 2014; 
11: 152. 
[192] Blair LJ, Zhang B, Dickey CA. Potential synergy between tau aggregation 
inhibitors and tau chaperone modulators. Alzheimers Res Ther, 2013; 5: 
41. 
[193] Calcul L, Zhang B, Jinwal UK, Dickey CA, Baker BJ. Natural products as a 
rich source of tau-targeting drugs for Alzheimer's disease. Future Med 
Chem, 2012; 4: 1751-61. 
[194] Paranjape SR, Riley AP, Somoza AD, Oakley CE, Wang CC, Prisinzano 
TE, Oakley BR, Gamblin TC. Azaphilones inhibit tau aggregation and 
dissolve tau aggregates in vitro. ACS Chem Neurosci, 2015; 6: 751-60. 
[195] Frost B, Diamond MI. The expanding realm of prion phenomena in 
neurodegenerative disease. Prion, 2009; 3: 74-7. 
[196] Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, 
Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block 
 37 
tau aggregate seeding in vitro markedly decrease pathology and improve 
cognition in vivo. Neuron, 2013; 80: 402-14. 
[197] Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the 
outside to the inside of a cell. The Journal of biological chemistry, 2009; 
284: 12845-52. 
[198] Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, 
Belaygorod L, Cairns NJ, Holtzman DM, Diamond MI. Proteopathic tau 
seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A, 2014; 111: 
E4376-85. 
[199] Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular 
propagation of Tau aggregation by fibrillar species. The Journal of 
biological chemistry, 2012; 287: 19440-51. 
 
 
 
 38 
Chapter 2 
Stabilizing the Hsp70-Tau Complex Normalizes  
Proteostasis in a Model of Tauopathy 
 
 
2.1 Introduction 
As discussed in Chapter 1, Hsp70 is a chaperone that normally scans the 
proteome and “decides” whether proteins should be retained or degraded by 
linking them to either the folding or turnover pathways. This activity is critical to 
normal protein homeostasis (or proteostasis), yet it appears to fail in many 
protein-misfolding diseases. As discussed in Chapter 1, it is especially important 
to understand the molecular mechanisms by which Hsp70 makes decisions for 
the microtubule-binding protein tau. Hsp70 is a multi-domain protein that uses 
ATP hydrolysis to regulate its affinity for client proteins. Here, we use a chemical 
biology strategy, in combination with genetics, to systematically perturb the 
affinity of Hsp70 for tau. This approach revealed that tight complexes between 
Hsp70 and tau are associated with accelerated turnover while transient 
interactions are linked to tau retention. Further, we found that disease-associated 
tau mutants, including A152T and K280Q, have an intrinsically weaker affinity for 
Hsp70 but that chaperone binding could be chemically restored to enhance their 
 39 
degradation. Together, these results suggest that persistence of the Hsp70-client 
complex is one important parameter governing Hsp70-mediated quality control.     
 
2.2 Allosteric modulation of Hsp70 regulates tau proteostasis 
Hsp70/HSPA1A and Hsc70/HSPA8 are highly conserved molecular chaperones 
that are expressed in the cytosol of all eukaryotic cells. These factors are often 
referred to as  “triage” chaperones because they bind to misfolded proteins and 
somehow choose to preserve them [1, 2] or shuttle them to the lysosome-
autophagy pathway or UPS for degradation [3, 4]. Although they play a complex 
and important role in proteostasis, members of the Hsp70 family have a relatively 
simple structure, composed of a 45 kDa nucleotide binding domain (NBD) and 25 
kDa substrate binding domain (SBD) [5, 6]. The NBD has a deep cleft for binding 
ATP, while client proteins bind in a β-sandwich region of the SBD [7]. These two 
domains are allosterically linked, with nucleotide turnover in the NBD controlling 
the affinity of SBD-client interactions [8-12]. In the ATP-bound form, clients bind 
Hsp70s with fast-on, fast-off kinetics, while hydrolysis to the ADP-bound form 
stabilizes the SBD-client interaction by slowing the off-rate [13]. 
 
As discussed in Chapter 1, co-chaperones bind to Hsp70/Hsc70 and regulate 
this nucleotide cycling. These co-chaperones include J-proteins, which 
accelerate ATP hydrolysis, and NEFs that promote the discharge of ADP [14, 
15]. Together, J proteins and NEFs coordinate turnover, ultimately regulating the 
affinity of Hsp70s for their clients. Then, additional co-chaperone families, 
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including the tetratricopeptide repeat (TPR) domain proteins, bind Hsp70s and 
help direct the fate of the bound clients. Another important co-chaperone Hsc70 
interacting protein (HIP) binds to the NBD and blocks interactions with NEFs, 
essentially prolonging the association of Hsp70s with their clients [16]. Together, 
Hsp70, Hsc70 and their co-chaperones cooperate to identify unfolded proteins 
and somehow enact the “decision” to either retain or degrade them. This process 
is central to health and proteostasis because it limits accumulation of misfolded 
proteins, blocks aggregation and aids in proper folding. However, the molecular 
mechanisms that guide the logic of quality control are not clear. How does Hsp70 
“know” whether a client is competent for folding or whether it is prone to 
misfolding? 
 
2.3 Tau as a model substrate for understanding chaperone triage 
MAPT/tau has served as an important client for understanding chaperone-
mediated quality control [17-19]. As introduced in Chapter 1, the accumulation of 
tau is a pathological feature of many neurodegenerative disorders, including 
Alzheimer’s disease (AD), frontotemporal dementia (FTD) and progressive 
supranuclear tauopathy (PSP). Tau is an intrinsically disordered protein [20] that 
normally stabilizes microtubules. Mutations, such as P301L and A152T [21-24], 
and/or PTMs, such as hyperphosphorylation and acetylation [25-27], disrupt this 
normal function by damaging the affinity of tau for microtubules and promoting its 
aggregation as discussed in Chapter 1. Members of the Hsp70 family are well 
known to play an important role in tau quality control [18, 28], serving to protect 
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against tauopathies. In Chapter 4, we will discuss how these mutations and 
PTMs alter tau proteostasis in disease relevant tau mutant cell models. Both 
Hsc70 and Hsc70 bind to the microtubule-binding repeats of tau [29, 30] to limits 
its aggregation. Further, over-expression of Hsp70 leads to a dramatic reduction 
in tau [18, 30] through activation of the UPS degradation pathways. This pro-
degradation activity of Hsp70 was isolated to the C-terminal domain [30], a 
region that contains the least similarity between Hsc70 and Hsp70. Interestingly, 
over-expression of Hsc70, despite its overall high similarity with Hsp70, causes 
retention of tau (Appendix 2.3D) [30]. This diametrically opposed activity seems 
to occur through preferentially enhanced coupling between Hsp70, tau and CHIP. 
However, over-expression of a dominant negative form of Hsc70 also leads to 
enhanced turnover of tau [2], suggesting that both Hsc70 and Hsp70 are capable 
of directing tau to the degradation pathway. The differential effects of Hsp70 
paralogs on tau stability as well as other Hsp70 substrates will be further 
explored in Chapter 4. The quality control decisions made by Hsc70 and Hsp70 
in the tau-bound complex are further tuned by co-chaperones. For example, 
over-expression of DnaJA1, BAG3 or CHIP promotes tau turnover through a 
mechanism that requires Hsp70s [31-33]. Together, these results show a close 
relationship between Hsp70s, their co-chaperones and tau homeostasis, but the 
molecular mechanisms are not clear. In other words, the players are known but it 
isn’t yet clear how they coordinate their actions. 
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We wanted to use a chemical biology approach to better understand how Hsp70s 
“decide” to retain or degrade tau. Inhibitors of Hsp70’s ATPase activity, such as 
YM-01, are known to reduce accumulation of phosphorylated tau in cell-based 
models [34] in a process that requires the chaperone [31]. In these findings, we 
saw an opportunity to use YM-01 as a chemical probe to unravel the molecular 
mechanisms of Hsp70-mediated quality control. To do this, we first had to 
synthesize an analog of YM-01, JG-48, which had spectral properties that 
permitted access to a wider variety of mechanistic assays. We found that JG-48, 
but not a closely related, control compound, JG-273, stabilized the ADP-bound 
state of Hsc70 and blocked the ability of NEFs to facilitate ADP and client 
release. The net effect of this allosteric perturbation is that the affinity of Hsp70s 
for tau is significantly enhanced in vitro and in cells. To test whether affinity for 
tau might be linked to the “decision” to degrade, we used a collection of chemical 
inhibitors, belonging to distinct chemical series, and a new series of Hsc70 point 
mutants to systematically enhance or decrease the affinity of chaperone for tau. 
The results, discussed in this chapter, significantly advance our understanding of 
the mechanism of Hsp70-mediated quality control and suggest a path towards 
the discovery of compounds that might normalize tau levels in disease. 
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2.4 Results 
2.4.1 JG-48 reduces tau accumulation in multiple models and restores 
long-term potentiation. 
YM-01 and its analogs are known to enhance tau turnover through interactions 
with Hsp70 [31, 34]. However, these compounds contain a cationic pyridinium 
that precludes many in vitro studies because they absorb at the same 
wavelengths that are used in common chaperone assays (e.g. 535 to 620 nm, 
see Appendix 2.1B). To provide a molecule suitable for use in these expanded 
platforms, we assembled JG-48 using a previously established synthetic route 
[35] (Appendix 2.1A). At the same time, we synthesized a control compound, JG-
273, that lacks the fused phenyl group predicted to be important for binding [36]. 
As anticipated, JG-48 and JG-273 lacked the strong absorbance in the region of 
535 to 620 nm (Appendix 2.1B), which previously hindered use of YM-01.  
 
Figure 2.1 JG-48 reduces tau levels in cellular models of tauopathy. JG-48, but not JG-273, significantly 
reduces tau in HeLa C3 cells stably transfected with 4R0N tau. Statistical analysis was performed using a 2-
way ANOVA with Dunnett’s test.*p<0.001, **p<0.005. JG-48 also reduces phosphorylated, endogenous tau 
in SHSY-5Y neuroblastoma cells. Cells were treated for 24 hours.  
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The ability of JG-48 and JG-273 to reduce tau burden was then tested in HeLa 
C3 cells stably transfected with human 4R0N tau. These cells were treated for 24 
hours, lysed and the total tau levels analyzed by Western blot. We found that JG-
48, but not JG-273, reduced tau levels by ~50% at 30 µM (Figure 2.1). Then, to 
test if JG-48 could reduce endogenous tau, SHSY-5Y neuroblastoma cells were 
treated. We found that JG-48 decreased total tau levels, but it was even more 
effective at clearing phosphorylated tau (Figure 2.1), as indicated by an antibody 
that recognizes the paired helical filament (PHF) form that is present in these 
cells and in the brains of tauopathy patients [37].  
 
We next tested the potency of JG-48 in brain slices from the rTg4510 transgenic 
mouse model of tauopathy [38]. rTg4510 mice express the tau mutant, P301L, 
and they present many of the symptoms associated with tauopathies, including 
tau tangles in the forebrain, neuron loss and memory impairment [39]. Brain slice 
cultures from these mice were treated for six hours with JG-48. We found that 
this treatment reduced total tau levels and that it was especially effective against 
phosphorylated tau (Figure 2.2A). A key feature of this rTg4510 model is that 
hippocampal brain slices show deficits in long-term potentiation (LTP) when 
compared to WT brain slices from non-transgenic mice [40, 41]. Therefore, we 
evaluated the ability of JG-48 to restore LTP in rTG4510 brain slices using a 
previously described theta burst stimulation method [31]. JG-48 (10 µM)  
significantly improved LTP in the brain slices from rTg4510 mice when compared  
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Figure 2.2 Characterization of JG-48 in transgenic tauopathy models. (A) Acute hippocampal slice cultures 
from 3-4 month old rTg4510 tau transgenic mice were treated with JG-48 (10 µM) for 6 hours. 
Electrophysiology experiments show that JG-48 restores synaptic plasticity. fEPSP traces are an average of 
JG-48 (n=7) or vehicle-treated (n=17). Statistical analysis was performed using a 2-way ANOVA with 
Bonferroni posttest. *** p<0.001. (B) Brain aggregates were infected with 10% rTg4510 brain homogenates 
from 15 to 25 days in culture and treated with YM-01 or JG-48 (10 µM) for 24 hrs prior to harvesting at 35 
days in culture. They were stained with anti-phospho-tau (red), anti-beta tubulin (green) and DAPI (blue). 15-
20 confocal images were stacked and phospho-tau intensity was measured with Image J. N=6. *p<0.0001, 
**p<0.0003. Bar = 25 μm. 
to the vehicle control (Figure 2.2A). Importantly, no effect was seen when JG-48 
was added to brain slice cultures from non-transgenic, wild type mice (Appendix 
2.1C). This control is important because it shows that the compound does not 
artificially enhance plasticity; rather, JG-48 appeared to preferentially accelerate 
clearance of pathogenic tau to improve neuronal function. Finally, we created 
aggregate cultures from rTg4510 brains and treated them with compounds to 
understand whether tau was reduced in neurons. This system was used 
because, compared to brain slices, the aggregate model provides a more 
convenient platform for immunofluorescence and imaging. We found that tau 
levels in tubulin-positive neurons were significantly reduced by either YM-01 or 
JG-48 (10 µM) (Figure 2.2B). These results establish JG-48 as a chemical probe 
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for better understanding the mechanisms of chaperone-mediated tau quality 
control. 
 
2.4.2 JG-48 binds the NBD of Hsc70 but does not inhibit ATP binding  
Our overall strategy was to explore the activity of JG-48 in a battery of both in 
vitro and cellular models in an attempt to understand how Hsp70s might regulate 
tau homeostasis. Our first question was whether JG-48 might compete with 
nucleotide (ATP or ADP) for binding to the chaperone, which would provide a 
potential clue to its mechanism-of-action. NMR titration and docking experiments 
had previously shown that compounds similar to JG-48, such as MKT-077 and 
JG-98, bind in a deep, conserved pocket of the NBD of Hsc70 [34, 36, 42]. To 
confirm that JG-48 binds similarly, we repeated the HSQC titration study with 15N 
Hsc70 NBD in the presence of ADP. In these studies, we used Hsc70NBD, rather 
than Hsp70NBD because the peak assignments were available, but the predicted 
binding site is 100% conserved between these paralogs [36]. Consistent with the 
previous work, JG-48 caused selective chemical shift perturbations (CSPs) in 
residues adjacent to a deep cleft composed of hydrophobic and anionic residues 
(R72, D199, E175, G201, T204, F205 and T226) (Figure 2.3A). Guided by the 
CSPs, we performed docking simulations of JG-48 bound to Hsc70NBD (PDB: 
3C7N). Similar to what has been found with previous analogs, the most favorable 
poses positioned JG-48 in a cleft between subdomains IIA and IIB (Figure 2.3A). 
In the docked binding mode, the benzothiazole ring system of JG-48, which is 
missing in JG-273, was predicted to make a number of important interactions.  
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Figure 2.3 JG-48 does not compete with ATP for binding to Hsc70. (A) Docking of JG-48 to the NBD of 
Hsc70. Based on NMR chemical shift perturbations, the binding site of JG-48 was modeled. JG-48 is 
predicted to bind a deep cleft in Hsc70, which is not overlapping with the ATP/ADP-binding cleft. 
Hydrophobics in orange, apolar in green, anionic in red, cationic in blue. (B) Positive controls, ATP and 
VER-155008 (VER) compete with a fluorescent ATP tracer (ATP-FAM) for binding to the NBD of Hsc70. 
Results are the average of three independent experiments performed in triplicate and the error bars 
represent the standard deviations.   
The docked pose of JG-48 suggested that the molecule would not directly 
interfere with nucleotide binding. Indeed, there appeared to be a channel through 
the protein, with nucleotide on one end and JG-48 on the other (Figure 2.3A). To 
directly test this idea experimentally, we adapted a fluorescence polarization (FP) 
assay [43] in which competition with a tight binding (KD ~ 400 nM) ATP probe, 
N6-(6-Amino)hexyl-ATP-6-FAM (or ATP-FAM), is measured. We first confirmed 
that both unlabeled ATP and a known competitive inhibitor, VER-155008 (VER) 
[43], interrupted tracer binding with IC50 values of 200 ± 19 nM and 390 ± 28 nM, 
respectively (Figure 2.3B). In contrast, titration with JG-48 had no effect on ATP-
FAM binding, confirming that it does not compete with ATP. Thus, its activities on 
Hsp70 appeared to be allosteric. 
 
2.4.3 JG-48 weakly inhibits ATPase activity 
We then turned to a series of biochemical assays, including those that measure 
ATP hydrolysis, client folding and co-chaperone interactions, to understand the 
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Figure 2. JG-48 does not compete with ATP for binding to Hsc70. (A) Docking of JG-48 to the NBD of Hsc70. Based on NMR
chemical shift perturbations, the binding site of JG-48 was modeled. JG-48 is predicted to bind a deep cleft in Hsc70, which is not
overlapping with the ATP/ADP-binding cleft. Hydrophobics in orange, apolar in green, anionic in red, cationic in blue. (B) Positive
controls, ATP and VER-155008 (VER) compete with a fluorescent ATP tracer (ATP-FAM) for binding to the NBD of Hsc70. Results
are the av rage of three ind pendent experiments performed in triplicate and th  error bars represent the standard deviat ons.  
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impact of JG-48 binding on Hsp70 functions in vitro. First, we tested the ability of 
JG-48 to inhibit Hsc70’s steady state ATPase activity using a colorimetric assay 
[44]. In these studies, we used JG-273 as the negative control and two 
characterized inhibitors, VER [43] and myricetin [45] as positive controls. We 
tested each compound against human Hsc70 in the presence of its co-
chaperones. By itself, Hsc70 is a weak ATPase; however, steady-state 
hydrolysis is known to be significantly increased in the presence of J-proteins 
and NEFs [44, 46]. Thus, the relevant ATPase activity in cells is thought to be a 
product of the three factors working together: the Hsc70, a J protein and a NEF 
[47]. There are typically multiple J proteins and NEFs expressed in mammalian 
cells [48] and the function of the chaperone is heavily influenced by which co-
chaperones are bound [49-51]. To get a picture of how compounds might impact 
the whole range of possible complexes, we systematically tested them against 
some of the most abundant combinations composed of Hsc70, DnaJA1, DnaJA2, 
DnaJB1, DnaJB4, BAG1, BAG2 and BAG3 (Figure 2.4A). As expected, JG-273 
combination (Appendix 2.2A), so it wasn’t evaluated further. Both of the positive 
controls, myricetin and VER (50 µM), inhibited the activity of all the chaperone 
combinations tested (Figure 2.4B and Appendix 2.2A). We found that JG-48 also 
inhibited ATPase activity, stimulated by either J proteins or members of the BAG 
family of NEFs, but this effect was relatively modest (Figure 2.4B and Appendix 
2.2A).  
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Figure 2.4 JG-48 is an inhibitor of chaperone functions. (A) Schematic of the Hsp70 system, highlighting the 
J protein and NEF family of co-chaperones. Hsp70 works with a J protein and NEF to hydrolyze ATP and 
refold denatured luciferase in vitro. In this study, we combined Hsc70 with the indicated co-chaperones. (B) 
Summary of the effects of JG-48 (and the negative control, JG-273) on steady state ATPase activity. MYR = 
myricetin VER = VER-155008. All compounds at 50 µM. Results are the average of at least three 
independent experiments performed in triplicate each. Table colors represent the percent reduction in 
ATPase rate at maximum stimulation. Representative curves are shown. (C) Summary of the effects of JG-
48, JG-273 and VER on Hsc70-mediated luciferase refolding. All compounds at 50 µM. Results are the 
average of at least two independent experiments performed in triplicate each. DnaJA1 is not competent for 
luciferase folding. Table colors represent the percent reduction in luminescence signal at maximum 
stimulation. 
Figure 3. JG-48 is an inhibitor of chaperone functions. (A) Schematic of the Hsp70 system, highlighting the J protein 
and NEF family of co-chaperones. Hsp70 works with a J protein and NEF to hydrolyze ATP and refold denatured 
luciferase in vitro. In this study, we combined Hsc70 with the indicated co-chaperones. (B) Summary of the effects of 
JG-48 (and the negative co trol, JG-273) on st ady state ATPase activity. MYR = myricetin VER = VER-155008. All 
compounds at 50 µM. Results are the average of at least three independent experiments perf rme  in triplicate each. 
Table colors r present the percent reductio  in ATPase rat  at aximum timulation. Representative urves are 
shown. See the Supplem ntal Information for addition l d tails. (C) Summary of th  effects of JG-48, JG-273 and VER 
on Hsc70-mediated luciferase refolding. All compounds at 50 µM. Results are t   f at least two independent 
experim nts performed in triplicate each. DnaJA1 is not competant for luciferase folding. Table olors represent the 
percent reduction in lu inescence sign l at maximum stimulation. See Figure S2 for addition l details.
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2.4.4 JG-48 strongly inhibits substrate refolding by Hsc70  
While informative, the ATPase assays do not report on Hsp70-client interactions. 
To explore this activity, we used a well-established assay in which Hsc70 and its 
co-chaperones cooperate to refold denatured firefly luciferase in vitro. This assay 
is known to require dynamic interactions between luciferase, J proteins and 
Hsp70s, providing a functional read-out of client cycling [52]. Similar to the 
design of the ATPase assays, we tested the inhibitory activity of JG-48, JG-273 
and VER against Hsc70 and a panel of its co-chaperones. DnaJA1 does not 
support robust refolding of luciferase [49, 50], so it wasn’t included. In control 
experiments, we found that none of the compounds directly interfered with 
luciferase activity (Appendix 2.2B), allowing us to test them in this platform 
without artifacts. We found that JG-48 and VER, but not JG-273, were dramatic 
inhibitors of chaperone-mediated luciferase refolding. Indeed, both JG-48 and 
VER reduced the amount of recovered luminescence by approximately 60% 
(Figure 2.4C and Appendix 2.2C). Compared to VER, JG-48 had even broader 
activity against all of the chaperone complexes.  
 
2.4.5 JG-48 inhibits client release from Hsc70  
The dramatic effects of JG-48 on luciferase refolding suggested that it might 
strongly impact client-chaperone interactions. To test this idea more directly, we 
turned to an FP assay in which binding to a labeled client peptide, HLA-FAM, is 
measured [53]. We found that Hsc70 binds the tracer with an apparent KD of 5.1 
± 0.9 µM in the presence of 1 mM ADP, consistent with previous reports [49]. 
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Titration of BAG1 into this mixture released the HLA-FAM tracer with an EC50 of 
3.7 ± 0.8 µM (Figure 2.5A), consistent with previous reports [49]. For these 
experiments, BAG1 was used because it appears to be particularly important for 
tau [54, 55]. Then, we measured the ability of JG-48 to impact BAG1 activity. We 
found that JG-48, but not JG-273, stabilized the interaction with tracer by 7-fold 
(BAG1 EC50 25 ± 8.6 µM) (Figure 2.5A). 
 
Figure 2.5 JG-48 limits NEF binding and activity. (A) BAG1 accelerated release of a peptide tracer (HLA-
FAM) from the SBD of Hsc70 was measured and the effects of 50µM compounds determined. The apparent 
EC50 values for BAG-1 are shown in the table. Results are the average of three independent experiments 
performed in triplicate each. Error bars represent the SD. (B) The interaction between Hsc70 and BA1 was 
measured by FCPIA. JG-98 and YM-01, but not the negative control JG-273, block the protein-protein 
interaction. JG-48 partially disrupted the interaction, but only at high concentrations. Results are the average 
of three independent experiments performed in triplicate each and the error bars represent SD. 
NEFs promote release of clients from Hsc70 and Hsp70 by binding to the NBD 
[56-59]. To test if JG-48 could directly impact the protein-protein interaction 
between NEFs and Hsc70, biotinylated chaperone was immobilized on beads 
and incubated with fluorescently labeled BAG1 in a flow cytometry protein 
interaction assay (FCPIA) format. We found that JG-48, but not JG-273 or VER, 
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inhibited BAG1 binding, but with a relatively weak IC50 of 100 µM (Figure 2.5B). 
Thus, JG-48 had a much more dramatic effect on luciferase folding and HLA-
FAM release than it did in this assay, suggesting that its major effects are to 
promote client binding through allosteric control.  
 
2.4.6 Chemical and genetic manipulation of tau affinity reveals a 
correlation with tau turnover in cells 
Next, we wanted to test if JG-48 would increase binding to tau, as it did for the 
model HLA-FAM client. To do this, we employed an ELISA [29] in which Hsc70 is 
immobilized and binding to 4R0N tau measured with a labeled antibody. In this 
format, Hsc70 had an affinity of ~5 µM for tau in the presence of ADP, while 
replacing ADP with ATP or non-hydrolyzable ATPgS weakened the apparent 
affinity of Hsc70 for tau by 101 and 177% (Table 2.1). DMSO alone had no effect 
on the strength of the complex in the presence of ADP, but JG-48 increased 
binding approximately 2-fold (KD = 2.4 ± 0.3 µM) (Appendix 2.3A). This result 
suggests that, similar to what was observed in the FP assay with HLA-FAM, JG-
48 also stabilizes chaperone-tau complexes.  
 
Together, these results suggested a model in which stabilization of the tau 
complex might possibly be a signal for promoting its turnover. To test this idea, 
we wanted to systematically control the affinity of Hsc70 for tau and then 
measure the corresponding effects on tau levels in cells. Towards this goal, we 
assembled a collection of known inhibitors of Hsc70, including VER [43], MAL3- 
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Table 2.1 Summary of the results from ELISA and Western blot experiments 
 
101 [60], JG-98 [36] and YM-01 [31, 61]. Importantly, these compounds belong to 
three distinct chemical series and bind non-overlapping sites on Hsc70, so they 
provide a more rigorous test of the model than using only a single chemotype. In 
the ELISA, we found that MAL3-101, JG-98 and YM-01 enhanced binding of 
Hsc70 to tau by approximately 2-fold (Table 2.1 and Appendix 2.3B), similar to 
what we found for JG-48. However, VER was mildly destabilizing, decreasing the 
affinity of the Hsc70-tau complex by 36%. This result might be consistent with the 
design of VER, as it was intended to mimic the weakly-binding, ATP-bound state 
[43].  
 
To complement these chemical perturbations, we also wanted to use point 
mutations in Hsc70 to alter the affinity for tau. We considered this experiment to 
be very important because the selectivity of small molecules in cells is often 
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uncertain, so combining them with genetics is a way to critically assess 
selectivity. Accordingly, we mutated residues in the proposed allosteric site in 
Hsc70 that is bound by JG-48 (see Fig. 2.3) to see if any of these residues, when 
mutated, might also allosterically disrupt affinity for tau. We found that mutations 
in R76A and Y149A had little impact on tau affinity in the ELISA platform (Table 
2.1), so we used these variants as controls. However, H227A and L228A 
significantly weakened the affinity for tau by 40 to 80%, providing a genetic way 
to test the effects of affinity changes on tau homeostasis. 
 
With this collection of genetic and chemical tools in-hand, we treated HeLa C3 
cells or transiently over-expressed each of the Hsc70 point mutants. We found 
that strengthening the affinity for tau tended to reduce its levels (Table 2.1 and 
Figure 2.6A). For example, JG-98 enhanced Hsc70 binding by 2-fold in vitro and 
reduced tau levels by about 75% compared to the controls. Conversely, the 
H227A and L228A mutations weakened the interaction in vitro and their over-
expression caused a reproducible increase in tau levels (Table 2.1). To 
determine if JG-48 can increase binding of Hsp70 to tau in a cell model, we 
performed immunoprecipitations of V5-tagged tau from HeLa C3 cells after 
treatment with JG-48. Consistent with the ELISA, JG-48 significantly enhanced 
binding of Hsp70 to tau (Figure 2.6B). Taken together, these results suggested a 
correlation between apparent affinity and tau turnover in cells (Figure 2.6A). 
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Figure 2.6 Affinity of the Hsc70-tau complex, measured in vitro, roughly correlates with the stability of tau in 
cells. (B) JG-48 increases co-immunoprecipitation of Hsp72 with tau. A representative blot of two 
independent experiments is shown. (C) Correlation between the relative affinity of the Hsc70-tau complex 
from the ELISA with the levels of tau in treated cells. 
 
2.4.7 JG-48 preferentially stabilizes binding of Hsp70 to disease-
associated tau variants 
One of the unexplained aspects of JG-48 activity is its ability to preferentially 
enhance the turnover of disease-associated tau variants (see Figure 2.2). To 
better understand this selection process, we measured binding of Hsc70 to 
disease-associated tau variants in the ELISA format. A152T is a point mutation 
linked to PSP and other tauopathies, while K280Q mimics a lysine acetylation 
that is also associated with these disorders [21, 62, 63].  We found that, 
compared to wild type 4R0N tau, these variants had significantly worse affinity for 
Hsc70. Specifically, A152T had an affinity of 9.9 ± 1.0 µM and K280Q had an 
affinity of 16 ± 1.9 µM (Figure 2.7A), compared to the 5.8 µM of wild type. These 
results suggest that some disease-associated variants have a weakened affinity 
for chaperone, which might contribute to their aberrant accumulation in disease. 
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Because the point mutations are not located in known chaperone-binding sites 
[29, 30, 64], these effects likely occur through long-rage structural changes.  
 
Figure 2.7 JG-48 improves the binding of Hsp70 to disease related mutants as well as their clearance. (A) 
ELISA results show that JG-48 increases the binding of Hsc70 to tau variants with point mutants related to 
tauopathy. Results are the average of two independent experiments performed in triplicate and error bars 
represent the SD. (B) JG-48, but not JG-273, reduces K280Q and A152T levels in transiently transfected 
HeLa cells. Results are the average of two independent experiments and error is SEM. Statistical analysis 
was performed using a 2-way ANOVA with Dunnett’s test.*p<0.05, **p<0.005. 
Next, we tested whether JG-48 might enhance the affinity of Hsc70 for the A152T 
and K280Q forms of tau. Indeed, JG-48 had a dramatic effect on the affinity of 
these complexes. JG-48 (10 µM) increased affinity for A152T tau by 5-fold and 
K280Q tau by nearly 7-fold (Figure 2.7A). In the presence of JG-48, these 
affinities were now comparable to, or better than, the affinity of the wild type 
complex. These results suggest the possibility that JG-48 normalizes tau 
interactions and thereby promotes clearance. Indeed, the levels of tau in cells 
expressing K280Q, A152T and 4R0N tau were highly sensitive to JG-48, but not 
JG-273 (Figure 2.7B). 
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2.4.8 Over-expression of Hsc70 interacting protein (HIP) mimics the 
effects of JG-48 on tau turnover 
Based on these results, we considered a model in which chaperone uses affinity 
for its clients to guide quality control decisions (Figure 2.8). When tau is released 
from microtubules, it is known to encounter the chaperones [1]. The tau-bound 
chaperone would then be expected to cycle through nucleotide states, in 
collaboration with co-chaperones. In the proposed model, Hsc70 and Hsp70 
might “choose” to release tau back to the microtubule for re-binding if the ADP- 
bound complex is sufficiently transient. However, if the tau complex is relatively 
long-lived, it might favor degradation, perhaps through recruitment of UPS or 
autophagy effectors. A key prediction of this model is that stabilizing the tau 
 
Figure 2.8 Model for Hsc70-mediated tau triage, in which prolonged association in the ADP-bound state 
favors turnover. JG-48 activates tau degradation by stabilizing the Hsc70 substrate-bound state. 
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complex should shift the balance towards turnover. This model might explain why 
over-expression of Hsc70 protects tau levels, while Hsp70 favors degradation, 
because Hsp70 is known to have a significantly tighter affinity for tau [30]. 
 
To test this model in a different way, we over-expressed the co-chaperone HIP in 
HeLa C3 cells. As mentioned above, HIP competes with NEFs for binding to 
Hsp70 and Hsc70 and, like JG-48, it stabilizes client binding [16]. Indeed, we 
found that over-expression of HIP in HeLa C3 cells decreased tau to a level 
comparable with that seen after JG-48 treatment (Figure 2.9). This result, 
obtained using a completely complimentary approach, supports the general 
model. 
 
 
2.5 Discussion 
A network of chaperones, co-chaperones and stress response pathways is 
tasked with maintaining normal proteostasis [65]. In this network, Hsp70s are 
considered to be the “triage chaperones” that are involved with the folding or 
degradation of many clients [66, 67]. This system is emerging as a potential drug 
target in a number of diseases, including cancer and neurodegeneration [68-71]. 
Therefore, there is great interest in better understanding the molecular 
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Figure 2.9 Hsc70 Interacting Protein (HIP) 
phenocopies compound effect on tau stability. HIP 
has the same effect on tau stability as JG-48 
suggesting a similar mechanism of action. A 
representative blot of two independent experiments 
is shown. 
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mechanisms of Hsp70 with the ultimate goal of rebalancing these decisions to 
treat disease.  
 
In this study, we have taken advantage of a new set of chemical probes, 
combined with new point mutants, to explore these mechanisms. As mentioned 
in Chapter 1, the key enabling observation was that Hsp70 inhibitors, such as 
YM-01, cause a robust loss of tau in disease models [31]. These findings 
suggested to us that YM-01 might be a powerful chemical probe for 
understanding Hsp70 mechanisms. Before embarking on such a study, we first 
had to resolve problematic features of YM-01, removing spectral properties that 
interfered with many biochemical measurements. This exercise yielded JG-48, 
which retained the ability to reduce abnormal tau in cultured cells and in other 
models of tauopathy (see Figure 2.1 and 2.2). By systematically examining many 
possible mechanisms (e.g. effects on ATPase activity, protein-protein 
interactions, etc.), we eventually found that the stability of the tau complex, as 
measured in vitro, seemed to best predict effects on tau turnover in cells. This 
prediction was then tested using an expanded collection of chemical and genetic 
perturbations, leading to a model in which one of the factors governing client 
triage (at least for tau) appeared to be its affinity for the chaperone.  
 
This model, like many, leads to interesting, unanswered questions. What are the 
key factors that normally determine the affinity of Hsp70/Hsc70 for its clients? We 
found that some disease-associated tau mutants, such as K280Q, have a 
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weakened intrinsic affinity. This diminished binding might allow them to partially 
avoid the chaperone system, perhaps contributing to their accumulation and role 
in disease. Thus, it is tempting to speculate that Hsp70/Hsc70 might use affinity 
to enact similar quality control decisions for other clients too. These chaperones 
typically interact with extended, linear polypeptides containing hydrophobic 
residues, such as those commonly found in the interior of globular folded proteins 
[66, 72]. Thus, if a client is folded, it likely loses affinity for Hsp70s, whereas, if a 
client has trouble folding, it might be predicted to bind better. This feature might 
allow Hsp70 to preferentially remain bound to misfolded clients and, under 
conditions of sufficient dwell time, recruit effectors of degradation. This elegant 
model might explain why Hsp70 is able to operate on an entire proteome 
because relatively simple, physical metrics are used to enact fate decisions. 
 
As mentioned above, over-expression of Hsp70 is known to lead to tau 
degradation, while over-expression of Hsc70 leads to its retention [30]. More 
recently, a dominant negative mutation of Hsc70 was found to induce tau 
degradation [2], suggesting that Hsc70, like Hsp72, is capable of linking tau to 
degradation if its ATPase activity is disrupted. Consistent with this idea, the 
binding site for JG-48 is invariant between Hsc70 and Hsp72; thus, our results 
suggest that interruption of either paralog’s ATPase activity in cells may initiate 
tau turnover. Still Hsp70 is expected to play a prominent role because it has a 
tighter intrinsic affinity for tau and because it better couples with CHIP [30]. The 
expression of Hsp70 is strongly induced by stress, so a stress-associated 
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change in the Hsc70:Hsp70 ratio might favor turnover of tau by increasing the 
proportion that is stably bound by chaperone. Likewise, aging might dampen the 
stress response [73, 74] and make cells less able to defend themselves against 
tau accumulation. 
 
The binding site of Hsc70 and Hsp70 on tau is overlapping with the regions 
required for microtubule binding [29]. Further, this same region is required for tau 
aggregation [75]. Thus, there are multiple protein-protein interactions that 
converge on this functionally important, but potentially dangerous region [75, 76]. 
As mentioned above, many disease-associated changes in tau, such as PTMs 
and point mutants, reduce binding of tau to microtubules, perhaps flooding the 
cytosol with aggregation-prone tau molecules. Hsp70s need to deal with this 
situation by either helping tau back onto the microtubule or by recruiting 
degradation effectors, such as CHIP. The results outlined here suggest that the 
logic of this system (e.g. whether this tau is ultimately retained or degraded) may 
be the result of a delicate balance of competing affinities. In disease or aging, 
this delicate balance may be tipped towards tau aggregation, whereas JG-48 or 
stress responses might counter-balance this disruption by removing excess tau.  
 
It seems likely that the decision to retain or degrade tau should be impacted by 
additional factors, including the availability of co-chaperones. NEFs might be 
particularly important because they would be expected to help release tau from 
the Hsp70 complex. In other words, NEFs might be the key timing mechanism of 
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quality control. This general concept is supported by the findings that BAG1 
overexpression increases total tau levels in an Hsp70 dependent manner [54]. 
Beyond tau, BAG2 and HspBP1 are known to prevent CHIP ubiquitination of the 
other Hsp70 clients, Raf-1 and cystic fibrosis transmembrane conductance 
regulator (CFTR) [77, 78], and BAG5 interferes with CHIP-assisted ubiquitination 
of α-synuclein [79] and the tumor suppressor PTEN [80]. These findings support 
the idea that the release of clients is associated with retention and that NEFs are 
important in “tuning” client dwell time. However, it is important to note that BAG1 
coordinates with CHIP to target some Hsc70 clients for proteasomal degradation 
[55, 81]. Additionally, BAG2 is reported to increase ubiquitin-independent 
degradation of phosphorylated tau [82]. These findings illustrate the difficulty in 
identifying clear “rules” for protein quality control and, rather, point to a model 
that needs to take into account the specific properties of the individual clients, 
including its intrinsic affinity for chaperone. That being said, over-expression of 
HIP increases the clearance of not only tau, but other Hsp70 clients such as α-
synuclein and polyQ-AR [83, 84], so client affinity may be a fundamental 
mechanism of quality control. 
 
2.6 Methods 
2.6.1 Cell culture and immunoblotting 
HeLa C3 cells were stably transfected with V5-4R0N tau as previously described. 
Cells were cultured in supplemented Opti-MEM media. Cells were plated into 6-
well plates (Corning) or 12-well plates (Corning) and treated with compound at 
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indicated concentrations for 24 hrs before lysis with RIPA buffer (150 mM sodium 
chloride, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, 
pH 8.0) supplemented with protease inhibitor, PMSF and NaF. Following 
quantification, lysates were loaded to 10% gels (BioRad) and proteins identified 
via Western blot. For Hsc70 mutant transfections, HeLa C3 cells were plated into 
12-well plates (Corning) and indicated amount of plasmid was added with 
Lipofectamine 3000 (Invitrogen). Transfection was allowed to proceed for 24 hrs 
before lysis with RIPA buffer. For HIP transfection, HeLa C3 cells were plated 
into 6-well plates (Corning) and indicated amounts of plasmid were added with 
Lipofectamine 2000 (Invitrogen). Transfection was allowed to proceed for 24 hrs 
before lysis with RIPA buffer. Cell or tissue lysates were separated and 
immonoblotted via Western blot. All quantification of Western blots was 
performed with NIH Image J or Biorad Image Lab analysis.   
 
2.6.2 Brain aggregate cultures 
Brain aggregates are prepared from E15 days rTg4510 mouse brains. Briefly, a 
pool of E15 day mouse brains are dissociated through two nylon meshes and 
plated in a 96-well plate. A sphere-shaped brain aggregate formed in each well is 
cultured in DMEM H21 supplemented with glucose (6 g/L), gentamicin (50 mg/L) 
and 10% FBS. At 15 days in culture, they are infected with 5 μL of 10% brain 
homogenates of rTg4510 mice for 10 days. They are treated with 10 μM of YM-
01 or JG-48 for 24 hrs before harvesting at 35 days in culture. They are fixed with 
4% paraformaldehyde for 3 days. Fixed brain aggregates are washed with PBS 
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for 1 hr (3X) and incubated with blocking buffer (0.3% Triton X-100, 0.1% Tween 
20, 2% bovine serum albumin and 10% normal goat serum in PBS) overnight 
and stained with primary antibodies (PHF-tau (MN1020, Thermo Scientific) and 
anti-beta tubulin (H-235, Santa Cruz Biotech); 1:100) for 3 days. After incubation 
with primary antibodies, they are washed with PBS and incubated with secondary 
antibodies (goat anti-rabbit IgG conjugated with Alexa633 and goat anti-mouse 
conjugated with Alexa568, Jackson Immunoresearch Laboratory; 1:800) 
overnight. After washing with PBS for 1 hr (3X), they were coversliped with 
Vectashield mounting media containing DAPI (H-1500, Vector laboratories). 
Confocal images are taken with a Leica SP8 confocal microscope and 15-20 z-
sectioned images are stacked together before measuring phospho-tau intensity 
with Image J. 
 
2.6.3 Slice cultures 
Hippocampal slices from 4 month old rTg4510 or wild type mice were perfused 
with JG-48 (30 µM) or 1% DMSO vehicle control for 6 hours. Baseline signal was 
recorded for 20 min, LTP was induced with TBS (5 bursts of 200 Hz separated by 
200 ms, repeated 6 times with 10 s between the 6 trains), and LTP was recoded 
for 60 min as previously described [31]. Changes in fEPSP slope are expressed 
as a percentage of baselines. 
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2.6.4 Protein expression and purification 
Hsc70, Hsp70 and their co-chaperones were expressed and purified using 
previously reported methods [49]. Apo chaperone was prepared from several 
days of dialysis in assay buffer (0.017% Triton X-100, 100 mM Tris-HCl, 20 mM 
KCl, and 6 mM MgCl2, pH 7.4) at 4 °C to remove nucleotide. 
 
2.6.5 NMR 
Titration studies were carried out as previously described [36]. NMR samples of 
160 μM 15N labeled Hsc70NBD in 25 mM TrisHCl, 10 mM KCl, 8 mM MgCl2, 10 
mM PO42-, 0.015% NaN3, 5% D2O and pH 7.0 was treated with either DMSO 
alone or JG-48 (200 µM). TROSY-HSQC data was processed in NMR PIPES 
and converted to SPARKY format. Spectra were manually analyzed in SPARKY.  
 
2.6.6 Fluorescence Polarization  
ATP-FAM. Fluorescence polarization experiments were performed in 384-well, 
black, low volume, round-bottom plates (Corning) using a SpectraMax plate 
reader. Increasing amounts of compound were incubated with nucleotide-free 
Hsc70 (400nM) and ATP-FAM (20 nM) (Jena Bioscience) for three hours at room 
temperature in assay buffer (0.017% Triton X-100, 100 mM Tris-HCl, 20 mM KCl, 
and 6 mM MgCl2, pH 7.4) prior to measurement by plate reader (Ex. 485 nm, Em. 
535nm, 530nm cutoff). The final DMSO concentration in each well was 4% and 
compounds were serially diluted two-fold in 100% DMSO. All data was 
subsequently analyzed by Prism (Graphpad Software).  
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HLA-FAM. Experiments were adapted from previously reported methods [49]. 
Briefly, 5 µM Hsc70 in the presence of 1 mM ADP was incubated with 25 nM 
HLA-FAM and treated with increasing concentrations of NEF proteins in 384-well, 
black, low volume, round-bottom plates (Corning) in the presence and absence 
of compound for 2 hrs at RT in assay buffer (0.017% Triton X-100, 100 mM Tris-
HCl, 20 mM KCl, and 6 mM MgCl2, pH 7.4). Following incubation, fluorescence 
polarization was measured using a SpectraMax plate reader (Ex. 485nm, Em. 
535nm, 530nm cutoff). All data was subsequently analyzed by Prism (Graphpad 
Software). 
 
2.6.7 ATPase Assay 
Assay was adopted from previously reported methods [44]. Briefly, Hsc70 (1 μM), 
J-protein (0.2 μM), 1 mM ATP and increasing amounts of NEF were incubated for 
1-2 hours in assay buffer (0.017% Triton X-100, 100 mM Tris-HCl, 20 mM KCl, 
and 6 mM MgCl2, pH 7.4) in the presence and absence of compound. The final 
DMSO concentration was 4%. Afterwards, 80 µL of malachite green reagent was 
added for phosphate detection followed by the addition of sodium citrate to halt 
non-enzymatic ATP hydrolysis. Absorbance was measured by a SpectraMax 
plate reader (OD620) to determine phosphate concentration. 
 
2.6.8 Luciferase Refolding 
Assay was adopted from previously reported methods [85]. Briefly, denatured 
luciferase (100 nM) was incubated with Hsc70 (1 µM), J-protein (0.2 µM), 1 mM 
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ATP and increasing amounts of NEF in assay buffer (23 mM HEPES, 120 mM 
KAc, 1.2 mM MgAc, 2.2 mM DTT, 1 mM ATP, 8.8 µM creatine phosphate, 
35U/mL creatine kinase pH 7.4) for one hour in the presence and absence of 
compound. The final DMSO concentration was 4%. After the addition of the 
SteadyGlo reagent (Promega), luminescence was measured in a SpectraMax 
plate reader to determine the amount of refolded luciferase. 
 
2.6.9 Flow Cytometry Protein Interaction Assay (FCPIA) 
Procedure is adapted from previously reported methods [86]. Biotinylated Hsc70 
was immobilized on polystyrene streptavidin coated beads (Spherotech), 
incubated with Alexa-Fluor 488 labeled NEF (50 nM) and increasing amounts of 
compound in buffer A (25 mM HEPES, 5 mM MgCl2, 10 mM KCl, 0.03% Tween-
20 pH 7.5). Protein complex inhibition was detected by measuring bead-
associated fluorescence using an Accuri C6 Flow Cytometer. DMSO is used as a 
negative control and 1 µM excess unlabeled Hsc70 is used as a positive control. 
 
2.6.10 Tau Binding ELISA 
Method was adapted from a previous report [29]. Briefly, 1 µM human Hsc70 (30 
µL) was immobilized overnight at 37 °C in clear, non-sterile 96-well plates 
(Thermo) in 50mM MES (pH 5.5) and 0.5 mM DTT with 1 mM ADP. Wells were 
washed with 100 µL of PSB-T (3 x 3 min., rocking) prior to the addition of 30 µL 
of 4RON tau solution in binding buffer (25 mM HEPES, 40 mM KCl, 8 mM MgCl2, 
100 mM NaCl, 0.01% Tween, pH 7.4) with 1 mM ADP and 1 µL of either DMSO 
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or compound for 3 hrs at RT. After blocking in 5% milk, quantification of tau 
binding was performed using rabbit anti-tau (H150) primary antibody (Santa 
Cruz, sc-5587, 1:2000 in TBS-T, 50 µL/well) and goat anti-rabbit HRP-conjugated 
secondary (Anaspec, 28177, 1:2000 in TBS-T, 50 µL/well). TMB substrate (Cell 
Signaling, 7400L) and 1N HCl were used to detect binding. Absorbance was 
measured using a SpectraMax plate reader (OD450). Minimal, non-specific 
binding of 4R0N tau to empty wells was subtracted as background and curves 
were fit using non-zero intercept hyperbolic fits in Prism (GraphPad Software).    
 
2.6.11 Immunoprecipitation of V5-Tau 
The co-immunoprecipitation procedure was adopted from previously described 
methods [29]. Briefly, HeLa C3 cells were treated with bortezomib in a final 
concentration of 5 μM for 4 hours prior to lysis in mammalian protein extraction 
reagent (Thermo Scientific). Following protein quantification, 5 mg of lysate was 
incubated with 40 μL of anti-tau antibody (Santa Cruz, sc-166060) and 50 μM 
JG-48 or DMSO (5%) at 4 °C in the dark overnight. Lysate was incubated with 
normal goat IgG with DMSO (4%) as a negative control. Beads were then 
conjugated to Protein A/G agarose beads (Santa Cruz, sc-2003) for 4 hours at 4 
°C and washed 3 times with 100 μL of PBS (Gibco) at 1000xg for 1 minute. 
Proteins were eluted by boiling at 96 °C in 40uL of SDS loading dye, and 10 μL 
of sample were separated on 4-15% Tris-trycine gels (Bio-rad) and transferred to 
nitrocellulose membrane. The membranes were blocked in nonfat milk (5% milk 
in TBS, 0.5% Tween) for 1 hour, incubated with primary antibodies for Tau 
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(Santa Cruz, sc-5587) and Hsp72 (Enzo, ADI-SPA-811) overnight at 4 °C in the 
dark, washed, and then incubated with a horseradish peroxidase-conjugated 
secondary antibody (Anaspec, 28177) for 1 hour. Finally, membranes were 
developed using chemiluminescence (Thermo Scientific, Supersignal® West 
Pico).       
 
2.6.12 Protein Dynamics and Molecular Modeling 
Computational modeling of JG-48 binding to Hsc70NBD (PDB: 3C7N) was 
obtained using similar methods as previously described [34, 35]. Briefly, 
AUTODOCK-4.2 was used for the docking of JG-48 to Hsc70NBD with the 
following parameters: GA runs = 100, initial population size = 1500, max number 
of evaluations = long, max number of surviving top individuals = 1, gene mutation 
rate = 0.02, rate of crossover = 0.8, GA crossover mode: two points, Caushy 
distribution mean for gene mutation = 0, Cauchy distribution variance for gene 
mutation = 1, number of generations for picking worst individuals = 10. The 
docked structures were clustered and then evaluated using PyMOL. All 
calculations were completed on an Apple MacBookPro computer equipped with a 
64-bit 2.4 GHz Intel Core 2 Duo processor running MacOSX 10.6.8. 
 
2.6.13 Synthesis of JG-48 and JG-273 
First, functionalized anilines were cyclized by reaction with potassium ethyl 
xanthate, and the product was methylated by methyl iodide. The substituted 2-
(methylthio)benzothiazole was reacted with p-TsOMe to afford its 
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methylthioiminium salt, which was subsequently condensed with various N-
ethylrhodanine. The product was activated by p-TsOMe, followed by the 
condensation with 1-((1,3-dioxoisoindolin-2-yl)methyl)-2-methylpyridin-1-ium 
bromide. Finally, the protection group on the pyridine nitrogen was removed in 
the presence of catalytic amounts of aqueous ammonium hydroxide. Final 
products were collected in overall yield of approximately 40%. 
 
JG-48: 1H NMR (400 MHz, DMSO) δ 8.55 (d, J = 4.1 Hz, 1H), 8.12 (s, 1H), 7.67 
(dd, J = 7.9, 5.2 Hz, 1H), 7.63 (dd, J = 7.4, 1.8 Hz, 1H), 7.46 (d, J = 8.7 Hz, 1H), 
7.27 (d, J = 8.0 Hz, 1H), 6.97 (ddd, J = 7.3, 4.9, 1.1 Hz, 1H), 6.25 (s, 1H), 3.98 (s, 
3H), 3.91 (q, J = 7.0 Hz, 2H), 1.21 (t, J = 7.1 Hz, 3H). ESI-MS: calculated for 
C20H17F3N3OS2+ 436.08, found 436.04. 
 
JG-273: 1H NMR (400 MHz, DMSO) δ 8.47 (d, J = 4.3 Hz, 1H), 7.59 (td, J = 7.8, 
1.7 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H), 6.90 (dd, J = 6.7, 5.4 Hz, 1H), 6.08 (s, 1H), 
3.81 (d, J = 7.1 Hz, 2H), 3.65 (t, J = 7.3 Hz, 2H), 3.32 (s, 3H), 3.08 (t, J = 7.2 Hz, 
2H), 1.14 (t, J = 7.0 Hz, 3H). ESI-MS: calculated for C15H18N3OS2+ 320.09, found 
320.13. 
 
Notes 
This work was adapted from published material entitled “Stabilizing the Hsp70-
Tau Complex Normalizes Proteostasis in a Model of Tauopathy” Young, ZT, 
Rauch, JN; Assimon, VA; Jinwal, UK; Ahn, M; Li, X; Dunyak, BM; Ahmad, A; 
 71 
Carlson, GA; Srinivasan, SR; Zuiderweg, ERP; Dickey, CA; Gestwicki, JE. (2016) 
Cell Chemical Biology (in press). 
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2.7 Appendix 
 
Appendix 2.1 Compound synthesis and characterization. (A) Synthetic route to JG-48 and JG-273. (a) 
Potassium ethyl xanthate, DMF, 4 h, 125 °C; 2. methyl iodide, triethyl-amine, ethanol, 1 h, 80 °C (b) methyl 
p-toluenesulfonate, anisole, 125 °C; for JG-273, was used as starting material. (c) 3-ethylrhodanine, 
triethylamine, acetonitrile, 4 h, 25 °C (d) methyl p-toluenesulfonate, DMF, 3 h, 135 °C (e) triethyl-amine, 
acetonitrile, 3 h, 70 °C (f) aqueous ammonia, DCM/methanol (1:3), 1 h, r.t. See the methods for NMR and 
MS characterization. (B) Spectral properties of JG-48, showing that it is less fluorescent at 535/620 nm, 
which is critical for its use in biochemical assays. (C) JG-48 (10 µM) has no effect on LTP in non-transgenic 
hippocampal slices from 3-4 month old WT mice. fEPSP traces are an average of JG-48 (n=9) or vehicle-
treated (n=4). 
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Appendix 2.2 Representative results from ATPase and luciferase refolding experiments. (A) Stimulation of 
ATPase activity by DnaJA2 is mildly inhibited. Similar results were seen for other DnaJ family members (se 
Figure 2.3.B). Likewise, inhibitors blocked stimulation of Hsc70 by BAG-1 and similar results were seen for 
other NEFs (see Figure 2.3.B). The control compound, JG-273, was inactive. Results are the average of 
three independent experiments performed in triplicate each. Error bars represent the standard deviations. 
Compounds were assayed at 50µM. Hsc70 = 1 µM. (B) None of the compounds (50µM) interfere with the 
enzyme activity of native firefly luciferase. (C) Luciferase refolding was measured by luminescence after 
treatment of denatured luciferase with chaperone systems. Representative results are shown for DnaJA2 
and BAG-1, while similar results were seen for other J proteins and NEFs (see Figure 2.3.B). Results are the 
average of two independent experiments performed in triplicate each. Error bars represent the standard 
deviation. Compounds were assayed at 50µM. Hsc70 = 1 µM. (D) Chemical structures of Hsp70 modulators 
assayed. 
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Appendix 2.3 Controls and raw data for the correlation studies in Table 2.1 and Figure 2.5. (A) ELISA study 
on the effects of Hsc70 inhibitors on tau affinity. (B) Sample of the raw data showing the effects of Hsc70 
manipulations on tau levels in HeLaC3 cells. Results are representative of experiments performed in 
duplicate each and error bars represent the SEM. (C) Sample of the raw data showing the effects of Hsc70 
mutations on tau levels in HeLaC3 cells. Results are representative of experiments performed in duplicate 
each and error bars represent the SEM. (D) Raw data showing the effects of Hsc70 paralogs on tau levels in 
HeLaC3 cells. Results are representative of experiments performed in triplicate each and error bars 
represent the SEM. 
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Chapter 3 
Functional Genomics Guides Hsp70 Target Validation in a Phenotype 
Driven Medicinal Chemistry Campaign 
 
 
3.1 Introduction 
In Chapter 2, I described the use of rhodacyanine analogs, such as JG-48, as 
inhibitors of the molecular chaperone Hsp70. In addition to its roles in tau 
homeostasis, Hsp70 is also predicted to be a promising target in cancer because 
of its high expression in transformed cells and its key roles in anti-apoptotic 
signaling. Therefore, there was interest in developing JG-48 and its analogs as 
possible anti-cancer agents. Accordingly, hit-to-lead studies on JG-48 produced 
~450 analogs and led to improvements in both potency (EC50 ~ 30 nM) and 
safety (therapeutic index ~100) in cell-based viability assays. Like most 
successful hit-to-lead studies, we noticed “jumps” in safety and efficacy as the 
campaign progressed, ultimately improving activity by approximately two orders 
of magnitude. In phenotypic assays, these improvements are often ascribed to 
better on-target binding, reduced off-target binding, better membrane 
permeability or some combination of these factors. However, the “black box” 
nature of phenotypic assays often prevents deeper insight into the mechanistic 
origins of the improvements, precluding the purposeful exploitation of the driving 
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feature. We envisioned that this model system and our experience in Hsp70 
biology (see Chapter 1 and 2) might provide an opportunity to reveal the 
mechanistic reasons of improved activity throughout the medicinal chemistry 
campaign in “real time”. Specifically, we reasoned that full-genome CRISPR 
knockdown technology (termed CRISPRi) might be deployed to profile the on- 
and off-target activity of benchmark molecules through the chemical series, with 
a special focus on molecules near the activity “leaps”. Using this approach, we 
confirmed that the rhodacyanines require Hsp70 for their activity in cells, but, 
unexpectedly, we found that greater selectivity was associated with a switch from 
inhibition of mitochondrial and cytoplasmic Hsp70 to preferential inhibition of 
endoplasmic reticulum Hsp70. Using microscopy and genetics, we confirmed that 
compounds partitioned into distinct sub-cellular compartments and that this 
localization was important for their relative safety in normal fibroblasts. These 
findings provide unprecedented insight into the mechanistic reasons for improved 
activity during phenotype-driven medicinal chemistry campaigns. In addition, they 
illustrate that specific Hsp70 paralogs are better targets than others for cancer.  
 
3.2 Current methods for target validation  
Treating disease requires the careful selection of relevant protein targets that can 
be modulated to produce a desired phenotype. Often, the suitability of the target 
is first confirmed using genetics, such as knockdowns or the results of genome-
wide association studies (GWAS). Then, the initial inhibitor scaffold is uncovered 
through a screening approach and iteratively improved through a medicinal 
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chemistry campaign to advance affinity, selectivity, pharmacokinetics and other 
parameters. At the conclusion of the campaign, confirmation of target 
engagement in cells and animals and phenotype evaluation in a given disease 
model are performed to help guide the selection of candidates for further clinical 
and pre-clinical development. The initial goal of a clinical trial, especially for novel 
targets, is often to confirm (or deny) that engaging the target is indeed safe and 
effective.  
 
While drug discovery can bottleneck at the pharmacokinetic and 
pharmacodynamics stage [1], rigorous assessment of target engagement 
remains a major challenge to overcoming costly failures of potential drugs in 
Phase I and Phase II clinical trials [2-5]. Retrospective analyses of failed trials 
performed by major pharmaceutical companies suggest that target engagement 
is sometimes not satisfyingly confirmed, raising questions as to whether the initial 
hypothesis of the target’s possible role in disease was addressed.  
 
How does one know that a phenotypic change occurs through the action of a 
small molecule on a specific protein target? One approach is to use 
computational protein modeling to predict compound binding sites and 
interactions; however, this practice works best when a target is known and a 
protein structure is available. Furthermore, this approach, along with biochemical 
characterization of rationally designed compounds binding to known targets, 
does not account for off-target or non-specific binding to proteins which can lead 
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to complications early in clinical development. Another method is 
chemoproteomics, in which immobilized small molecules are used to identify 
binding partners. Eluted proteins can be separated and analyzed by mass 
spectroscopy to identify or confirm binding of compounds to a protein targets, a 
method which was recently applied to find chemical probes for the chaperones 
Hsp70 [6] and Hsp90 [7]. Another form of chemoproteomics, competitive activity 
based protein profiling (ABPP), utilizes affinity probes based on natural protein 
ligands. Competitive ABPP can be used to characterize compounds by revealing 
proteins that are blocked from binding the probes in the presence of test 
compounds [8]. Chemoproteomics is valuable in its ability to evaluate compound 
selectivity in that small molecules with multiple binding partners can be easily 
distinguished. Nevertheless, this approach is currently limited to application with 
protein classes such as kinases, cysteine proteases and ATP binding proteins 
which have ligands that are easily modifiable into affinity probes [2, 8]. A variant 
of this approach is theranostics, in which the molecule is appended to an imaging 
agent suitable for PET, such that target engagement and retention can be 
directly correlated with outcomes [9]. 
 
Because of the time and cost involved in probe development, these approaches 
rarely allow careful analysis of target engagement throughout the medicinal 
chemistry campaign. Rather, these methods are often deployed at the conclusion 
of the process, only on the “best” molecules. We wondered if emerging methods 
in whole-genome CRISPR screens might be used to over-come this limitation 
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and provide detailed insight into target validation at each incremental step in a 
medicinal chemistry campaign, with the goal of providing “real time” guidance 
into on- and off-target binding.  
 
3.3 CRISPR genetic screens as a new tool for target identification 
Functional genetic screening modalities like RNA interference (RNAi), have been 
applied to cancer and neurodegenerative disease models in order to identify 
targets of small molecules [10, 11] or identify genes with the potential to become 
drug targets. Recently, clustered regularly interspaced short palindromic repeats 
(CRISPR) has emerged as a complementary method, with superior selectivity 
and the ability to be adopted for either gene deletion, modification or 
amplification. The CRISPR interference (CRISPRi) technology utilizes an 
adapted Cas9 nuclease system with a designed short hairpin guide RNA 
(sgRNA) that both activates Cas9 and recognizes a specific DNA sequence 
leading to gene silencing through inhibition of translation [12]. With a designed 
library of sgRNAs to target specific genes, CRISPRi can be used for profiling 
genome wide repression of protein expression [13]. When applied to drug 
discovery, benefits of CRISPRi include a comprehensive exploration of small 
molecule mechanism through definition of on-target and off-target pathway 
activation. Functional genomic screens also provide insights into mechanisms of 
compound trafficking, such as which ABC transporters might be used to gain 
entry. CRISPRi screens can even be performed in parallel with CRISPR 
activation (CRISPRa), in which the dCas9 is appended to transcriptional 
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activation proteins, such that the sgRNA drives over-expression of the target 
protein. For some targets, especially those with some redundancy or multiple 
paralogs, CRISPRa might be expected to provide highly complementary 
information about which target is most important for the phenotype.  
 
Here we report that genome wide CRISPRi/a screens can be used to confirm the 
molecular chaperone Hsp70 as the target of the rhodacyanine compound series 
described in Chapter 2. Additionally, comprehensive sgRNA library coverage of 
Hsp70 paralogs revealed un-expected, preferential to organelle-specific Hsp70s 
that is tightly linked to the relative safety of the molecules. Fluorescence 
microscopy confirmed the proposed compound localization in the mitochondria, 
cytoplasm and ER. Using this knowledge, we used the compounds as chemical 
probes to reveal which distinct Hsp70 paralogs are superior targets for cancer, 
and tauopathy.  
 
3.4 Results 
3.4.1 Improvement of Hsp70 inhibitors through a structure-guided 
medicinal chemistry campaign. 
As discussed in Chapters 1 and 2, rhodacyanines, such as MKT-077, JG-48 and 
JG-98, bind to Hsp70 in a highly conserved allosteric pocket [14, 15]. 
HSPA8/Hsc70 is the constitutively expressed form of Hsp70 and is primarily 
located in the cytosol along with HSPA1A/Hsp72, which is highly expressed 
during cell stress. HSPA5 is the gene encoding binding immunoglobulin protein 
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(BiP), the endoplasmic reticulum (ER) localized form of Hsp70. Another major 
form is HSPA9 or mortalin which regulates protein homeostasis in the 
mitochondria. Sequence alignment shows that while these proteins have different 
localization in cells, the hydrophobic cleft where MKT-077 analogs bind has little 
variability (Appendix 3.1A).  
 
Other members of the Gestwicki group have been interested in developing MKT-
077 and its analogs as potential treatments for cancer. Based on the binding site 
of MKT-077 and JG-98 in Hsc70, Dr. Xiaokai Li synthesized a library of ~450 
analogs and, in collaboration with Dr. Hao Shao, tested each of them for anti-
proliferative activity in two breast cancer cell lines, MDA-MB-231 and MCF7, as 
well as two lines of normal fibroblasts, MEFs and IMR90s. Using MTT assays 
performed in quadruplicate, they calculated a growth inhibition value (GI50) and 
then calculated a relative therapeutic index (TI) by comparing the activity against 
the transformed and normal cells. In addition, each compound was tested for 
solubility by HPLC, projected membrane permeability in PAMPA assays and for 
metabolic stability in mouse liver microsome experiments. Compounds were 
synthesized and tested in groups of approximately 20 to 30 molecules and the 
holistic results of the assays were examined to help guide the next round of 
synthesis, with the goal of optimizing safety, solubility, potency and stability. 
Binding of a subset of the molecules to Hsc70 was tested in vitro, using 
biotinylated compounds in an ELISA format [16]. In addition, the binding site of a 
subset of molecules, including JG-98 and JG-48, were confirmed using HSQC 
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NMR [16]. Finally, a subset of molecules was tested for anti-tumor activity in 
xenograft models. After calculation of pharmacokinetic and pharmacodynamic 
parameters, Dr. Hao Shao developed a dosing scheme and found that JG-98 
and JG-231 were active in preventing tumor growth in mice (unpublished) [16, 
17]. Together, these results tentatively confirmed that Hsp70 is a potential drug 
target for breast cancer. Similar studies with other collaborators have shown that 
Hsp70 is also a good target for castration-resistant prostate cancer and multiple 
myeloma (data not shown), suggesting that this target might play relatively broad 
roles. Two former graduate students in the Gestwicki laboratory. Drs. Sharan 
Srinivasan and Laura Cesa, led studies to suggest that Hsp70 stabilizes anti-
apoptotic proteins, including IAP1/2 (data not shown). I contributed to many of 
these efforts, through the synthesis of a subset of analogs and the testing of 
others in assays described in Chapter 2. However, my primary interest was to 
leverage the ongoing medicinal chemistry campaign to understand target 
engagement and target selectivity. In turn, my goal was to use this knowledge to 
more deeply probe the roles of Hsp70 in tau homeostasis, as discussed in 
Chapter 1. More specifically, the relatively rapid pace of the anti-cancer projects 
provided a convenient platform for using CRISPRi/a, as described above. 
Importantly, the challenges facing this project were similar to many oncology 
drug discovery projects, in that the assays are primarily phenotypic (e.g. cell 
viability) so it isn’t always clear why improvements in potency or safety arise.   
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When we plotted compound number versus the anti-cancer GI50 values, the 
improvement in potency is clear (Figure 3.1A). Similarly, the relative safety of the 
molecules also improved, from about TI ~ 3 to TI >30 (Fig 3.1A; Appendix 3.7). 
Benchmark molecules through the campaign were then selected for closer 
inspection, including molecules from the early part of the series (i.e. MKT-077 
and JG-98; Figure 3.1B) and those points throughout the campaign (i.e. JG-194, 
JG-231, JG-294 and JG-345; Figure 3.1B). These particular compounds were 
selected because they represented points in the campaign associated with 
marked improvements in either potency or safety. We wondered if these 
transitions might be ascribed to specific changes in target engagement.  
 
Figure 3.1 Summary of the rhodacyanine chemical series. (A) Chronological compound number versus 
MCF-7 EC50 shows a strong increase in potency throughout the chemical series. (B) Diversity in the 
modifications to the rhodacyanine scaffold drive potency. (C) CRISPRi screens identify rhodacyanines which 
show preferential binding to Hsp70 paralogs  
MKT-077
JG-40
JG-98
JG-194
JG-231
JG-294
JG-345
JG-40 JG-98
JG-194
JG-231
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A. Increasing potency in the rhodacyanine chemical series is correlated with safety
C. Hsp70 inhibitor CRISPRi screenB. Structures of key compounds
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Using the benchmark compounds, we conducted comprehensive CRISPRi 
screening in collaboration with Luke Gilbert and Jonathan Weissman (UCSF). 
For these experiments, K562 cells with a stable and inducible dCas9 expression 
system are infected by lentiviral methods with a well-designed sgRNA library for 
broad gene silencing. Infected cells are treated with compounds JG-98, JG-194 
and JG294 and passaged for about 10 doublings. Treated cells are harvested 
and subjected to deep sequencing for sgRNA quantification (Figure 3.1C).  
Statistical comparison of sgRNA guide abundance in treated and untreated 
populations identifies genes that are significantly enriched or depleted by 
compound treatment. We expect guides for genes that are sensitive to 
compound treatment to deplete in the treated population when compared to 
untreated control cells. Guides for genes that confer resistance will enrich in the 
treated population when compared to control cells. We use rho (ρ) to represent 
compound phenotypes based on fold change in cell count compared to 
unselected cells. Plotting significant changes in frequency of sgRNA against rho 
reveals genes that are sensitive to compound (negative ρ) and resistant to 
compound (positive ρ) (Appendix 3.2, 3.3 and 3.4).  
 
Thanks to the use of a well-designed CRISPRi guide library with excellent 
coverage of the Hsp70 family of genes, we find varying degrees of preference for 
Hsp70 paralogs among the compounds. All three compounds show sensitivity to 
the Hsp70 paralogs HSPA9 (mitochondria) and HSPA5 (ER); however, both JG-
98 and JG-194 are most sensitive to HSPA9 while JG-294 shows a preference 
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for HSPA5 (Appendix 3.2, 3.3 and 3.4). Compounds JG-98 and JG-194 have 
very similar CRISPRi profiles in cells; however, comparison of JG-194 to JG-294 
highlights the differences in sensitive genes (Figure 3.2A, Appendix 3.7). In line 
with these results, GO term enrichment analysis of JG-194 hits reveals disruption 
of mitochondrial protein networks while JG-294 appears to mostly affect protein 
synthesis gene sets (Figure 3.2B). These findings point to potentially significant 
differences in compound mechanisms in cells, which might explain variabilities in 
potency and safety index. This is an important result because it shows, for the 
first time, that improvements in a medicinal chemistry campaign can arise from 
changes in on- and off-target binding. We are currently validating addition genes 
from the CRISPR screens, especially those that are not Hsp70 paralogs. One 
interest set is the ABC transporters because preliminary evidence suggests that 
the rhodacyanines might use these proteins to enter cells. Other possible off-
target proteins are included in Tables 3.2 and 3.3. We are also completing 
CRISPRa screens on each benchmark molecule. Recent results on JG-294 
seem to confirm the suspected role of BiP (data not shown). Unlike ABPP, this 
approach cannot be used to discern if a target is directly bound, only that altering 
its levels impacts the phenotype. Thus, some of the genes identified by CRISPR 
may be indirectly involved. Biochemical binding studies will be needed to explore 
this issue. Regardless, we were excited to see that Hsp70s (the desired target) 
were predominant in the datasets. The CRISPR screens take approximately 1 
month to complete and four molecules can be routinely tested at one time, so the 
speed of whole-genome interrogation is favorable. 
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Figure 3.2 Summary of CRISPRi screening data. (A) JG-98 and JG-194 have highly similar sensitive and 
resistant genes in cells suggesting these compounds have overlapping mechanisms. In contrast, JG-294 
has only a moderately similar CRISPRi profile to JG-98 and JG194, which underscores the differences in 
efficacy and safety for these compounds. (B) Identification of GO terms for compounds JG-194 and JG-294 
reveals a significant number of mitochondrial targets for JG-194 and several early protein synthesis targets 
for JG-294.   
3.4.2 Rhodacyanines partition distinctly in cells by fluorescence 
microscopy 
The CRISPR screens suggested that there was a “switch” from 
cytoplasmic/mitochondrial Hsp70s to ER Hsp70 during the course of the 
medicinal chemistry campaign. Specifically, JG-98 and JG-194 seemed to 
require mortalin for activity, while JG-294 and JG-345 required BiP. In order to 
test this theory, we first needed to confirm that compounds do in fact localize 
differently in cells by microscopy. We utilized the intrinsic fluorescence of the 
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rhodacyanine scaffold along with HeLa cells stably expressing fluorescent 
organelle markers to observe and quantify compound localization in live cells. 
Because of the broad excitation and emission spectrum of the compounds 
(Appendix 3.8), we used a far red monomeric infrared fluorescent protein (mIFP) 
to label the mitochondria and ER while preventing signal overlap with compounds 
[18]. After treatment with 1µM compound for 30 minutes, live cells were washed 
and imaged. Using a Manders calculation [19, 20], colocalization was quantified 
for each compound in both ER and mitochondrial labeled cells. Specifically, I 
found that both JG-98 and JG-194 show just over %70 signal colocalization with 
the mitochondria while the fraction of signal colocalization with the ER (~50%) is 
similar to that which is seen with a commercially available mitochondrial probe 
(Mito Tracker® Green) (Figure 3.4). These results confirm the HSPA9 sensitivity 
observed for JG-98 and JG-194 in the CRISPR screen. Interestingly, JG-231, a 
close analog of JG-294, shows the most ER localization in cells with 80% signal 
overlap. Preliminary results from a collaboration with Jeffrey Brodsky’s lab show 
that JG-231 induces mRNA levels and expression of HSPA5 and proteins 
involved in the regulation of the unfolded protein response (UPR) including 
CHOP (data not shown). We expect future CRISPRi/a screening of JG-231 to 
reveal important protein targets related to its subcellular localization.  
 
Although the CRISPRi results comparing JG-98 to JG-294 indicate a difference 
in cellular targets and mechanism, JG-294 has a cellular distribution profile 
similar to that off JG-98. It is possible that a longer incubation is required to   
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Figure 3.3 Measurement of compound localization in HeLa cells by fluorescence microscopy. (A) 
Rhodacyanines localize with mitochondria in cells. Images are representative of experiments performed in 
duplicate. (B) Only JG-231 localizes with the ER in cells. Images are representative of experiments 
performed in duplicate. (C) Control experiments show that the mitochondrial probe MitoTracker® colocalizes 
with mIFP labeled mitochondria but not ER. (D) Quantification of compound localization using Mander’s 
coefficients. Results are averages of at least two independent calculations and error bars represent SEM.  
observe distinct localization of JG-294 in cells; however, for these initial 
experiments, we monitored fluorescence after a 30-minute incubation in order to 
distinguish results from confounding factors such as cell death and potential 
degradation of signal. Now that we have validated fluorescence microscopy as a 
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platform for probing compound localization in cells, future experiments will utilize 
Z-stacks for 3D reconstruction of cellular organelles and robust colocalization 
quantification.  
 
3.4.3 Paralog specific rhodacyanines reduce tau levels with varying 
efficiency 
As discussed in chapters 1 and 2, Hsp70 is a strong target for normalizing tau 
homeostasis in instances of tau mislocalization or accumulation. While the 
effects of modulating Hsc70 and Hsp72 on tau stability are well-characterized, 
the roles of Hsp70 paralogs like BiP and mortalin have only been somewhat 
explored. The accumulation of tau in transgenic mice induces the unfolded 
protein response (UPR) in the ER in response to impairment of normal 
endoplasmic reticulum associated degradation (ERAD) [21]. A similar result was 
observed in HEK cells with inducible tau expression. In these cells, upregulation 
of tau simultaneously induced UPR as measured by increases in levels of BiP, 
ubiquitin and a pathway associated kinase [21]. Furthermore, activation of the 
UPR increases tau phosphorylation prior to tau aggregation signifying therapeutic 
potential in modulating ER degradation and stress pathways as a means of 
preventing tau pathogenesis [22, 23].  
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Figure 3.4 Rhodacyanines increase degradation of tau variants in HEK cells. Cells were treated with 5µM 
compound with the exception of JG-40 and JG-48 which were used at 10µM. Compounds were tested in 
duplicate and representative western blots are shown. Error bars represent the SEM. 
Given precedence for the role of the ER and BiP in tau quality control, we probed 
the ability of rhodacyanines to modulate tau levels in cells. HEK cells stably 
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expressing doxycycline (DOX) inducible tau variants were treated with 
compounds to measure degradation of disease-related tau mutants P301S,  
A152T and D348G. Each of these mutations cause aberrations in tau 
homeostasis which induce tau accumulation or aggregation and eventual cell 
death [24-28]. We also treated HEK cells expressing a tau variant with deletions 
of residues important for microtubule binding referred to as ∆277/278/308/309 
tau. Immunostaining of cell lysates shows that active compounds totally reduce 
tau levels after 24 hours for all of the tau variants tested (Figure 3.4). The 
strongest phenotype is observed with compounds JG-98, JG-194, JG-231 and 
JG-345, while the negative control JG-258 has no effect. Interestingly, all of 
these active compounds show preference for mitochondrial or ER Hsp70 
paralogs over the cytosolic versions which points to chaperone networks in these 
two organelles playing a significant role in tau degradation. Overexpression of 
BiP in the tau inducible cells leads to a dramatic reduction in tau levels, further 
pointing to BiP as an underexplored yet promising target for regulating tau 
homeostasis (Figure 3.5).  
 
Figure 3.5 BiP overexpression reduces levels of tau variants in HEK293 cells. Experiment was performed in 
duplicate and a representative blot is shown. C=control T=transfected. Error bars represent SEM. 
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As discussed in Chapter 2, we used Hsp70 mutants to illustrate that Hsp70 
affinity for substrates like tau is roughly correlated with client degradation in cells. 
Future work will utilize Hsp70 mutants to elucidate the role and function of Hsp70 
paralogs in models for diseases like tauopathy. Using docking models and 
previously reported protein NMR results [14, 16], Victoria Assimon, a former 
student in the lab, and I have designed and characterized Hsc70 point mutants 
with modified resides within the rhodacyanine binding site (Appendix 3.9A). 
Through analysis of co-chaperone mediated ATPase activity and luciferase 
refolding activity, I found that some mutants exhibit WT-like activity while others 
are either hyperactive or hypoactive (Appendix 3.9B and 3.9C). We expect the 
variability in enzymatic behavior of the Hsp70 mutants to manifest in vivo as 
mutants that stabilize substrate binding are likely to present phenotypes very 
different from mutants that destabilize Hsp70-tau complexes. Therefore, 
application of these point mutants to Hsp70 paralogs like BiP and mortalin are 
likely to result in varying phenotypes that will aid in understanding the role of 
subcellular Hsp70 networks in the initiation and transmission of pathology.  
 
3.5 Discussion 
CRISPR screening strategies have emerged for the identification of drug targets, 
resistance mechanisms and functional genomics. Here, we applied this 
technology to better understand how medicinal chemistry campaigns evolve 
during a phenotype-driven optimization. In the past, such optimization steps 
might have been “black box” efforts in which potency is improved without insight 
 100 
into on- or off-target interactions. As discussed above, our novel implementation 
of CRISPRi technology revealed distinct compound targets and we envision that 
this approach might represent a way to explain efficacy and/or safety “jumps” in a 
medicinal chemistry series. For example, we found that rhodacyanines exhibit 
preferential binding to individual Hsp70 paralogs (or sets of paralogs) and that 
less toxic/more effective molecules tended to bind BIP. JG-294 may be a 
particularly good lead candidate for developing BIP/HSPA5 selective inhibitors 
and future work in the Gestwicki laboratory will exploit these observations to 
further improve selectivity. In addition, we plan to complete additional CRISPRi 
screens to further aid in the design of more potent, selective and safe 
compounds. This effort will need to include a CRISPR-based method for 
simultaneously removing both cytoplasmic paralogs (Hsc70 and Hsp72) because 
these forms seem to be partly redundant. Because of the central role of Hsp70 in 
protein homeostasis, these CRISPR tools, as well as paralog specific Hsp70-
binding compounds will be particularly helpful in understanding which forms can 
be safely targeted for an individual disease. 
 
In addition to revealing Hsp70 paralog selectivity, the CRISPR screens also 
revealed other interesting mechanisms related to these compounds. For 
example, some of the genes that displayed strong resistance phenotypes 
following JG-294 treatment were members of the ER membrane protein complex 
(EMC) (Appendix 3.6 and 3.7). Because the role of the EMC is not well 
understood [29, 30], there is great opportunity to use JG-294 as a chemical 
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biology tool to understand functions of this protein complex and its implication in 
disease. Another important observation was that ABC transporters appeared to 
be broadly required for compound efficacy. For example, ABCC1 is a member of 
the multi drug resistant protein family, which is responsible for transporting 
biomolecules across cellular membranes. Knockdown limited compound activity, 
suggesting that it might serve a role in drug uptake. Additionally, we found that 
ATP1A1 and ATP1B3, which encode sodium and potassium ATPases, were 
strong hits in the CRISPRi screens. Because these proteins regulate osmolarity 
and the compounds contain a cationic pyridinium, these ion channels may also 
be involved in compound transport into the cell. Knowledge of compound 
trafficking mechanisms is likely to improve chances for success at the drug 
development and pre-clinical stages where an understanding drug 
pharmacokinetics is critical. Among the other genes identified in the CRISPR 
screens, there are likely off-target interaction partners. Although we have not yet 
validated any of these off-target partners, this approach may provide new 
opportunities to further guide safety and selectivity. 
 
Previous work has identified cytosolic Hsc70 networks and the compound JG-40 
as regulators of Dengue virulence [31]. However, JG-40 and JG-48 have weak 
activity in reducing tau levels in inducible tau models, whereas the compounds 
later in the chemical series, such as JG-294, exhibit strong anti-tau activity 
(Figure 3.5). These results suggest that certain Hsp70 paralogs are better targets 
for some diseases (e.g. cytosolic Hsp70 for Dengue viral infection and BIP for 
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tauopathies). Thus, molecules in this series might prove to be powerful chemical 
probes for understanding which Hsp70 paralogs are linked to individual diseases. 
We envision that it will be important to supplement these chemical tools with 
genetic ones, such as the point mutants developed above, because of the 
potential for off-target binding. 
 
The comprehensive and unbiased nature of CRISPRi screen makes application 
of this technology invaluable to drug discovery efforts. In this Chapter, I used 
whole genome CRISPR screen to understand compound selectivity and 
trafficking. Each screen required approximately 1 month to complete and four 
compounds can be explored simultaneously in the most recent set-up at UCSF.  
The throughput of this method permits testing of key molecules throughout a 
medicinal chemistry campaign – not just the lead candidates. I found that this 
approach could rather quickly characterize the targets of small molecules and 
help elucidate their mechanism of action. This method has the potential to 
remove the single largest barrier to phenotypic screens – which is the target 
identification step [32]. In addition, this approach can simultaneously identify 
biomarkers or sets of biomarkers. Our results illustrate that functional genomics 
offers many benefits, especially when used to in conjunction with phenotypic 
assays and medicinal chemistry campaigns.  
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3.6 Methods 
3.6.1 Synthesis 
JG-98: 1H-NMR (400 MHz, DMSO-d6): δ 8.26 (d, J = 4.0 Hz, 1H), 8.04 (d, J = 4.0 
Hz, 1H), 7.89 (d, J = 4.0 Hz, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.51 (dd, J = 8.0, 4.0 
Hz, 1H), 7.43-7.30 (m, 5H), 6.50 (s, 1H), 5.75 (s, 2H), 4.09-4.01 (m, 5H), 0.94 (t, 
J = 8.0 Hz, 3H). ESI-MS: calculated for C24H21ClN3OS3+ 498.05; found 498.05. 
JG-194: 1H-NMR (400 MHz, DMSO-d6): δ 8.26 (d, J = 4.0 Hz, 1H), 7.89 (d, J = 
4.0 Hz, 1H), 7.75 (s, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.43 (t, J = 8.0 Hz, 2H), 7.39-
7.33 (m, 4H), 6.52 (s, 1H), 5.76 (s, 2H), 4.14-4.05 (m, 5H), 2.40 (s, 3H), 0.98 (t, J 
= 8.0 Hz, 3H). ESI-MS: calculated for C25H24N3OS3+ 478.11; found 478.07. 
JG-231: 1H-NMR (400 MHz, DMSO-d6): δ 8.24 (d, J = 4.0 Hz, 1H), 8.07 (d, J = 
2.0 Hz, 1H), 7.88 (d, J = 4.0 Hz, 1H), 7.70 (d, J = 12.0 Hz, 1H), 7.55 (dd, J = 8.0, 
4.0 Hz, 1H), 7.24 - 7.20 (m, 2H), 6.76 (s, 1H), 5.97 (s, 2H), 4.21 (q, J = 8.0 Hz, 
2H), 4.10 (s, 3H), 1.18 (t, J = 8.0 Hz, 3H). ESI-MS: calculated for 
C22H18BrClN3OS4+ 581.92; found 581.89. 
JG-258: 1H-NMR (400 MHz, DMSO-d6): δ 8.22 (d, J = 4.0 Hz, 1H), 7.83 (d, J = 
4.0 Hz, 1H), 7.38 (d, J = 8.0 Hz, 2H), 7.35 - 7.29 (m, 3H), 6.43 (s, 1H), 5.71 (s, 
2H), 4.00 – 3.85 (m, 4H), 3.45 (s, 3H), 3.22 (t, J = 8.0 Hz, 2H), 0.88 (t, J = 8.0 Hz, 
3H). ESI-MS: calculated for C20H22N3OS3+ 416.09; found 416.02. 
JG-294: 1H-NMR (400 MHz, DMSO-d6): δ 8.21 (d, J = 2.0 Hz, 1H), 8.20 (d, J = 
4.0 Hz, 1H), 7.88 (d, J = 4.0 Hz, 1H), 7.69 (dd, J = 8.0, 2.0 Hz, 1H), 7.64 (d, J = 
12.0 Hz, 1H), 7.29 (d, J = 4.0 Hz, 1H), 6.93 (d, J = 4.0 Hz, 1H), 6.79 (s, 1H), 5.95 
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(s, 2H), 4.21 (q, J = 8.0 Hz, 2H), 4.11 (s, 3H), 1.19 (t, J = 8.0 Hz, 3H). ESI-MS: 
calculated for C23H18BrF3N3O2S3+ 599.97; found 599.99.  
JG-345: 1H-NMR (400 MHz, DMSO-d6): δ 8.06-7.99 (m, 2H), 7.87 (d, J = 4.0 Hz, 
1H), 7.80 (s, 1H), 7.62 (t, J = 8.0 Hz, 2H), 7.52 (t, J = 8.0 Hz, 1H), 7.40 (t, J = 
12.0 Hz, 1H), 6.91 (d, J = 8.0 Hz, 1H), 6.41 (s, 1H), 6.02 (s, 2H), 4.14 (s, 3H), 
3.99 (q, J = 4.0 Hz, 2H), 3.90 (s, 3H), 2.70 (q, J = 8.0 Hz, 2H), 1.22 (t, J = 8.0 Hz, 
3H), 0.87 (t, J = 8.0 Hz, 3H). ESI-MS: calculated for C28H28N3O3S3+ 550.13; found 
550.05. 
 
3.6.2 CRISPRi screening methods and data analysis 
Cell culture, DNA transfections, viral production, and construction of CRISPRi/a 
cell lines. HEK293T cells were maintained in Dulbecco’s modified eagle medium 
(DMEM) in 10 % FBS, 100 units/mL streptomycin and 100 µg/mL penicillin with 
or without 2mM glutamine. K562 cells were grown in RPMI-1640 with 25mM 
HEPES and 2.0 g/L NaHCo3 in 10 % FBS, 2 mM glutamine, 100 units/mL 
streptomycin and 100 µg/mL penicillin. Lentivirus was produced by transfecting 
HEK293T with standard packaging vectors using TransIT®-LTI Transfection 
Reagent (Mirus, MIR 2306). Viral supernatant was harvested 72 hours following 
transfection and filtered through a 0.45 μm PVDF syringe filter.  
To construct the CRISPRi K562 cell line, K562 cells were lentivirally transduced 
to express our previously described dCas9-BFP-KRAB fusion protein from the 
SFFV promoter. Pure polyclonal populations of CRISPRi K562 cells were sorted 
by flow cytometry using a BD FACS Aria2 for stable BFP expression.  
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High throughput pooled CRISPRi/a screening. CRISPRi K562 cell lines were 
infected with sgRNA libraries as previously described [33].  The infection was 
scaled to achieve an effective multiplicity of infection of less than one sgRNA per 
cell.  Two days after infection, cells were selected with 0.75-1 μg / mL puromycin 
(Tocris) for 2 days, and then allowed to recover for 2 or 3 days before starting the 
screens. For the CRISPRi genome-scale growth and HSP70 inhibitor screens, 
cells were passaged or treated with two pulses of 400nM and then 520nM JG98, 
200nM and then 270nM JG194 or one pulse of 250nM JG294 over 17 days to 
achieve between 8.5 and 14 population doublings difference between untreated 
and drug treated treated cell. The untreated, JG98 and JG194 were performed 
as biological replicate screens while only one JG294 screen was performed. 
Cells were maintained at a density of between 250,000 and 1,000,000 cells / mL 
continually maintaining a library coverage of at least 500-1000 cells per sgRNA. 
Populations of cells expressing this library of sgRNAs were either harvested at 
the outset of the experiment (the t0 time point), grown under standard conditions 
(untreated), or treated with HSP70 inhibitors. Genomic DNA was harvested from 
all samples; the sgRNA-encoding regions were then amplified by PCR and 
sequenced on an Illumina HiSeq-2500 using custom primers at high coverage 
with previously described protocols (http://weissmanlab.ucsf.edu/links/links.html). 
From this data, we quantified the frequencies of cells expressing different 
sgRNAs in each sample. The data from replicate screens was averaged. From 
this data we quantified the phenotype of each sgRNA, which have previously 
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defined for growth (g) or resistance to treatment (r) [34]. A python script for 
processing our CRISPRi library sequencing data is available at 
https://github.com/mhorlbeck/ScreenProcessing. 
 
Bioinformatic analysis of hit genes. Hit genes were ranked based on average 
phenotype of the 3 most extreme sgRNAs targeting them or by a Mann-Whitney 
test. Pathways and gene sets enriched among hit genes were identified using 
GSEA and DAVID software.  
 
Individual re-test of sgRNA phenotypes and CRISPRi/a transcript repression and 
activation. Individual phenotype re-test experiments for sgRNAs from the HSP70 
inhibitor screens were performed as competitive growth experiments on partially-
transduced populations of CRISPRi K562 cells. Briefly, cells were partially 
transduced ~25-60%. Three or four days following infection, cells were counted 
and seeded in 24 well plates at 0.25-0.5 million cells / mL. Triplicate samples for 
each sgRNA were grown under standard conditions or, were treated with 325nM 
or 350nM JG294. Each population of cells was allowed to grow or recover for 5 
or 6 days. The absolute cell number and percentage of cells that express BFP 
(indicating sgRNA expression) was measured for each sample at the beginning 
and end of the experiment. Rho scores were calculated as described previously 
[13]. 
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3.6.3 Fluorescence Microscopy 
Plasmids containing N-terminally labeled mIFP-Calenexin and a mIFP labeled 
mitochondrial targeting sequence were transfected into HeLa cells using a 
nucleofection protocol. Polyclonal selection for stable expression was performed 
with Geneticin. Cells expressing mIFP-Calnexin were sorted by flow cytometry 
using a BD FACS Aria II. Cells were maintained in Minimum Essential Medium 
supplemented with penicillin/streptomycin and FBS.  For microscopy, cells were 
plated into 96 well µclear plates (Greiner 655090) and incubated 48hrs with 
25µM billiverdin prior to compound treatments. Cells were then treated with 1µM 
compound at 2% DMSO and Hoescht for 30 min. Cells were washed and imaged 
in Fluorobrite Dulbecco’s Modified Eagle Medium. Images were captured using a 
Nikon spinning disk confocal microscope with a 40X objective. Image 
deconvolution and colocalization analysis was performed with IamgeJ.   
 
3.6.4 Cell culture and immunoblotting 
Stably expressing tau cells were harvested using the T-Rex™ HEK 293 system. 
Transfection of tau PCDNA3 tau plasmids was performed using a nucleofection 
protocol followed by hygromycin selection. Cells were maintained in Dulbecco’s 
Modified Eagle Medium supplemented with penicillin/streptomycin and FBS. 
Immunostaining for tau levels was performed in either 12 well or 6 well plates in 
which tau expression was induced with 3ng/mL of DOX along with compound 
treatment at either 10µM (JG-40 and JG-48) or 5µM (all others) for 24 hours 
(0.2% DMSO). Cells were lysed with MPer buffer supplemented with protease 
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inhibitor and 10µg of proteins were separated by gel electrophoresis. 
Immunoblotting was performed with D8 mouse tau (sc-166060) and rabbit 
GAPDH (cell signaling, 2118) and mouse (cell signaling, 7076) and rabbit (cell 
signaling, 7074) HRP-conjugated secondaries. Quantification and image analysis 
was performed using Biorad Image Lab. 
 
Contributions 
Zapporah T. Young performed all fluorescence microscopy imaging and 
quantification, transfections of Hsp70 paralogs and compound characterization in 
tauopathy models. Luke Gilbert and Jonathon Weissman performed CRISPRi 
screening, data analysis and validation. Victoria Assimon and Zapporah Young 
designed, produced and characterized the Hsp70 mutants. Xiaokai Li and Hao 
Shao synthesized and characterized compounds referenced in this study. 
Experiments were designed by Zapporah T. Young and Jason E. Gestwicki.  
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3.7 Appendix 
 
Appendix 3.1 Hsp70 alignment and rhodacyanine synthesis. A. Alignment of Hsp70 paralogs shows a highly 
conserved NBD. Residues with significant shifts by protein NMR in the presence of compound are 
highlighted in red. B. Synthetic route for JG compound. (a) 1. Potassium ethyl xanthate, DMF, 4 h, 125 °C; 
2. methyl iodide, triethyl- amine, ethanol, 1 h, 80 °C; (b) methyl p-toluenesulfonate, anisole, 125 °C; (c) N-
substituted rhodanine, triethylamine, acetonitrile, 4 h, 25 °C; (d) methyl p-toluenesulfonate, DMF, 3 h, 135 
°C; (e) 1. triethylamine, acetonitrile, 3 h, 80 °C, 2. Cl-ion exchange column. 
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Appendix 3.2 CRISPRi reveals JG-98 treated cells are sensitive to HSPA9 (mortalin). 
HSPA9
HSPA8
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Appendix 3.3 CRISPRi reveals JG-194 treated cells are more sensitive to HSPA9 (mortalin) than HSPA5 
(BiP). 
HSPA9
HSPA5
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Appendix 3.4 CRISPRi reveals JG-294 treated cells are most sensitive to HSPA5 (BiP) over HSPA9 
(mortalin) and HSPA8 (Hsc70). 
HSPA5
HSPA9
HSPA8
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Appendix 3.5 CRISPRi reveals JG-98 and JG-194 have similar profiles in cells. HSPA9 (mortalin) is 
highlighted in yellow. 
HSPA9
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Appendix 3.6 CRISPRi reveals JG-98 and JG-294 have distinct profiles in cells. 
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Appendix 3.7 CRISPRi reveals JG-194 and JG-294 have distinct profiles in cells. 
 
Appendix 3.8 Intrinsic fluorescence of rhodacyanine analogs. 
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Appendix 3.9 Development and characterization of Hsc70 NBD point mutants. (A) Point mutantions withing 
the rhodacyanien binding site as tools for probing effecs of Hsc70 perturbations (B) and (C) Results are 
average of two independent experiments performed in triplicate. Error bars represent the SEM. 
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A. Hsc70 NBD with residues important for rhodacyanine binding shown in blue
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Table 3.1 Summary of rhodacyanine characterization 
Compound MW 
MDA-MB-
231 EC50 
(µM) 
MCF-7 
EC50 (µM) 
MEF 
EC50 (µM) 
IMR90 
EC50 (µM) 
Solubility 
(µM) 
Microsome 
Stability 
t1/2 (min) 
JG40 435.96 6.2 ± 1.0 8.5 ± 3.0 >50 NT NT NT 
JG98 534.54 0.53 ± 0.05 0.7 ± 0.2 24 ± 1.3 1.4 ± 0.2 31 68 
JG194 514.12 0.082 ± .009 0.20 ± 0.02 1.9 ± 0.1 1.8 ± 0.3 16 40 
JG231 619.45 0.27 ± 0.03 0.12 ± 0.01 2.5 ± 0.1 4.6 ± 0.3 16 NT 
JG294 636.94 0.12 ± 0.01 0.062 ± .006 3.5 ± 0.4 9.5 ± 1.9 31 60 
JG345 586.18 0.031 ± .008 0.067 ± .007 1.0 ± 0.1 3.1 ± 0.7 32 25 
 
Table 3.2 Top 50 CRISPRi hits for JG-98 and JG-194 
JG-98	 JG-194	
Hit	 Gene	 p	value	 rho	 Hit	 Gene	 p	value	 rho	
1	 ATP1A1	 5.68E-08	 0.4544	 1	 PFKP	 4.47E-08	 -0.2438	
2	 CYB5B	 9.08E-08	 0.2734	 2	 ATP1A1	 4.51E-08	 0.4478	
3	 DICER1	 1.53E-07	 0.2399	 3	 CYB5B	 4.76E-08	 0.3504	
4	 PGAM1	 2.35E-07	 -0.1493	 4	 KIAA1191	 4.98E-08	 -0.2447	
5	 PEX5	 2.49E-07	 0.1902	 5	 ZNF281	 5.97E-08	 0.1083	
6	 KIAA1191	 4.34E-07	 -0.1497	 6	 GOT1	 6.19E-08	 -0.1140	
7	 ABCC4	 5.15E-07	 -0.1891	 7	 MTX2	 6.65E-08	 -0.3884	
8	 ASNA1	 5.75E-07	 0.2472	 8	 HUWE1	 8.59E-08	 -0.1044	
9	 IGF2BP1	 6.82E-07	 0.0892	 9	 PYROXD1	 9.29E-08	 0.1312	
10	 BTAF1	 7.37E-07	 0.2892	 10	 PNP	 9.53E-08	 -0.1333	
11	 UFM1	 8.21E-07	 0.1784	 11	 FAM136A	 9.58E-08	 -0.2357	
12	 NAA50	 9.53E-07	 0.1098	 12	 APOOL	 1.26E-07	 0.2447	
13	 MCUR1	 1.10E-06	 -0.1599	 13	 NAA50	 1.67E-07	 0.1133	
14	 TSC22D1	 1.20E-06	 0.1327	 14	 PEX5	 2.08E-07	 0.2573	
15	 PFKP	 1.37E-06	 -0.2457	 15	 SLC5A6	 2.08E-07	 0.0676	
16	 TMEM161B	 1.66E-06	 0.4756	 16	 ERAL1	 2.28E-07	 -0.2504	
17	 PSMA1	 1.82E-06	 0.1888	 17	 ABCC4	 2.32E-07	 -0.2691	
18	 RNF149	 1.86E-06	 -0.1051	 18	 LIN7C	 2.34E-07	 -0.1336	
19	 G3BP1	 1.90E-06	 -0.1074	 19	 NONO	 2.94E-07	 -0.1672	
20	 ERAL1	 2.05E-06	 -0.1220	 20	 PGAM1	 4.43E-07	 -0.1585	
21	 EIF4E	 2.22E-06	 0.1464	 21	 MINOS1-NBL1	 4.77E-07	 0.2658	
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22	 MTX2	 2.67E-06	 -0.2474	 22	 CDK6	 4.90E-07	 0.0952	
23	 IFITM1	 2.78E-06	 0.1090	 23	 PRPS1	 5.09E-07	 0.1734	
24	 RAD21	 3.19E-06	 -0.1005	 24	 HSCB	 5.37E-07	 -0.1706	
25	 POLG2	 3.90E-06	 0.1261	 25	 TRAP1	 6.34E-07	 -0.0986	
26	 PYROXD1	 4.26E-06	 0.1158	 26	 RBM6	 6.39E-07	 -0.1028	
27	 ABCC1	 4.59E-06	 -0.2632	 27	 MED23	 6.63E-07	 -0.2059	
28	 CCDC51	 4.64E-06	 -0.4094	 28	 PSMA7	 6.65E-07	 0.0864	
29	 HSCB	 4.81E-06	 -0.0694	 29	 TOMM5	 6.69E-07	 0.0968	
30	 PRPS1	 5.44E-06	 0.1439	 30	 GRAMD1A	 6.83E-07	 0.0941	
31	 NDRG3	 5.73E-06	 0.2215	 31	 NPC2	 7.24E-07	 -0.1530	
32	 SUGT1	 5.76E-06	 0.1822	 32	 UBL7	 7.39E-07	 0.0665	
33	 ATP5J2-PTCD1	 6.27E-06	 -0.1542	 33	 CLPP	 7.67E-07	 -0.1835	
34	 DENND1A	 6.49E-06	 -0.1084	 34	 ZCCHC6	 8.06E-07	 0.1014	
35	 PIGO	 6.51E-06	 0.2268	 35	 DSTYK	 8.40E-07	 -0.1092	
36	 SPI1	 8.11E-06	 0.1561	 36	 STEAP3	 8.56E-07	 -0.0904	
37	 DPH6	 8.64E-06	 0.2259	 37	 DAZAP1	 8.61E-07	 0.1618	
38	 VPS29	 9.29E-06	 0.3132	 38	 BTAF1	 8.70E-07	 0.3325	
39	 PSMD1	 9.42E-06	 0.1146	 39	 CBFA2T3	 8.79E-07	 -0.3766	
40	 APOOL	 9.50E-06	 0.2110	 40	 EIF4E	 8.80E-07	 0.1882	
41	 HSP90AB1	 9.68E-06	 -0.0741	 41	 SLC38A5	 9.20E-07	 0.1212	
42	 KCNK5	 9.69E-06	 0.2185	 42	 WDHD1	 9.97E-07	 -0.1526	
43	 RPRD2	 1.02E-05	 0.1936	 43	 SLC7A1	 1.00E-06	 0.1533	
44	 TMEM185B	 1.12E-05	 -0.0677	 44	 MAX	 1.01E-06	 -0.0831	
45	 RHOBTB1	 1.17E-05	 -0.1415	 45	 DICER1	 1.04E-06	 0.3115	
46	 TFAM	 1.27E-05	 -0.1307	 46	 YIPF5	 1.06E-06	 0.0726	
47	 IMP3	 1.30E-05	 0.1357	 47	 COPS7B	 1.07E-06	 -0.1223	
48	 HK2	 1.40E-05	 -0.2286	 48	 GRSF1	 1.10E-06	 -0.2444	
49	 MTA1	 1.40E-05	 0.1137	 49	 MMD	 1.10E-06	 0.1679	
50	 FAM210A	 1.41E-05	 -0.1566	 50	 PGK1	 1.15E-06	 -0.2557	
368	 HSPA9	 1.67E-03	 -0.1909	 365	 HSPA9	 1.31E-04	 -0.2795	
3844	 HSPA8	 7.53E-02	 0.0521	 1715	 HSPA5	 1.15E-02	 -0.0740	
 
Table 3.3 Top 50 CRISPRi hits for JG-294 
JG-294	
Hit	 Gene	 p	value	 rho	
1	 SLC29A3	 4.42E-08	 0.5362	
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2	 SLC18B1	 6.16E-08	 -0.7157	
3	 PQLC2	 6.37E-08	 0.3370	
4	 VPS29	 7.30E-08	 0.6834	
5	 ATP1A1	 8.27E-08	 0.5805	
6	 KIAA0141	 9.31E-08	 0.3249	
7	 PPRC1	 1.77E-07	 -0.5036	
8	 SQLE	 3.87E-07	 0.2181	
9	 VPS35	 5.16E-07	 0.4341	
10	 HPS5	 7.64E-07	 -0.2310	
11	 RAD9B	 8.68E-07	 0.3126	
12	 NFYC	 1.21E-06	 0.2008	
13	 PIGO	 1.41E-06	 0.3397	
14	 ZIC2	 1.41E-06	 -0.3500	
15	 RNF214	 1.57E-06	 0.2087	
16	 C7orf26	 1.96E-06	 0.1679	
17	 WDR91	 1.96E-06	 0.2929	
18	 STAG2	 2.08E-06	 -0.3442	
19	 SHOC2	 2.34E-06	 0.2314	
20	 ANKRD17	 2.86E-06	 0.1794	
21	 PWWP2A	 3.00E-06	 0.1886	
22	 GLCE	 3.12E-06	 0.1997	
23	 KCNK5	 3.54E-06	 0.2847	
24	 SOS1	 4.52E-06	 0.2911	
25	 KLF1	 4.71E-06	 -0.2748	
26	 PLEKHH3	 5.70E-06	 0.1655	
27	 TMEM147	 6.12E-06	 0.2911	
28	 XPO1	 6.28E-06	 0.3377	
29	 CCND3	 6.58E-06	 0.1797	
30	 CYB5B	 7.03E-06	 0.2513	
31	 ZMAT5	 7.35E-06	 0.1642	
32	 COPS7B	 7.42E-06	 -0.1694	
33	 SLC38A5	 7.99E-06	 0.1636	
34	 CSDE1	 8.04E-06	 -0.2163	
35	 WDR11	 8.99E-06	 -0.3077	
36	 TMED10	 9.20E-06	 0.1954	
37	 TFDP1	 9.27E-06	 0.2216	
38	 TAL1	 9.29E-06	 -0.2509	
39	 NAA50	 9.55E-06	 0.2060	
40	 CNBP	 9.97E-06	 0.1964	
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41	 TMEM161B	 1.01E-05	 0.6163	
42	 COX7C	 1.03E-05	 0.1111	
43	 COPS4	 1.12E-05	 -0.2957	
44	 MCM3AP	 1.26E-05	 0.2623	
45	 PLEKHA1	 1.29E-05	 0.1575	
46	 EIF2B2	 1.34E-05	 -0.2730	
47	 PTPN7	 1.44E-05	 -0.1621	
48	 DBR1	 1.73E-05	 0.1814	
49	 STOML2	 1.77E-05	 0.1889	
50	 NAA60	 1.91E-05	 0.1235	
144	 HSPA5	 2.62E-04	 -0.3129	
386	 HSPA9	 2.46E-03	 -0.2250	
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Chapter 4 
Conclusions and Future Directions 
 
 
4.1 Conclusions 
Dysfunctions in protein quality control underlie the initiation of disease in the cell. 
Molecular chaperones are major regulators of protein homeostasis; thus, 
improving chaperone function is a promising therapeutic avenue. However, the 
best routes for achieving this remain unclear. As discussed in Chapter 1, the 
intrinsically disordered protein tau is prone to regulation by molecular 
chaperones. This makes it a perfect model substrate for improving our basic 
understanding of the mechanisms of chaperone-mediated proteostasis in order 
to effectively target chaperone function for the treatment of disease. Specifically, 
this thesis work is focused on using tauopathy models to explore the ways in 
which the molecular chaperone Heat shock protein 70 (Hsp70) normalizes 
proteostasis.  
 
One goal of my thesis was to determine how manipulation of Hsp70 by 
rhodacyanines directs tau fate. We identified a brain penetrant analog, JG-48, 
and in Chapter 2, I used biochemical assays to measure JG-48 effects on Hsp70 
enzymatic activity and interactions with co-chaperones. We hypothesized that 
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stalling Hsp70 in the ADP bound state was a result of inhibition of Hsp70 
interactions with a class of co-chaperones called nucleotide exchange factors 
(NEFs). With the help of a former student Jennifer Rauch, I verified that 
rhodacyanine analogs allosterically inhibit NEF binding, and as a result, 
compounds prevent substrate release from Hsp70. These findings expanded our 
understanding of the Hsp70-co-chaperone system and contributed to our work 
characterizing compounds in cancer [1, 2]. With no previous reports of small 
molecule inhibitors of Hsp70-NEF interactions in the literature, rhodacyanines 
represent first in class NEF inhibitors.  
 
In Chapter 3, we initiated a strategic collaboration with Luke Gilbert and Jonathan 
Weissman to characterize rhodacyanines with strong anti-cancer activity using 
CRISPRi technology. We were interested in using functional genomics to 
understand shifts in potency and safety observed in the later stages of the 
medicinal chemistry campaign. From these genetic screens we learned that 
rhodacyanines exhibit preferential binding to organelle specific Hsp70 paralogs. 
We felt that fluorescence microscopy would be the best way to confirm these 
result in vivo since we could utilize the intrinsic fluorescence of the rhodacyanine 
scaffold. Therefore, I developed stable cells lines expressing mitochondria and 
endoplasmic reticulum (ER) targeting sequences and proteins labeled with 
monomeric infrared protein (mIFP). Analysis of colocalization by microscopy 
combined with results from compound characterization in tauopathy models 
revealed that organelle partitioning by rhodacyanines might explain variability in 
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potency. The results from this study will guide our future efforts to optimize the 
rhodacyanine scaffold as a precision medicine tool for targeting paralogs of 
Hsp70 in various proteostasis disorders. 
 
The work described in this thesis has advanced our understanding of Hsp70-
mediated protein quality control. We developed a “dwell time” model for directing 
the fate of bound Hsp70 substrates by stalling the ATPase cycle in the ADP-
bound state. Now that we know how to manipulate Hsp70 for client degradation, 
we can apply this model to diseases in which aberrations in protein quality 
control have overburdened the cell. Additionally, we discovered targeting specific 
Hsp70 paralogs may provide a new and safer alternative to global Hsp70 
modulation. Overall this work represents the first steps in developing Hsp70-
targeting small molecule therapeutics for tauopathies, cancer and diseases 
related to collapses in protein homeostasis.  
 
4.2 Future Directions 
4.2.1 Development of tauopathy models for studying proteostasis 
networks 
In Chapter 1, we summarized the mechanisms of normal and abnormal tau 
homeostasis, and the many points of therapeutic intervention tau misregulation 
pathways. To begin exploring targets for normalizing tau homeostasis, we need 
to first develop useful and robust models of tauopathy. Previously, the Gestwicki 
lab used HeLa C3 cells overexpressing full length tau to characterize 
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rhodacyanine activity in cells. While this model was useful for monitoring 
changes in tau levels following compound treatment, I found that overexpression 
of tau in these cells resulted in primarily soluble and mislocalized tau or free tau 
as illustrated by immunofluorescene staining. As reviewed in Chapter 1, tau is 
normally localized to the microtubule network where it aids in polymerization and 
provides cytoskeletal stability. Therefore, for our future studies we wanted to 
develop a more biologically relevant model for studying tau homeostasis. To do 
this, I made HEK293 cell lines with inducible expression of wild type tau as well 
as disease relevant point mutants and deletions (Chapter 1). A commercially 
available targeted integration system was used to produce stable cell lines with 
homogenous expression of tau. We chose HEK293 cells, because they lack 
endogenous tau; therefore, we can be confident that our experiments are well-
controlled. In these cells, tau was labeled with an N-terminal GFP tag, making 
protein levels easily quantifiable by microscopy and flow cytometry. Initially I 
created cells lines with inducible expression of the following tau mutants: A152T, 
P301S and D348G (Figure 4.1A). Each of these mutations are associated with 
disease and provide tools for assessing differences in homeostasis when 
compared to wild-type tau. I have also prepared a cell line expressing tau with 
deletions of residues reported to be important for microtubule binding referred to 
as ∆277/278/308/309 tau (Figure 4.1A). 
 
 To characterize these cell lines, I first observed tau localization by fluorescence 
microscopy. After induction of wild-type tau expression with doxycycline (DOX), 
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immunofluorescence staining of tubulin shows that GFP-tau localizes well to the 
microtubule (data not shown). Imaging of the GFP-tau mutants yields a similar 
cytoskeletal profile and morphology (Figure 4.1B). This is in agreement with 
previous reports of a similar inducible tau cell model whereby expression of tau 
promoted microtubule stabilization [3]. A DOX incubation time-course illustrated 
that nearly 100% of cells exhibit tau induction after 20 hours by flow cytometry 
and western blot (Figure 4.1C). These preliminary results confirm successful 
development of a biologically relevant system with normal tau localization and 
controllable expression. 
 
Figure 4.1 HEK293 cells with inducible tau expression as new models of tauopathy. A. Diagram of GFP-tau 
construct, mutations and deletions shown in red. (B) After 24hr induction of tau expression with DOX, tau 
imaging suggests localization to microtubule networks. (C) Tau expression is sensitive to length of DOX 
incubation. Flow cytometry analysis shows maximum expression after 20hrs of DOX treatment. Similar 
results are observed by western blot.  
To demonstrate the utility of these tauopathy models in assessing mechanisms 
of tau quality control, the half-life of each tau variant was measured. After 
induction of tau with DOX for 24 hours, time points were taken every 24 hours for 
up to 7 days. For P301S tau, levels reached half-maximal expression at 
approximately 40 hours by western blot (Figure 4.2A) and flow cytometry (Figure 
4.2B). Tau variants have shorter half-lives compared to wild-type, suggesting an 
B. GFP-tau localizes to microtubules in HEK293 cells 
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increase in rates of clearance for tau mutants (Figure 4.2B). As discussed in 
Chapter 1, mutations decrease tau binding to microtubules resulting in an 
increased population of soluble or free tau. This may explain the differences in 
stability of the tau variants as the abnormal or free tau is more susceptible to 
entry into degradation pathways.  
 
Figure 4.2 Determination of tau stability in HEK293 cells. (A) Western blot shows tau levels decline steadily 
following termination of induction. (B) Half-life determination by flow cytometry reveals that tau variants are 
less stable compared to wild-type tau. All results are averages of experiments performed in duplicate. Error 
bars represent SEM.  
 
4.2.2 Tauopathy models for drug discovery  
With robust and meaningful models of tauopathy, we are now prepared to 
evaluate mechanisms of tau proteostasis using rhodacyanines, Hsp70 paralogs, 
Hsp70 mutants, and functional genomics. The Gestwicki lab has synthesized 
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described above would provide valuable SAR and guide the development of new 
and more potent analogs. As a first step, I have measured the activity of 
biochemically interesting rhodacyanines including JG-48 using a high-throughput 
flow cytometry platform. In these experiments, the expression of GFP-P301S tau 
was induced with DOX and increasing amounts of compound were added 
simultaneously for 24 hours. Following treatment cells were analyzed by flow 
cytometry to quantify the amount of GFP-tau expressing cells. Results indicated 
a reduction in tau levels at high concentrations of JG-48 (Figure 4.3A). 
Preliminary experiments suggest this will be a valuable platform for analyzing 
compounds. VER-155008, an ATP-competitive inhibitor of Hsp70, greatly 
reduced tau levels and may be used for future studies as a positive control. 
Additionally, these experiments can be conducted in a 96 well plate format 
making this method suitable for assaying compounds in high volume.  
 
Figure 4.3 Development of a high-throughput flow cytometry tau degradation assay. Cells were treated in 96 
well cell culture plates before resuspension for quantification of GFP signal by FACS. Data shown 
represents average of two independent experiments performed in duplicate each. Error bars represent SEM. 
Because the positively charged rhodacyanines have a strong and broad intrinsic 
fluorescence (Chapter 3), they cannot be assayed in the current GFP-tau models 
due to signal overlap. However, the development of tau models with expression 
0.1 1 10 100
0
50
100
Compound (uM)
%
 G
FP
 T
au
 S
ig
na
l
VER
JG-48
VER
JG-48
11
>25
IC50 
(µM)
 131 
of far red labeled tau should overcome these challenges. The potential for 
success in identifying compounds with potent anti-tau activity is highlighted in 
Chapter 3, where immunoblotting of rhodacyanine treated cells showed 
significant reduction in tau levels. We also plan to use the tau models to evaluate 
activators of the ubiquitin proteasome degradation pathway, developed from an 
ongoing project guided by Kojo Opoku-Nsiah, a current student in the lab. 
Phenotypic screens using high-content imaging and a UCSF library of brain 
penetrant compounds is yet another future application of these cell models. 
Meredith Kuo, a current postdoc in the lab is directing this effort.    
 
4.2.3 Tauopathy models for target identification 
In Chapter 3, I detailed the benefits of using functional genomics for target 
validation, specifically gene regulation. In collaboration with the Weissman lab, 
we utilized CRISPRi technology to identify sensitive and resistant rhodacyanine 
phenotypes based on gene knockdown. A more traditional method of genome 
wide knockdown uses short hairpin RNA (shRNA) libraries to control gene 
expression. This method yields results similar to those of CRISPRi/a [4]. 
Application of shRNA screening to tauopathy models could identify novel 
therapeutic targets and reveal important protein networks specific for a given tau 
variant. For example, we hypothesize that D348G will have impaired degradation 
via the lysosome-autophagy pathway given that the mutated residue is within an 
autophagy degradation targeting sequence. Therefore, we might expect shRNA 
screens in D348G cells to reveal sensitivity and resistance phenotypes for 
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autophagic pathways. The development of reliable controls and methods is 
required for genome wide studies, and Sue Ann Mok, a postdoc in the lab, is 
pursuing the design and optimization of shRNA screens.     
 
4.3 Optimization of the rhodacyanine scaffold  
Currently we are screening more rhodacyanine compounds using CRISPRi in 
collaboration with Jonathan Weissman’s lab. With knowledge gained from the 
CRISPRi screens described in Chapter 3, combined with fluorescence 
microscopy we will design and synthesize more rhodacyanines with selectivity for 
Hsp70 paralogs. One approach is to increase modifications to ring D (Figure 5.4) 
based on previous work [5], substitutions of ring D appear to be driving the shifts 
in potency and selectivity, despite the fact that docking models place this ring 
outside of the binding pocket. Efforts to make potent anti-cancer compounds like 
JG-98 more drug-like and suitable for development as tauopathy therapeutics are 
ongoing. We reported that removing the cationic nitrogen from ring C increases 
brain uptake in mice [6]. However, in modifying the charged nitrogen, ring D was 
also removed. Thus, future synthesis will focus on reintroducing the important 
ring D to the neutral scaffold. A current postdoc in the lab, Hao Shao, is  
developing synthetic methods to add the fourth ring to the neutral scaffold.     
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Figure 4.4 Molecular docking of JG-48 in the NBD of Hsc70 directs synthesis of future analogs.   
4.4 Probing Hsp70 kinetics 
In Chapter 2, we describe a model for Hsp70 “triage” of substrates like tau in 
which trapping Hsp70-substrate complexes leads to increased degradation of 
substrates in vivo. Future studies should use optimized rhodacyanines as probes 
for measuring Hsp70 protein-protein interaction kinetics. Knowledge of on/off 
rates for Hsp70 clients in the presence and absence of compound will further 
validate our dwell time theory and advance our understanding of chaperone 
biology. Furthermore, methods to quantify rates of substrate release by stopped 
flow, surface plasmon resonance (SPR) or some other means could be used to 
rank order compounds in the rhodacyanine chemical series and determine 
structure activity relationships (SAR) for identifying strong candidates.  
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